WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICA

N PUBLISHED UNDER THE PATENT (

ERATION TREATY (PCT)

(51) International Patent Classification 0:

14/33, A61K 38/16, 39/08

C12N 15/31, 1/21, C12P 21/02, C07K

A1

(11) International Publication Number:

WO 98/07864

(43) International Publication Date:

26 February 1998 (26.02.98)

(21) International Application Number:

PCT/GB97/02273

(22) International Filing Date:

22 August 1997 (22.08.97)

(30) Priority Data:

9617671.4 9625996.5

23 August 1996 (23.08.96) . GB GB

13 December 1996 (13.12.96)

(60) Parent Application or Grant

(63) Related by Continuation

US Filed on

08/782.893 (CIP) 27 December 1996 (27.12.96)

(71) Applicants (for all designated States except US): MICRO-BIOLOGICAL RESEARCH AUTHORITY CAMR (CEN-TRE FOR APPLIED MICROBIOLOGY & RESEARCH) [GB/GB]; Porton Down, Salisbury, Wiltshire SP4 0JG (GB). THE SPEYWOOD LABORATORY LIMITED [GB/GB]; 14 Kensington Square, London W8 5HH (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SHONE, Clifford, Charles [GB/GB]; Microbiological Research Authority CAMR (Centre for Applied Microbiology & Research), Porton Down, Salisbury, Wiltshire SP4 0JG (GB). QUINN,

Conrad, Padraig [GB/GB]; Microbiological Research Authority CAMR (Centre for Applied Microbiology & Research), Porton Down, Salisbury, Wiltshire SP4 0JG (GB). FOSTER, Keith, Alan [GB/GB]; Microbiological Research Authority CAMR (Centre for Applied Microbiology & Research), Porton Down, Salisbury, Wiltshire SP4 0JG (GB).

(74) Agent: SCHLICH, George, William; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU. IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, I'R, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: RECOMBINANT TOXIN FRAGMENTS

(57) Abstract

A polypeptide has first and second domains which enable the polypeptide to be translocated into a target cell or which increase the solubility of the polypeptide, or both, and further enable the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

Al.	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	I.T	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑÜ	Australia	GA	Gabon	1.V	Latvia	SZ .	Swaziland
AZ.	Azerbaijan	GB	United Kingdom	MC	Мопасо	TD	Chad
ВА	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	ΙE	Ireland	MN	Mongolia	'UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JР	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
Cl	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		


RECOMBINANT TOXIN FRAGMENTS

This invention relates to recombinant toxin fragments, to DNA encoding these fragments and to their uses such as in a vaccine and for *in vitro* and *in vivo* purposes.

The clostridial neurotoxins are potent inhibitors of calcium-dependent neurotransmitter secretion in neuronal cells. They are currently considered to mediate this activity through a specific endoproteolytic cleavage of at least one of three vesicle or pre-synaptic membrane associated proteins VAMP, syntaxin or SNAP-25 which are central to the vesicle docking and membrane fusion events of neurotransmitter secretion. The neuronal cell targeting of tetanus and botulinum neurotoxins is considered to be a receptor mediated event following which the toxins become internalised and subsequently traffic to the appropriate intracellular compartment where they effect their endopeptidase activity.

The clostridial neurotoxins share a common architecture of a catalytic L-chain (LC, ca 50 kDa) disulphide linked to a receptor binding and translocating H-chain (HC, ca 100 kDa). The HC polypeptide is considered to comprise all or part of two distinct functional domains. The carboxy-terminal half of the HC (ca 50 kDa), termed the $H_{\rm C}$ domain, is involved in the high affinity, neurospecific binding of the neurotoxin to cell surface receptors on the target neuron, whilst the amino-terminal half, termed the $H_{\rm N}$ domain (ca 50 kDa), is considered to mediate the translocation of at least some portion of the neurotoxin across cellular membranes such that the functional activity of the LC is expressed within the target cell. The $H_{\rm N}$ domain also has the property, under conditions of low pH, of forming ion-permeable channels in lipid membranes, this may in some manner relate to its translocation function.

For botulinum neurotoxin type A (BoNT/A) these domains are considered to reside within amino acid residues 872-1296 for the $H_{\rm C}$, amino acid residues 449-871 for the $H_{\rm N}$ and residues 1-448 for the LC. Digestion with trypsin effectively degrades the $H_{\rm C}$ domain of the BoNT/A to generate a non-toxic fragment designated $LH_{\rm N}$,



It is therefore possible to provide functional definitions of the domains within the neurotoxin molecule, as follows:

(A) clostridial neurotoxin light chain:

-a metalloprotease exhibiting high substrate specificity for vesicle and/or plasma - membrane associated proteins involved in the exocytotic process. In particular, it cleaves one or more of SNAP-25, VAMP (synaptobrevin / cellubrevin) and syntaxin.

(B) clostridial neurotoxin heavy chain H_N domain:

- -a portion of the heavy chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell.
- -the domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell.
- -the domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH.
- -the domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone.
- (C) clostridial neurotoxin heavy chain H_c domain.
- -a portion of the heavy chain which is responsible for binding of the native

- 3 -

holotoxin to cell surface receptor(s) involved in the intoxicating action of clostridial toxin prior to internalisation of the toxin into the cell.

The identity of the cellular recognition markers for these toxins is currently not understood and no specific receptor species have yet been identified although Kozaki et al. have reported that synaptotagmin may be the receptor for botulinum neurotoxin type B. It is probable that each of the neurotoxins has a different receptor.

It is desirable to have positive controls for toxin assays, to develop clostridial toxin vaccines and to develop therapeutic agents incorporating desirable properties of clostridial toxin.

However, due to its extreme toxicity, the handling of native toxin is hazardous.

The present invention seeks to overcome or at least ameliorate problems associated with production and handling of clostridial toxin.

Accordingly, the invention provides a polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to neuronal exocytosis and wherein said second domain is adapted (i) to translocate the polypeptide into the cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into the cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of any clostridial neurotoxin precursor that can be converted into toxin by proteolytic action. Accordingly, the invention may thus provide a single polypeptide chain containing a domain equivalent to a clostridial toxin light chain and a domain providing the functional aspects of the H_N of a clostridial toxin heavy chain, whilst lacking the functional aspects of a clostridial toxin H_C domain.

For the purposes of the invention, the functional property or properties of the H_N of a clostridial toxin heavy chain that are required to be exhibited by the second domain of the polypeptide of the invention are either (i) translocation of the polypeptide into a cell, or (ii) increasing solubility of the polypeptide compared to solubility of the first domain on its own or (iii) both (i) and (ii). References hereafter to a H_N domain or to the functions of a H_N domain are references to this property or properties. The second domain is not required to exhibit other properties of the H_N domain of a clostridial toxin heavy chain.

A polypeptide of the invention can thus be soluble but lack the translocation function of a native toxin-this is of use in providing an immunogen for vaccinating or assisting to vaccinate an individual against challenge by toxin. In a specific embodiment of the invention described in an example below a polypeptide designated LH₄₂₃/A elicited neutralising antibodies against type A neurotoxin. A polypeptide of the invention can likewise thus be relatively insoluble but retain the translocation function of a native toxin - this is of use if solubility is imparted to a composition made up of that polypeptide and one or more other components by one or more of said other components.

The first domain of the polypeptide of the invention cleaves one or more vesicle or plasma-membrane associated proteins essential to the specific cellular process of exocytosis, and cleavage of these proteins results in inhibition of exocytosis, typically in a non-cytotoxic manner. The cell or cells affected are not restricted to a particular type or subgroup but can include both neuronal and non-neuronal cells. The activity of clostridial neurotoxins in inhibiting exocytosis has, indeed, been observed almost universally in eukaryotic cells expressing a relevant cell surface receptor, including such diverse cells as from Aplysia (sea slug), Drosophila (fruit fly) and mammalian nerve cells, and the activity of the first domain is to be understood as including a corresponding range of cells.

The polypeptide of the invention may be obtained by expression of a recombinant nucleic acid, preferably a DNA, and is a single polypeptide, that is to say not

cleaved into separate light and heavy chain domains. The polypeptide is thus available in convenient and large quantities using recombinant techniques.

In a polypeptide according to the invention, said first domain preferably comprises a clostridial toxin light chain or a fragment or variant of a clostridial toxin light chain. The fragment is optionally an N-terminal, or C-terminal fragment of the light chain, or is an internal fragment, so long as it substantially retains the ability to cleave the vesicle or plasma-membrane associated protein essential to exocytosis. The minimal domains necessary for the activity of the light chain of clostridial toxins are described in J. Biol. Chem., Vol.267, No. 21, July 1992, pages 14721-14729. The variant has a different peptide sequence from the light chain or from the fragment, though it too is capable of cleaving the vesicle or plasma-membrane associated protein. It is conveniently obtained by insertion, deletion and/or substitution of a light chain or fragment thereof. In embodiments of the invention described below a variant sequence comprises (i) an N-terminal extension to a clostridial toxin light chain or fragment (ii) a clostridial toxin light chain or fragment modified by alteration of at least one amino acid (iii) a C-terminal extension to a clostridial toxin light chain or fragment, or (iv) combinations of 2 or more of (i)-(iii).

In further embodiments of the invention, the variant contains an amino acid sequence modified so that (a) there is no protease sensitive region between the LC and H_N components of the polypeptide, or (b) the protease sensitive region is specific for a particular protease. This latter embodiment is of use if it is desired to activate the endopeptidase activity of the light chain in a particular environment or cell. Though, in general, the polypeptides of the invention are activated prior to administration.

The first domain preferably exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin. The clostridial toxin is preferably botulinum toxin or tetanus toxin.

In an embodiment of the invention described in an example below, the toxin light

chain and the portion of the toxin heavy chain are of botulinum toxin type A. In a further embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type B. The polypeptide optionally comprises a light chain or fragment or variant of one toxin type and a heavy chain or fragment or variant of another toxin type.

In a polypeptide according to the invention said second domain preferably comprises a clostridial toxin heavy chain H_N portion or a fragment or variant of a clostridial toxin heavy chain H_N portion. The fragment is optionally an N-terminal or C-terminal or internal fragment, so long as it retains the function of the H_N domain. Teachings of regions within the H_N responsible for its function are provided for example in Biochemistry 1995, 34, pages 15175-15181 and Eur. J. Biochem, 1989, 185, pages 197-203. The variant has a different sequence from the H_N domain or fragment, though it too retains the function of the H_N domain. It is conveniently obtained by insertion, deletion and/or substitution of a H_N domain or fragment thereof. In embodiments of the invention, described below, it comprises (i) an N-terminal extension to a H_N domain or fragment, (iii) a C-terminal extension to a H_N domain or fragment by alteration of at least one amino acid, or (iv) combinations of 2 or more of (i)-(iii). The clostridial toxin is preferably botulinum toxin or tetanus toxin.

The invention also provides a polypeptide comprising a clostridial neurotoxin light chain and a N-terminal fragment of a clostridial neurotoxin heavy chain, the fragment preferably comprising at least 423 of the N-terminal amino acids of the heavy chain of botulinum toxin type A, 417 of the N-terminal amino acids of the heavy chain of botulinum toxin type B or the equivalent number of N-terminal amino acids of the heavy chain of other types of clostridial toxin such that the fragment possesses an equivalent alignment of homologous amino acid residues.

These polypeptides of the invention are thus not composed of two or more polypeptides, linked for example by di-sulphide bridges into composite molecules. Instead, these polypeptides are single chains and are not active or their activity is

significantly reduced in an in vitro assay of neurotoxin endopeptidase activity.

Further, the polypeptides may be susceptible to be converted into a form exhibiting endopeptidase activity by the action of a proteolytic agent, such as trypsin. In this way it is possible to control the endopeptidase activity of the toxin light chain.

In a specific embodiment of the invention described in an example below, there is provided a polypeptide lacking a portion designated $H_{\rm C}$ of a clostridial toxin heavy chain. This portion, seen in the naturally produced toxin, is responsible for binding of toxin to cell surface receptors prior to internalisation of the toxin. This specific embodiment is therefore adapted so that it can not be converted into active toxin, for example by the action of a proteolytic enzyme. The invention thus also provides a polypeptide comprising a clostridial toxin light chain and a fragment of a clostridial toxin heavy chain, said fragment being not capable of binding to those cell surface receptors involved in the intoxicating action of clostridial toxin, and it is preferred that such a polypeptide lacks an intact portion designated $H_{\rm C}$ of a clostridial toxin heavy chain.

In further embodiments of the invention there are provided compositions containing a polypeptide comprising a clostridial toxin light chain and a portion designated H_N of a clostridial toxin heavy chain, and wherein the composition is free of clostridial toxin and free of any clostridial toxin precursor that may be converted into clostridial toxin by the action of a proteolytic enzyme. Examples of these compositions include those containing toxin light chain and H_N sequences of botulinum toxin types A, B, C₁, D, E, F and G.

The polypeptides of the invention are conveniently adapted to bind to, or include, a ligand for targeting to desired cells. The polypeptide optionally comprises a sequence that binds to, for example, an immunoglobulin. A suitable sequence is a tandem repeat synthetic IgG binding domain derived from domain B of Staphylococcal protein A. Choice of immunoglobulin specificity then determines the target for a polypeptide - immunoglobulin complex. Alternatively, the

polypeptide comprises a non-clostridial sequence that binds to a cell surface receptor, suitable sequences including insulin-like growth factor-1 (IGF-1) which binds to its specific receptor on particular cell types and the 14 amino acid residue sequence from the carboxy-terminus of cholera toxin A subunit which is able to bind the cholera toxin B subunit and thence to GM1 gangliosides. A polypeptide according to the invention thus, optionally, further comprises a third domain adapted for binding of the polypeptide to a cell.

In a second aspect the invention provides a fusion protein comprising a fusion of (a) a polypeptide of the invention as described above with (b) a second polypeptide adapted for binding to a chromatography matrix so as to enable purification of the fusion protein using said chromatography matrix. It is convenient for the second polypeptide to be adapted to bind to an affinity matrix, such as a glutathione Sepharose, enabling rapid separation and purification of the fusion protein from an impure source, such as a cell extract or supernatant.

One possible second purification polypeptide is glutathione-S-transferase (GST), and others will be apparent to a person of skill in the art, being chosen so as to enable purification on a chromatography column according to conventional techniques.

As noted above, by proteolytic treatment, for example using trypsin, of a polypeptide of the invention it is possible to induce endopeptidase activity in the treated polypeptide. A third aspect of the invention provides a composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the clostridial toxin, said derivative further being non-toxic *in vivo* due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic *in vivo*. The activity of the derivative preferably approaches that of natural toxin, and is thus preferably at least 30% and most preferably at least 60% of natural toxin. The overall endopeptidase activity of the composition will, of course, also be determined by the amount of the derivative that is present.

While it is known to treat naturally produced clostridial toxin to remove the $H_{\rm C}$ domain, this treatment does not totally remove toxicity of the preparation, instead some residual toxin activity remains. Natural toxin treated in this way is therefore still not entirely safe. The composition of the invention, derived by treatment of a pure source of polypeptide advantageously is free of toxicity, and can conveniently be used as a positive control in a toxin assay, as a vaccine against clostridial toxin or for other purposes where it is essential that there is no residual toxicity in the composition.

The invention enables production of the polypeptides and fusion proteins of the invention by recombinant means.

A fourth aspect of the invention provides a nucleic acid encoding a polypeptide or a fusion protein according to any of the aspects of the invention described above.

In one embodiment of this aspect of the invention, a DNA sequence provided to code for the polypeptide or fusion protein is not derived from native clostridial sequences, but is an artificially derived sequence not preexisting in nature.

A specific DNA (SEQ ID NO: 1) described in more detail below encodes a polypeptide or a fusion protein comprising nucleotides encoding residues 1-871 of a botulinum toxin type A. Said polypeptide comprises the light chain domain and the first 423 amino acid residues of the amino terminal portion of a botulinum toxin type A heavy chain. This recombinant product is designated LH_{423}/A (SEQ ID NO: 2).

In a second embodiment of this aspect of the invention a DNA sequence which codes for the polypeptide or fusion protein is derived from native clostridial sequences but codes for a polypeptide or fusion protein not found in nature.

A specific DNA (SEQ ID NO: 19) described in more detail below encodes a polypeptide or a fusion protein and comprises nucleotides encoding residues 1-

1171 of a botulinum toxin type B. Said polypeptide comprises the light chain domain and the first 728 amino acid residues of the amino terminal protein of a botulinum type B heavy chain. This recombinant product is designated LH₇₂₈/B (SEQ ID NO: 20).

The invention thus also provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA according to the third aspect of the invention. The host cell is suitably not able to cleave a polypeptide or fusion protein of the invention so as to separate light and heavy toxin chains; for example, a non-clostridial host.

The invention further provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA encoding a fusion protein as described above, purifying the fusion protein by elution through a chromatography column adapted to retain the fusion protein, eluting through said chromatography column a ligand adapted to displace the fusion protein and recovering the fusion protein. Production of substantially pure fusion protein is thus made possible. Likewise, the fusion protein is readily cleaved to yield a polypeptide of the invention, again in substantially pure form, as the second polypeptide may conveniently be removed using the same type of chromatography column.

The LH_N/A derived from dichain native toxin requires extended digestion with trypsin to remove the C-terminal 1/2 of the heavy chain, the H_C domain. The loss of this domain effectively renders the toxin inactive *in vivo* by preventing its interaction with host target cells. There is, however, a residual toxic activity which may indicate a contaminating, trypsin insensitive, form of the whole type A neurotoxin.

In contrast, the recombinant preparations of the invention are the product of a discreet, defined gene coding sequence and can not be contaminated by full length toxin protein. Furthermore, the product as recovered from *E. coli*, and from other recombinant expression hosts, is an inactive single chain peptide or if expression

hosts produce a processed, active polypeptide it is not a toxin. Endopeptidase activity of LH₄₂₃/A, as assessed by the current *in vitro* peptide cleavage assay, is wholly dependent on activation of the recombinant molecule between residues 430 and 454 by trypsin. Other proteolytic enzymes that cleave between these two residues are generally also suitable for activation of the recombinant molecule. Trypsin cleaves the peptide bond C-terminal to Arginine or C-terminal to Lysine and is suitable as these residues are found in the 430-454 region and are exposed (see Fig. 12).

The recombinant polypeptides of the invention are potential therapeutic agents for targeting to cells expressing the relevant substrate but which are not implicated in effecting botulism. An example might be where secretion of neurotransmitter is inappropriate or undesirable or alternatively where a neuronal cell is hyperactive in terms of regulated secretion of substances other than neurotransmitter. In such an example the function of the H_C domain of the native toxin could be replaced by an alternative targeting sequence providing, for example, a cell receptor ligand and/or translocation domain.

One application of the recombinant polypeptides of the invention will be as a reagent component for synthesis of therapeutic molecules, such as disclosed in WO-A-94/21300. The recombinant product will also find application as a non-toxic standard for the assessment and development of *in vitro* assays for detection of functional botulinum or tetanus neurotoxins either in foodstuffs or in environmental samples, for example as disclosed in EP-A-0763131.

A further option is addition, to the C-terminal end of a polypeptide of the invention, of a peptide sequence which allows specific chemical conjugation to targeting ligands of both protein and non-protein origin.

In yet a further embodiment an alternative targeting ligand is added to the N-terminus of polypeptides of the invention. Recombinant LH_N derivatives have been designated that have specific protease cleavage sites engineered at the C-terminus

of the LC at the putative trypsin sensitive region and also at the extreme C-terminus of the complete protein product. These sites will enhance the activational specificity of the recombinant product such that the dichain species can only be activated by proteolytic cleavage of a more predictable nature than use of trypsin.

The LH_N enzymatically produced from native BoNT/A is an efficient immunogen and thus the recombinant form with its total divorce from any full length neurotoxin represents a vaccine component. The recombinant product may serve as a basal reagent for creating defined protein modifications in support of any of the above areas.

Recombinant constructs are assigned distinguishing names on the basis of their amino acid sequence length and their Light Chain (L-chain, L) and Heavy Chain (H-chain, H) content as these relate to translated DNA sequences in the public domain or specifically to SEQ ID NO: 2 and SEQ ID NO: 20. The 'LH' designation is followed by '/X' where 'X' denotes the corresponding clostridial toxin serotype or class, e.g. 'A' for botulinum neurotoxin type A or 'TeTx' for tetanus toxin. Sequence variants from that of the native toxin polypeptide are given in parenthesis in standard format, namely the residue position number prefixed by the residue of the native sequence and suffixed by the residue of the variant.

Subscript number prefixes indicate an amino-terminal (N-terminal) extension, or where negative a deletion, to the translated sequence. Similarly, subscript number suffixes indicate a carboxy terminal (C-terminal) extension or where negative numbers are used, a deletion. Specific sequence inserts such as protease cleavage sites are indicated using abbreviations, e.g. Factor Xa is abbreviated to FXa. L-chain C-terminal suffixes and H-chain N-terminal prefixes are separated by a / to indicate the predicted junction between the L and H-chains. Abbreviations for engineered ligand sequences are prefixed or suffixed to the clostridial L-chain or H-chain corresponding to their position in the translation product.


Following this nomenclature,

		- 13 -
LH ₄₂₃ /A	=	SEQ ID NO: 2, containing the entire L-chain and 423 amino acids of the H-chain of botulinum neurotoxin type A;
₂ LH ₄₂₃ /A	=	a variant of this molecule, containing a two amino acid extension to the N-terminus of the L-chain;
₂ L _{/2} H ₄₂₃ /A	= '	a further variant in which the molecule contains a two amino acid extension on the N-terminus of both the L-chain and the H-chain;
₂ L _{FXa/2} H ₄₂₃ /A	=	a further variant containing a two amino acid extension to the N-terminus of the L-chain, and a Factor Xa cleavage sequence at the C-terminus of the L-chain which, after cleavage of the molecule with Factor Xa leaves a two amino acid N-terminal extension to the H-chain component; and
₂ L _{FXa/2} H ₄₂₃ /A-IGF-1	= .	a variant of this molecule which has a further C-terminal extension to the H-chain, in this example the insulin-like growth factor 1 (IGF-1) sequence.

There now follows description of specific embodiments of the invention, illustrated by drawings in which:

Fig. 1 shows a schematic representation of the domain structure of botulinum neurotoxin type A (BoNT/A);

Fig. 2 shows a schematic representation of assembly of the gene for an embodiment of the invention designated LH_{423}/A ;



- Fig. 4 is a comparison of the first 33 amino acids in published sequences of native toxin and embodiments of the invention;
- Fig. 5 shows the transition region of an embodiment of the invention designated L/₄H₄₂₃/A illustrating insertion of four amino acids at the N-terminus of the H_N sequence; amino acids coded for by the *Eco* 47 III restriction endonuclease cleavage site are marked and the H_N sequence then begins ALN...;
- Fig. 6 shows the transition region of an embodiment of the invention designated $L_{FXa/3}H_{423}/A$ illustrating insertion of a Factor Xa cleavage site at the C-terminus of the L-chain, and three additional amino acids coded for at the N-terminus of the H-sequence; the N-terminal amino acid of the cleavage-activated H_N will be cysteine;
- Fig. 7 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated $L_{FXa/3}H_{423}/A$ -IGF-1, a fusion protein; the IGF-1 sequence begins at position G_{882} ;
- Fig. 8 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated $L_{FXa/3}H_{423}/A$ -CtxA14, a fusion protein; the C-terminal CtxA sequence begins at position Ω_{882} ;
- Fig.9 shows the C-terminal portion of the amino acid sequence of an

embodiment of the invention designated $L_{FXa/3}H_{423}/A-ZZ$, a fusion protein; the C-terminal ZZ sequence begins at position A_{890} immediately after a genenase recognition site (underlined);

show schematic representations of manipulations of

Figs. 10 & 11

polypeptides of the invention; Fig. 10 shows LH₄₂₃/A with N-terminal addition of an affinity purification peptide (in this case GST) and C-terminal addition of an Ig binding domain; protease cleavage sites R1, R2 and R3 enable selective enzymatic separation of domains; Fig. 11 shows specific examples of protease cleavage sites R1, R2 and R3 and a C-terminal fusion peptide sequence;

Fig. 1.2

shows the trypsin sensitive activation region of a polypeptide of the invention;

Fig. 13

shows Western blot analysis of recombinant LH₁₀₇/B expressed from *E.coli*; panel A was probed with anti-BoNT/B antiserum; Lane 1, molecular weight standards; lanes 2 & 3, native BoNT/B; lane 4, immunopurified LH₁₀₇/B; panel B was probed with anti-T7 peptide tag antiserum; lane 1, molecular weight standards; lanes 2 & 3, positive control *E.coli* T7 expression; lane 4 immunopurified LH₁₀₇/B.

The sequence listing that accompanies this application contains the following sequences:-

SEQ ID NO:

Sequence

1

DNA coding for LH₄₂₃/A

2	LH ₄₂₃ /A
3	DNA coding for $_{23}LH_{423}/A$ ($Q_2E,N_{26}K,A_{27}Y$), of which an N-terminal portion is shown in Fig. 4.
4	₂₃ LH ₄₂₃ /A (Q ₂ E,N ₂₆ K,A ₂₇ Y)
5	DNA coding for ₂ LH ₄₂₃ /A (Q ₂ E,N ₂₆ K,A ₂₇ Y), of which an N-
	terminal portion is shown in Fig.4
6	$_{2}LH_{423}/A (Q_{2}E,N_{26}K,A_{27}Y)$
7	DNA coding for native BoNT/A according to Binz et al
8 /	native BoNT/A according to Binz et al
9	DNA coding for L _{/4} H ₄₂₃ /A
10	L _{/4} H ₄₂₃ /A
11	DNA coding for L _{FXa} / ₃ H ₄₂₃ /A
12	L _{FXa} / ₃ H ₄₂₃ /A
13	DNA coding for $L_{FXa}/_3H_{423}/A$ -IGF-1
14	L _{FXa} / ₃ H ₄₂₃ /A-IGF-1
15	DNA coding for L _{FXa} / ₃ H ₄₂₃ /A-CtxA14
16	$L_{FXa}/_3H_{423}/A$ -CtxA14
17	DNA coding for L _{FXa/3} H ₄₂₃ /A-ZZ
18	L _{FXa/3} H ₄₂₃ /A-ZZ
19	DNA coding for LH ₇₂₈ /B
20	LH ₇₂₈ /B
21	DNA coding for LH ₄₁₇ /B
22	LH ₄₁₇ /B
23	DNA coding for LH ₁₀₇ /B
24	LH ₁₀₇ /B
25	DNA coding for LH_{423}/A ($Q_2E,N_{26}K,A_{27}Y$)
26	$LH_{423}/A (Q_2E, N_{26}K, A_{27}Y)$
27	DNA coding for LH ₄₁₇ /B wherein the first 274 bases are

28

modified to have an *E.coli* codon bias

DNA coding for LH₄₁₇/B wherein bases 691-1641 of the native BoNT/B sequence have been replaced by a degenerate DNA coding for amino acid residues 231-547 of the native BoNT/B polypeptide

Example 1

A 2616 base pair, double stranded gene sequence (SEQ ID NO: 1) has been assembled from a combination of synthetic, chromosomal and polymerase-chain-reaction generated DNA (Figure 2). The gene codes for a polypeptide of 871 amino acid residues corresponding to the entire light-chain (LC, 448 amino acids) and 423 residues of the amino terminus of the heavy-chain (H_c) of botulinum neurotoxin type A. This recombinant product is designated the LH₄₂₃/A fragment (SEQ ID NO: 2).

Construction of the recombinant product

The first 918 base pairs of the recombinant gene were synthesised by concatenation of short oligonucleotides to generate a coding sequence with an E. coli codon bias. Both DNA strands in this region were completely synthesised as short overlapping oligonucleotides which were phosphorylated, annealed and ligated to generate the full synthetic region ending with a unique KpnI restriction site. The remainder of the LH_{423}/A coding sequence was PCR amplified from total chromosomal DNA from $Clostridium\ botulinum\$ and annealed to the synthetic portion of the gene.

The internal PCR amplified product sequences were then deleted and replaced with the native, fully sequenced, regions from clones of *C. botulinum* chromosomal origin to generate the final gene construct. The final composition is synthetic DNA (bases 1-913), polymerase amplified DNA (bases 914-1138 and 1976-2616) and the remainder is of *C. botulinum* chromosomal origin (bases 1139-1975). The

assembled gene was then fully sequenced and cloned into a variety of *E.coli* plasmid vectors for expression analysis.

Expression of the recombinant gene and recovery of protein product

The DNA is expressed in *E. coli* as a single nucleic acid transcript producing a soluble single chain polypeptide of 99,951 Daltons predicted molecular weight. The gene is currently expressed in *E. coli* as a fusion to the commercially available coding sequence of glutathione S-transferase (GST) of *Schistosoma japonicum* but any of an extensive range of recombinant gene expression vectors such as pEZZ18, pTrc99, pFLAG or the pMAL series may be equally effective as might expression in other prokaryotic or eukaryotic hosts such as the Gram positive bacilli, the yeast *P. pastoris* or in insect or mammalian cells under appropriate conditions.

Currently, E. coli harbouring the expression construct is grown in Luria-Bertani broth (L-broth pH 7.0, containing 10 g/l bacto-tryptone, 5 g/l bacto-yeast extract and 10 g/l sodium chloride) at 37° C until the cell density (biomass) has an optical absorbance of 0.4- 0.6 at 600 nm and the cells are in mid-logarithmic growth Expression of the gene is then induced by addition isopropylthio- β -D-galactosidase (IPTG) to a final concentration of 0.5 mM. Recombinant gene expression is allowed to proceed for 90 min at a reduced temperature of 25°C. The cells are then harvested by centrifugation, are resuspended in a buffer solution containing 10 mM Na₂HPO₄, 0.5 M NaCl, 10 mM EGTA, 0.25% Tween, pH 7.0 and then frozen at -20°C. For extraction of the recombinant protein the cells are disrupted by sonication. The cell extract is then cleared of debris by centrifugation and the cleared supernatant fluid containing soluble recombinant fusion protein (GST- LH₄₂₃/A) is stored at -20°C pending purification. A proportion of recombinant material is not released by the sonication procedure and this probably reflects insolubility or inclusion body formation. Currently we do not extract this material for analysis but if desired this could be readily achieved using methods known to those skilled in the art.

The recombinant GST- LH_{423}/A is purified by adsorption onto a commercially prepared affinity matrix of glutathione Sepharose and subsequent elution with reduced glutathione. The GST affinity purification marker is then removed by proteolytic cleavage and reabsorption to glutathione Sepharose; recombinant LH_{423}/A is recovered in the non-adsorbed material.

Construct variants

A variant of the molecule, LH_{423}/A ($Q_2E,N_{26}K,A_{27}Y$) (SEQ ID NO: 26) has been produced in which three amino acid residues have been modified within the light chain of LH_{423}/A producing a polypeptide containing a light chain sequence different to that of the published amino acid sequence of the light chain of BoNT/A.

Two further variants of the gene sequence that have been expressed and the corresponding products purified are $_{23}LH_{423}/A$ ($Q_2E,N_{26}K,A_{27}Y$) (SEQ ID NO: 4) which has a 23 amino acid N-terminal extension as compared to the predicted native L-chain of BoNT/A and $_2LH_{423}/A$ ($Q_2E,N_{26}K,A_{27}Y$) (SEQ ID NO: 6) which has a 2 amino acid N-terminal extension (Figure 4).

In yet another variant a gene has been produced which contains a *Eco* 47 III restriction site between nucleotides 1344 and 1345 of the gene sequence given in (SEQ ID NO: 1). This modification provides a restriction site at the position in the gene representing the interface of the heavy and light chains in native neurotoxin, and provides the capability to make insertions at this point using standard restriction enzyme methodologies known to those skilled in the art. It will also be obvious to those skilled in the art that any one of a number of restriction sites could be so employed, and that the *Eco* 47 III insertion simply exemplifies this approach. Similarly, it would be obvious for one skilled in the art that insertion of a restriction site in the manner described could be performed on any gene of the invention. The gene described, when expressed, codes for a polypeptide, L_{/4}H₄₂₃/A (SEQ ID NO: 10), which contains an additional four amino acids between amino acids 448 and 449 of LH₄₂₃/A at a position equivalent to the amino terminus of the

heavy chain of native BoNT/A.

A variant of the gene has been expressed, L_{FXa/3}H₄₂₃/A (SEQ ID NO: 12), in which a specific proteolytic cleavage site was incorporated at the carboxy-terminal end of the light chain domain, specifically after residue 448 of L₇₄H₄₂₃/A. The cleavage site incorporated was for Factor Xa protease and was coded for by modification of SEQ ID NO: 1. It will be apparent to one skilled in the art that a cleavage site for another specified protease could be similarly incorporated, and that any gene sequence coding for the required cleavage site could be employed. Modification of the gene sequence in this manner to code for a defined protease site could be performed on any gene of the invention.

Variants of $L_{FXa/3}H_{423}/A$ have been constructed in which a third domain is present at the carboxy-terminal end of the polypeptide which incorporates a specific binding activity into the polypeptide.

Specific examples described are:

- (1) $L_{FXa/3}H_{423}/A$ -IGF-1 (SEQ ID NO: 14), in which the carboxy-terminal domain has a sequence equivalent to that of insulin-like growth factor-1 (IGF-1) and is able to bind to the insulin-like growth factor receptor with high affinity;
- (2) $L_{FXa/3}H_{423}/A$ -CtxA14 (SEQ ID NO: 16), in which the carboxy-terminal domain has a sequence equivalent to that of the 14 amino acids from the carboxy-terminus of the A-subunit of cholera toxin (CtxA) and is thereby able to interact with the cholera toxin B-subunit pentamer; and
- (3) $L_{\rm FXa/3}H_{423}/A$ -ZZ (SEQ ID NO: 18), in which the carboxy-terminal domain is a tandem repeating synthetic IgG binding domain. This variant also exemplifies another modification applicable to the current invention, namely the inclusion in the gene of a sequence coding for a protease cleavage site located between the end of the clostridial heavy chain sequence and the sequence coding for the binding

- 21 -

ligand. Specifically in this example a sequence is inserted at nucleotides 2650 to 2666 coding for a generase cleavage site. Expression of this gene produces a polypeptide which has the desired protease sensitivity at the interface between the domain providing H_N function and the binding domain. Such a modification enables selective removal of the C-terminal binding domain by treatment of the polypeptide with the relevant protease.

It will be apparent that any one of a number of such binding domains could be incorporated into the polypeptide sequences of this invention and that the above examples are merely to exemplify the concept. Similarly, such binding domains can be incorporated into any of the polypeptide sequences that are the basis of this invention. Further, it should be noted that such binding domains could be incorporated at any appropriate location within the polypeptide molecules of the invention.

Further embodiments of the invention are thus illustrated by a DNA of the invention further comprising a desired restriction endonuclease site at a desired location and by a polypeptide of the invention further comprising a desired protease cleavage site at a desired location.

The restriction endonuclease site may be introduced so as to facilitate further manipulation of the DNA in manufacture of an expression vector for expressing a polypeptide of the invention; it may be introduced as a consequence of a previous step in manufacture of the DNA; it may be introduced by way of modification by insertion, substitution or deletion of a known sequence. The consequence of modification of the DNA may be that the amino acid sequence is unchanged, or may be that the amino acid sequence is changed, for example resulting in introduction of a desired protease cleavage site, either way the polypeptide retains its first and second domains having the properties required by the invention.

Figure 10 is a diagrammatic representation of an expression product exemplifying features described in this example. Specifically, it illustrates a single polypeptide

incorporating a domain equivalent to the light chain of botulinum neurotoxin type A and a domain equivalent to the H_N domain of the heavy chain of botulinum neurotoxin type A with a N-terminal extension providing an affinity purification domain, namely GST, and a C-terminal extension providing a ligand binding domain, namely an IgG binding domain. The domains of the polypeptide are spatially separated by specific protease cleavage sites enabling selective enzymatic separation of domains as exemplified in the Figure. This concept is more specifically depicted in Figure 11 where the various protease sensitivities are defined for the purpose of example.

Assay of product activity

The LC of botulinum neurotoxin type A exerts a zinc-dependent endopeptidase activity on the synaptic vesicle associated protein SNAP-25 which it cleaves in a specific manner at a single peptide bond. The $_2LH_{423}/A$ ($Q_2E,N_{26}K,A_{27}Y$) (SEQ ID NO: 6) cleaves a synthetic SNAP-25 substrate *in vitro* under the same conditions as the native toxin (Figure 3). Thus, the modification of the polypeptide sequence of $_2LH_{423}/A$ ($Q_2E,N_{26}K,A_{27}Y$) relative to the native sequence and within the minimal functional LC domains does not prevent the functional activity of the LC domains.

This activity is dependent on proteolytic modification of the recombinant GST- $_2$ LH $_{423}$ /A (Q_2 E, N_{26} K, A_{27} Y) to convert the single chain polypeptide product to a disulphide linked dichain species. This is currently done using the proteolytic enzyme trypsin. The recombinant product (100-600 μ g/ml) is incubated at 37°C for 10-50 minutes with trypsin (10 μ g/ml) in a solution containing 140 mM NaCl, 2.7 mM KCl, 10 mM Na $_2$ HPO $_4$, 1.8 mM KH $_2$ PO $_4$, pH 7.3. The reaction is terminated by addition of a 100-fold molar excess of trypsin inhibitor. The activation by trypsin generates a disulphide linked dichain species as determined by polyacrylamide gel electrophoresis and immunoblotting analysis using polyclonal anti-botulinum neurotoxin type A antiserum.

₂LH₄₂₃/A is more stable in the presence of trypsin and more active in the in vitro

peptide cleavage assay than is 23LH₄₂₃/A. Both variants, however, are fully functional in the *in vitro* peptide cleavage assay. This demonstrates that the recombinant molecule will tolerate N-terminal amino acid extensions and this may be expanded to other chemical or organic moieties as would be obvious to those skilled in the art.

Example 2

As a further exemplification of this invention a number of gene sequences have been assembled coding for polypeptides corresponding to the entire light-chain and varying numbers of residues from the amino terminal end of the heavy chain of botulinum neurotoxin type B. In this exemplification of the disclosure the gene sequences assembled were obtained from a combination of chromosomal and polymerase-chain-reaction generated DNA, and therefore have the nucleotide sequence of the equivalent regions of the natural genes, thus exemplifying the principle that the substance of this disclosure can be based upon natural as well as a synthetic gene sequences.

The gene sequences relating to this example were all assembled and expressed using methodologies as detailed in Sambrook J, Fritsch E F & Maniatis T (1989) Molecular Cloning: A Laboratory Manual (2nd Edition), Ford N, Nolan C, Ferguson M & Ockler M (eds), Cold Spring Harbor Laboratory Press, New York, and known to those skilled in the art.

A gene has been assembled coding for a polypeptide of 1171 amino acids corresponding to the entire light-chain (443 amino acids) and 728 residues from the amino terminus of the heavy chain of neurotoxin type B. Expression of this gene produces a polypeptide, LH₇₂₈/B (SEQ ID NO: 20), which lacks the specific neuronal binding activity of full length BoNT/B.

A gene has also been assembled coding for a variant polypeptide, LH_{417}/B (SEQ ID NO: 22), which possesses an amino acid sequence at its carboxy terminus

equivalent by amino acid homology to that at the carboxy-terminus of the heavy chain fragment in native LH_{N}/A .

A gene has also been assembled coding for a variant polypeptide, LH_{107}/B (SEQ ID NO: 24), which expresses at its carboxy-terminus a short sequence from the amino terminus of the heavy chain of BoNT/B sufficient to maintain solubility of the expressed polypeptide.

Construct Variants

A variant of the coding sequence for the first 274 bases of the gene shown in SEQ ID NO: 21 has been produced which whilst being a non-native nucleotide sequence still codes for the native polypeptide.

Two double stranded, a 268 base pair and a 951 base pair, gene sequences have been created using an overlapping primer PCR strategy. The nucleotide bias of these sequences was designed to have an *E.coli* codon usage bias.

For the first sequence, six oligonucleotides representing the first (5') 268 nucleotides of the native sequence for botulinum toxin type B were synthesised. For the second sequence 23 oligonucleotides representing internal sequence nucleotides 691-1641 of the native sequence for botulinum toxin type B were synthesised. The oligonucleotides ranged from 57-73 nucleotides in length. Overlapping regions, 17-20 nucleotides, were designed to give melting temperatures in the range 52-56°C. In addition, terminal restriction endonuclease sites of the synthetic products were constructed to facilitate insertion of these products into the exact corresponding region of the native sequence. The 268 bp 5' synthetic sequence has been incorporated into the gene shown in SEQ ID NO: 21 in place of the original first 268 bases (and is shown in SEQ ID NO: 27). Similarly the sequence could be inserted into other genes of the examples.

Another variant sequence equivalent to nucleotides 691 to 1641 of SEQ ID NO: 21

, and employing non-native codon usage whilst coding for a native polypeptide sequence, has been constructed using the internal synthetic sequence. This sequence (SEQ ID NO: 28) can be incorporated, alone or in combination with other variant sequences, in place of the equivalent coding sequence in any of the genes of the example.

Example 3

An exemplification of the utility of this invention is as a non-toxic and effective immunogen. The non-toxic nature of the recombinant, single chain material was demonstrated by intraperitoneal administration in mice of GST-₂LH₄₂₃/A. The polypeptide was prepared and purified as described above. The amount of immunoreactive material in the final preparation was determined by enzyme linked immunosorbent assay (ELISA) using a monoclonal antibody (BA11) reactive against a conformation dependent epitope on the native LH_N/A. The recombinant material was serially diluted in phosphate buffered saline (PBS; NaCl 8 g/l, KCl 0.2 g/l, Na₂HPO₄ 1.15 g/l, KH₂PO₄ 0.2 g/l, pH 7.4) and 0.5 ml volumes injected into 3 groups of 4 mice such that each group of mice received 10, 5 and 1 micrograms of material respectively. Mice were observed for 4 days and no deaths were seen.

For immunisation, 20 μ g of GST-₂LH₄₂₃/A in a 1.0 ml volume of water-in-oil emulsion (1:1 vol:vol) using Freund's complete (primary injections only) or Freund's incomplete adjuvant was administered into guinea pigs via two sub-cutaneous dorsal injections. Three injections at 10 day intervals were given (day 1, day 10 and day 20) and antiserum collected on day 30. The antisera were shown by ELISA to be immunoreactive against native botulinum neurotoxin type A and to its derivative LH_N/A. Antisera which were botulinum neurotoxin reactive at a dilution of 1:2000 were used for evaluation of neutralising efficacy in mice. For neutralisation assays 0.1 ml of antiserum was diluted into 2.5 ml of gelatine phosphate buffer (GPB; Na₂HPO₄ anhydrous 10 g/l, gelatin (Difco) 2 g/l, pH 6.5-6.6) containing a dilution range from 0.5 μ g (5X10-6 g) to 5 picograms (5X10-12 g). Aliquots of 0.5 ml were injected into mice intraperitoneally and deaths recorded



over a 4 day period. The results are shown in Table 1 and Table 2. It can clearly be seen that 0.5 ml of 1:40 diluted anti- $GST_{-2}LH_{423}/A$ antiserum can protect mice against intraperitoneal challenge with botulinum neurotoxin in the range 5 pg - 50 ng (1 - 10,000 mouse LD50; 1 mouse LD50 = 5 pg).

TABLE 1. Neutralisation of botulinum neurotoxin in mice by guinea pig anti-GST-2LH₄₂₃/A antiserum.

Botulinum Toxin/mouse

Survivors On Day	0.5 µ g	0.005µg	0.0005 µ g	0.5ng	0.005ng	5pg	Control (no toxin)
1	0	4	4	4	4	4	. 4
2	-	4	4	4	4	4	4
3	• •	4	4	4	4	4	4
4	•	4	4	4	4	4	

TABLE 2. Neutralisation of botulinum neurotoxin in mice by non-immune guinea pig antiserum.

Botulinum Toxin/mouse

Survivors On Day	0.5µg	0.005 µ g	0.0005 µ g	0.5ng	0.0 05n g	5pg	Control (no toxin)
. 1	0	0 -	0	0	0	2	4
2	- '	•	-	•	•	0	4
3	-		•	•	•	•	4
4	•		•		•	•	4

Example 4

Expression of recombinant LH₁₀₇/B in E. coli.

As an exemplification of the expression of a nucleic acid coding for a LH_N of a clostridial neurotoxin of a serotype other than botulinum neurotoxin type A, the nucleic acid sequence (SEQ ID NO: 23) coding for the polypeptide LH_{107}/B (SEQ ID

NO: 24) was inserted into the commercially available plasmid pET28a (Novogen, Madison, WI, USA). The nucleic acid was expressed in *E. coli* BL21 (DE3) (New England BioLabs, Beverley, MA, USA) as a fusion protein with a N-terminal T7 fusion peptide, under IPTG induction at 1 mM for 90 minutes at 37°C. Cultures were harvested and recombinant protein extracted as described previously for LH_{423}/A .

Recombinant protein was recovered and purified from bacterial paste lysates by immunoaffinity adsorption to an immobilised anti-T7 peptide monoclonal antibody using a T7 tag purification kit (New England bioLabs, Beverley, MA, USA). Purified recombinant protein was analysed by gradient (4-20%) denaturing SDS-polyacrylamide gel electrophoresis (Novex, San Diego, CA, USA) and western blotting using polyclonal anti-botulinum neurotoxin type antiserum or anti-T7 antiserum. Western blotting reagents were from Novex, immunostained proteins were visualised using the Enhanced Chemi-Luminescence system (ECL) from Amersham. The expression of an anti-T7 antibody and anti-botulinum neurotoxin type B antiserum reactive recombinant product is demonstrated in Figure 13.

The recombinant product was soluble and retained that part of the light chain responsible for endopeptidase activity.

The invention thus provides recombinant polypeptides useful inter alia as immunogens, enzyme standards and components for synthesis of molecules as described in WO-A-94/21300.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT:
 - (A) NAME: MICROBIOLOGICAL RESEARCH AUTHORITY
 - (B) STREET: Centre For Applied Microbiology And Research, Porton Down
 - (C) CITY: Salisbury
 - (D) STATE: Wiltshire
 - (E) COUNTRY: UK
 - (F) POSTAL CODE (ZIP): SP4 0JG
 - (A) NAME: THE SPEYWOOD LABORATORY LIMITED
 - (B) STREET: 14 Kensington Square
 - (C) CITY: London
 - (E) COUNTRY: UK
 - (F) POSTAL CODE (ZIP): W8 5HH
 - (A) NAME: FOSTER; Keith Alan
 - (B) STREET: Centre For Applied Microbiology And Research, Porton Down
 - (C) CITY: Salisbury
 - (D) STATE: Wiltshire
 - (E) COUNTRY: UK
 - (F) POSTAL CODE (ZIP): SP4 0JG
 - (A) NAME: QUINN; Conrad Padraig
 - (B) STREET: Centre For Applied Microbiology And Research. Porton Down
 - (C) CITY: Salisbury
 - (D) STATE: Wiltshire
 - (E) COUNTRY: UK
 - (F) POSTAL CODE (ZIP): SP4 0JG
 - (A) NAME: SHONE; Clifford Charles
 - (B) STREET: Centre For Applied Microbiology And Research, Porton Down
 - (C) CITY: Salisbury
 - (D) STATE: Wiltshire
 - (E) COUNTRY: UK
 - (F) POSTAL CODE (ZIP): SP4 0JG
- (ii) TITLE OF INVENTION: Recombinant Toxin Fragments
- (iii) NUMBER OF SEQUENCES: 28
- (iv) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk

 - (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- (2) INFORMATION FOR SEQ ID NO: 1:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2616 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION:1..2616

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATG Met 1	CAG Gln	TTC Phe	GTG Val	AAC Asn 5	AAG Lys	CAG Gln	TTC Phe	AAC Asn	TAT Tyr 10	AAG Lys	GAC Asp	CCT Pro	GTA Val	AAC Asn 15	GGT Gly	48
								CCA Pro 25								96
								AAA Lys								144
								GGA Gly								192
								TAC Tyr								240
								AAG Lys								288
								CGT Arg 105								336
								AGT Ser								384
								GTG Val								432
								ATC Ile								480
								GGC								528
								TAC Tyr 185								576
ACG Thr	TTC Phe	GGT Gly 195	TTC Phe	GAG Glu	GAG Glu	AGC Ser	CTG Leu 200	GAG Glu	GTT Val	GAT Asp	ACC Thr	AAC Asn 205	CCG Pro	CTG Leu	TTG Leu	624
GGT Gly	GCA Ala 210	GGC Gly	AAG Lys	TTC Phe	GCA Ala	ACT Thr 215	GAT Asp	CCA Pro	GCG Ala	GTG Val	ACC Thr 220	CTG Leu	GCA Ala	CAC His	GAG Glu	672
CTG Leu 225	Ile	CAC His	GCC Ala	GGT Gly	CAT His 230	CGT Arg	CTG Leu	TAT Tyr	GGC Gly	ATT Ile 235	GCG Ala	ATT Ile	AAC Asn	CCG Pro	AAC Asn 240	720

				•			•			٠.	-					
CGC	GTG Val	TTC Phe	AAG Lys	GTT Val 245	Asn	ACC Thr	AAC Asn	GCC Ala	TAC Tyr 250	Tyr	GAG Glu	ATG Met	AGT Ser	GGT Gly 255	TTA Leu	768
GAA Glu	GTA Val	AGC Ser	Phe 260	Glu	GAA Glu	CTG	CGC Arg	ACG Thr 265	Phe	GGT Gly	GGC Gly	CAT	GAT Asp 270	Ala	AA G Lys	816
TTT Phe	ATC Ile	GAC Asp 275	AGC Ser	TTG Leu	CAG Gln	GAG Glu	AAC Asn 280	GAG Glu	TTC Phe	CGT Arg	CTG Leu	TAC Tyr 285	TAC	TAC	AAC Asn	864
AAG Lys	TTT Phe 290	Lys	GAT Asp	ATT Ile	GCA Ala	AGT Ser 295	ACA Thr	CTG Leu	AAC Asn	AAG Lys	GCT Ala 300	Lys	TCC Ser	ATT Ile	GTG Val	912
GGT Gly 305	Thr	ACT	GCT Ala	TCA Ser	TTA Leu 310	CAG Gln	TAT Tyr	ATG Met	AAA Lys	AAT Asn 315	GTT Val	TTT Phe	AAA Lys	GAG Glu	AAA Lys 320	960
TAT	CTC Leu	CTA Leu	TCT Ser	GAA Glu 325	GAT Asp	ACA Thr	TCT Ser	GGA Gly	AAA Lys 330	TTT Phe	TCG Ser	GTA Val	GAT Asp	AAA Lys 33.5	TTA Leu	1008
AAA Lys	TTT	GAT Asp	AAG Lys 340	Leu	TAC Tyr	AAA Lys	ATG Met	TTA Leu 345	ACA Thr	GAG Glu	ATT Ile	TAC Tyr	ACA Thr 350	GAG Glu	GAT Asp	1056
AAT Asn	TTT Phe	GTT Val 355	AAG Lys	TTT Phe	TTT Phe	AAA Lys	GTA Val 360	CTT Leu	AAC Asn	AGA Arg	AAA Lys	ACA Thr 365	TAT Tyr	TTG Leu	AAT Asn	1104
TTT	GAT Asp 370	AAA Lys	GCC Ala	GTA Val	TTT Phe	AAG Lys 375	ATA Ile	AAT Asn	ATA Ile	GTA Val	CCT Pro 380	AAG Lys	GTA Val	AAT Asn	TAC	1152
ACA Thr 385	ATA Ile	TAT Tyr	GAT Asp	GGA Gly	TTT Phe 390	AAT Asn	TTA Leu	AGA Arg	AAT Asn	ACA Thr 395	AAT Asn	TTA Leu	GCA Ala	GCA Ala	AAC Asn 400	1200
TTT Phe	AAT Asn	GGT Gly	CAA Gln	AAT Asn 405	ACA Thr	GAA Glu	ATT Ile	AAT Asn	AAT Asn 410	ATG Met	AAT Asn	TTT Phe	ACT Thr	AAA Lys 415	CTA Leu	1248
AAA Lys	AAT Asn	TTT Phe	ACT Thr 420	GGA Gly	TTG Leu	TTT Phe	GAA Glu	TTT Phe 425	TAT Tyr	AAG Lys	TTG Leu	CTA Leu	TGT Cys 430	GTA Val	AGA Arg	1296
GGG Gly	ATA Ile	ATA Ile 435	ACT Thr	TCT Ser	AAA Lys	ACT Thr	AAA Lys 440	TCA Ser	TTA Leu	GAT Asp	AAA Lys	GGA Gly 445	TAC Tyr	AAT Asn	AAG Lys	1344
GCA Ala	TTA Leu 450	AAT Asn	GAT Asp	TTA Leu	TGT Cys	ATC Ile 455	AAA Lys	GTT Val	AAT Asn	AAT Asn	TGG Trp 460	GAC Asp	TTG Leu	TTT Phe	TTT Phe	1392
			GAA Glu													1440
ATT Ile	ACA Thr	TCT Ser	GAT Asp	ACT Thr 485	AAT Asn	ATA Ile	GAA Glu	GCA Ala	GCA Ala 490	GAA Glu	GAA Glu	AAT Asn	ATT Ile	AGT Ser 495	TTA Leu	1488
GAT Asp	TTA Leu	ATA Ile	CAA Gln 500	CAA Gln	TAT Tyr	TAT Tyr	Leu	ACC Thr 505	TTT Phe	AAT Asn	TTT Phe	GAT Asp	AAT Asn 510	GAA Glu	CCT Pro	1536

									-	32	-					•
GAA Glu	AAT Asn	ATT Ile 515	TCA Ser	ATA Ile	GAA Glu	AAT Asn	CTT Leu 520	TCA Ser	AGT Ser	GAC Asp	ATT Ile	ATA Ile 525	GGC Gly	CAA Gln	TTA Leu	1584
			CCT Pro													1632
TTA Leu 545	GAT Asp	AAA Lys	TAT Tyr	ACT Thr	ATG Met 550	TTC Phe	CAT His	TAT Tyr	CTT Leu	CGT Arg 555	GCT Ala	CAA Gln	GAA Glu	TTT Phe	GAA Glu 560	1680
CAT His	GGT Gly	AAA Lys	TCT Ser	AGG Arg 565	ATT	GCT Ala	TTA Leu	ACA Thr	AAT Asn 570	TCT Ser	GTT Val	AAC Asn	GAA Glu	GCA Ala 575	TTA Leu	1728
TTA Leu	AAT Asn	CCT Pro	AGT Ser 580	CGT Arg	GTT Val	TAT Tyr	ACA Thr	TTT Phe 585	TTT Phe	TCT Ser	TCA Ser	GAC Asp	TAT Tyr 590	GTA Val	AAG Lys	1776
AAA Lys	GTT Val	AAT Asn 595	AAA Lys	GCT Ala	ACG Thr	GAG Glu	GCA Ala 600	GCT Ala	ATG Met	TTT Phe	TTA Leu	GGC Gly 605	TGG Trp	GTA Val	GAA Glu	1824
CAA Gln	TTA Leu 610	GTA Val	TAT Tyr	GAT Asp	TTT Phe	ACC Thr 615	GAT Asp	GAA Glu	ACT Thr	AGC Ser	GAA Glu 620	GTA Val	AGT Ser	ACT Thr	ACG Thr	1872
GAT Asp 625	AAA Lys	ATT Ile	GCG Ala	GAT Asp	ATA Ile 630	ACT Thr	ATA Ile	ATT Ile	ATT Ile	CCA Pro 635	TAT Tyr	ATA Ile	GGA Gly	CCT Pro	GCT Ala 640	1920
TTA Leu	AAT Asn	ATA Ile	GGT Gly	AAT Asn 645	ATG Met	TTA Leu	TAT Tyr	AAA Lys	GAT Asp 650	GAT Asp	TTT Phe	GTA Val	GGT Gly	GCT Ala 655	TTA Leu	1968
ATA Ile	TTT Phe	TCA Ser	GGA Gly 660	GCT Ala	GTT Val	ATT Ile	CTG Leu	TTA Leu 665	GAA Glu	TTT Phe	ATA Ile	CCA Pro	GAG Glu 670	ATT Ile	GCA Ala	2016
ATA Ile	CCT Pro	GTA Val 675	TTA Leu	GGT Gly	ACT Thr	TTT Phe	GCA Ala 680	CTT Leu	GTA Val	TCA Ser	TAT Tyr	ATT Ile 685	GCG Ala	AAT Asn	AAG Lys	2064
GTT Val	CTA Leu 690	ACC Thr	GTT Val	CAA Gln	ACA Thr	ATA Ile 695	GAT Asp	AAT Asn	GCT Ala	TTA Leu	AGT Ser 700	AAA Lys	AGA Arg	AAT Asn	GAA Glu	2112
AAA Lys 705	Trp	GAT Asp	GAG Glu	GTC Val	TAT Tyr 710	AAA Lys	TAT Tyr	ATA Ile	GTA Val	ACA Thr 715	AAT Asn	TGG Trp	TTA Leu	GCA Ala	AAG Lys 720	2160
Val	Asn	Thr	CAG Gln	Ile 725	Asp	Leu	Ile	Arg	Lys 730	Lys	Met	Lys	Glu	Ala 735	Leu	2208
GAA Glu	AAT Asn	CAA Gln	GCA Ala 740	GAA Glu	GCA Ala	ACA Thr	AAG Lys	GCT Ala 745	Ile	ATA Ile	AAC Asn	TAT Tyr	CAG Gln 750	TAT	AAT Asn	2256
CAA Gln	TAT Tyr	ACT Thr 755	GAG Glu	GAA Glu	GAG Glu	AAA Lys	AAT Asn 760	Asn	ATT Ile	AAT Asn	TTT Phe	AAT Asn 765	Ile	GAT Asp	GAT Asp	2304
TTA Leu	AGT Ser 770	Ser	AAA Lys	CTT Leu	AAT Asn	GAG Glu 775	TCT	ATA Ile	AAT Asn	AAA Lys	GCT Ala 780	Met	ATT	AAT Asn	ATA Ile	2352

														_			
	AAT Asn 785	AAA Lys	TTT Phe	TTG Leu	AAT Asn	CAA Gln 790	TGC Cys	TCT Ser	GTT Val	TCA Ser	TAT Tyr 795	TTA Leu	ATG Met	AAT Asn	TCT Ser	ATG Met 800	2400
	ATC Ile	CCT Pro	TAT Tyr	GGT Gly	GTT Val 805	AAA Lys	CGG Arg	TTA Leu	GAA Glu	GAT Asp 810	TTT Phe	GAT Asp	GCT Ala	AGT Ser	CTT Leu 815	AAA Lys	2448
	GAT Asp	GCA Ala	TTA Leu	TTA Leu 820	AAG Lys	TAT Tyr	ATA Ile	TAT Tyr	GAT Asp 825	AAT Asn	AGA Arg	GGA Gly	ACT Thr	TTA Leu 830	ATT Ile	GGT Gly	2496
(CAA Gln	GTA Val	GAT Asp 835	AGA Arg	TTA Leu	AAA Lys	GAT Asp	AAA Lys 840	GTT Val	AAT Asn	AAT Asn	ACA Thr	CTT Leu 845	AGT Ser	ACA Thr	GAT. Asp	2544
	ATA Ile	CCT Pro 850	TTT Phe	CAG Gln	CTT Leu	TCC Ser	AAA Lys 855	TAC Tyr	GTA Val	GAT Asp	AAT Asn	CAA Gln 860	AGA Arg	TTA Leu	TTA Leu	TCT Ser	2592
•					TAT Tyr			TAA		·					,		2616

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 872 amino acids

 - (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val

Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys .120

Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr

Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 150

Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170



Arg	Asn	Gly	Tyr 180	Gly	Ser	Thr	Gln	Tyr 185	Ile	Arg	Phe	Ser	Pro 190	Asp	Phe
Thr	Phe	Gly 195	Phe	Glu	Glu	Ser	Leu 200	Glu	Val	Asp	Thr	Asn 205	Pro	Leu	Leu
Gly	Ala 210	Gly	Lys	Phe	Ala	Thr 215	Asp	Pro	Ala	Val	Thr 220	Leu	Ala	His	Ġlu
Leu 225	Ile	His	Ala	Gly	His 230	Arg	Leu	Tyr	Gly	Ile 235	Ala	Ile	Asn	Pro	Asn 240
Arg	Val	Phe	Lys	Val 245	Asn	Thr	Asn	Ala	Tyr 250	Tyr	Glu	Met	Ser	Gly 255	Leu
Glu	Val	Ser	Phe 260	Glu	Glu	Leu	Arg	Thr 265	Phe	Gly	Gly	His	Asp 270	Ala	Lys
Phe	Ile	Asp 275	Ser	Leu	Gln	Glu	Asn 280	Glu	Phe	Arg	Leu	Tyr 285	Tyr	Tyr	Asn
Lys	Phe 290	Lys	Asp	Ile	Ala	Ser 295	Thr	Leu	Asn	Lys	Ala 300	Lys	Ser	Ile	Val
Gly 305	Thr	Thr	Ala	Ser	Leu 310	Gln	Tyr	Met	Lys	Asn 315	Val	Phe	Lys	Glu	Lys 320
Tyr	Leu	Leu	Ser	Glu 325	Asp	Thr	Ser	Gly	Lys 330	Phe	Ser	Val	Asp	Lys 335	Leu
Lys	Phe	Asp	Lys 340	Leu	Tyr	Lys	Met	Leu 345	Thr	Glu	Ile	Tyr	Thr 350	Glu	Asp
Asn	Phe	Val 355	Lys	Phe	Phe	Lys	Val 360	Leu	Asn	Arg	Lys	Thr 365	Tyr	Leu	Asn
Phe	Asp 370	Lys	Ala	Val	Phe	Lys 375	Ile	Asn	Ile	Val	Pro 380	Lys	Val	Asn	Tyr
Thr 385	Ile	Tyr	Asp	Gly	Phe 390	Asn	Leu	Arg	Asn	Thr 395	Asn	Leu	Ala		Asn .400
Phe	Asn	Gly	Gln	Asn 405	Thr	Glu	Ile	Asn	Asn 410	Met	Asn	Phe	Thr	Lys 415	Leu
Lys	Asn	Phe	Thr 420	Gly	Leu	Phe	Glu	Phe 425	Tyr	Lys	Leu	Leu	Cys 430	Val	Arg
Gly	Ile	Ile 435	Thr	Ser	Lys	Thr	Lys 440	Ser	Leu	Asp	Lys	Gly 445	Tyr	Asn	Lys
	450					455					460				Phe
Ser 465	Pro	Ser	Glu	Asp	Asn 470	Phe	Thr	Asn	Asp	Leu 475	Asn	Lys	Gly	Glu	Glu 480
Ile	Thr	Ser	Asp	Thr 485	Asn	Ile	Glu	Ala	Ala 490		Glu	Asn	Ile	Ser 495	Leu
Asp	Leu	Ile	Gln 500	Gln	Tyr	Tyr	Leu	Thr 505		Asn	Phe	Asp	Asn 510	Glu	Pro
Glu	Asn	Ile 515	Ser	Ile	Glu	Asn	Leu 520	Ser	Ser	Asp	Ile	Ile 525	Gly	Gln	Leu

Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 535 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Cly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 570 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala 635 Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys

(2) INFORMATION FOR SEQ ID NO: 3:

WO 98/07864 PCT/GB97/02273 - 36 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2685 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..2685
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GGA Gly 1	TCC Ser	CCA Pro	GGA Gly	ATT Ile 5	CAT His	ATG Met	ACG Thr	TCG Ser	ACG Thr 10	CGT Arg	CTG Leu	CAG Gln	AAG Lys	CTT Leu 15	CTA Leu		48
GAA Glu	TTC Phe	GAG Glu	CTC Leu 20	CCG Pro	GGT Gly	ACC Thr	ATG Met	GAG Glu 25	TTC Phe	GTG Val	AAC Asn	AAG Lys	CAG Gln 30	TTC Phe	AAC Asn	•	96
TAT Tyr	AAG Lys	GAC Asp 35	CCT Pro	GTA Val	AAC Asn	GGT Gly	GTT Val 40	GAC Asp	ATT Ile	GCC Ala	TAC	ATC Ile 45	AAA Lys	ATT Ile	CCA Pro	1	44
AAG Lys	TAC Tyr 50	GGC Gly	CAG Gln	ATG Met	CAG Gln	CCG Pro 55	GTG Val	AAG Lys	GCT Ala	TTC Phe	AAG Lys 60	ATT Ile	CAT His	AAC Asn	AAA Lys	1	92
ATC Ile 65	TGG Trp	GTT Val	ATT Ile	CCG Pro	GAA Glu 70	CGC Arg	GAT Asp	ACA Thr	TTT Phe	ACG Thr 75	AAC Asn	CCG Pro	GAA Glu	GAA Glu	GGA Gly 80	2	40
GAC Asp	TTG Leu	AAC Asn	CCG Pro	CCG Pro 85	CCG Pro	GAA Glu	GCA Ala	AAG Lys	CAG Gln 90	GTG Val	CCA Pro	GTT Val	TCA Ser	TAC Tyr 95	TAC Tyr	2	88
GAT Asp	TCA Ser	ACC Thr	TAT Tyr 100	CTG Leu	AGC Ser	ACA Thr	GAC Asp	AAC Asn 105	GAG Glu	AAG Lys	GAT Asp	AAC Asn	TAC Tyr 110	CTG Leu	AAG Lys	3	36
GGA Gly	GTG Val	ACC Thr 115	AAA Lys	TTA Leu	TTC Phe	GAG Glu	CGT Arg 120	ATT Ile	TAT Tyr	TCC Ser	ACT Thr	GAC Asp 125	CTG Leu	GGC Gly	CGT Arg	3	84
ATG Met	CTG Leu 130	CTG Leu	ACC Thr	TCA Ser	ATC Ile	GTC Val 135	CGC Arg	GGA Gly	ATC Ile	CCA Pro	TTT Phe 140	TGG Trp	GGT Gly	GGC Gly	AGT Ser	4	32
ACC Thr 145	ATT	GAC Asp	ACG Thr	GAG Glu	TTG Leu 150	AAG Lys	GTT Val	ATT	GAC Asp	ACT Thr 155	AAC Asn	TGC Cys	ATT Ile	AAC Asn	GTG Val 160	4	80
			GAC Asp										Leu			. 5	28
			TCC Ser 180													5	76
			TTG Leu													6	24

						,	•										
					GAC Asp												672
					CTG Leu 230												720
					CAC His												768
					CCG Pro												816
					GGT Gly												864
					GCG Ala												912
					TAC Tyr 310												960
					ATT												1008
					GAG Glu												1056
					AAA Lys												1104
					GAG Glu												1152
Asn	Arg	Lys	Thr	Tyr	TTG Leu 390	Asn	Phe	Asp	Lys	Ala	Val	Phe	Lys	Ile	Asn		1200
					AAT Asn												1248
AAT Asn	ACA Thr	AAT Asn	TTA Leu 420	GCA Ala	GCA Ala	AAC Asn	TTT Phe	AAT Asn 425	GGT Gly	CAA Gln	AAT Asn	ACA Thr	GAA Glu 430	ATT Ile	AAT Asn	•	1296
			Phe		AAA Lys												1344
Tyr	AAG Lys 450	TTG Leu	CTA Leu	TGT Cys	GTA Val	AGA Arg 4 5 5	GGG Gly	ATA Ile	ATA Ile	ACT Thr	TCT Ser 460	AAA Lys	ACT Thr	AAA Lys	TCA Ser		1392
					AAT Asn 470								Ile				1440

	-											•					
AAT Asn	AAT Asn	TGG	GAC Asp	TTG Leu 485	Pne	TTT Phe	AGT Ser	CCT	TCA Ser 490	Glu	GAT Asp	AAT Asn	TTT Phe	ACT Thr 495	AAT Asn		1488
GAT Asp	CTA Leu	AAT Asn	AAA Lys 500	GGA Gly	GAA Glu	GAA Glu	ATT Ile	ACA Thr 505	TCT	GAT Asp	ACT Thr	AAT Asn	ATA Ile 510	GAA Glu	GCA Ala		1536
GCA Ala	GAA Glu	GAA Glu 515	AAT Asn	ATT Ile	AGT Ser	TTA Leu	GAT Asp 520	TTA Leu	ATA Ile	CAA Gln	CAA Gln	TAT Tyr 525	TAT Tyr	TTA Leu	ACC Thr		1584
TTT Phe	AAT Asn 530	TTT Phe	GAT Asp	AAT Asn	GAA Glu	CCT Pro 535	GAA Glu	AAT Asn	ATT Ile	TCA Ser	ATA Ile 540	GAA Glu	AAT Asn	CTT Leu	TCA Ser		1632
AGT Ser 545	GAC Asp	ATT Ile	ATA Ile	GGC Gly	CAA Gln 550	TTA Leu	GAA Glu	CTT Leu	ATG Met	CCT Pro 555	AAT Asn	ATA Ile	GAA Glu	AGA Arg	TTT Phe 560		1680
CCT Pro	AAT Asn	GGA Gly	AAA Lys	AAG Lys 565	TAT Tyr	GAG Glu	TTA Leu	GAT Asp	AAA Lys 570	TAT Tyr	ACT Thr	ATG Met	TTC Phe	CAT His 575	TAT Tyr		1728
CTT Leu	CGT Arg	GCT Ala	CAA Gìn 580	GAA Glu	TTT Phe	GAA Glu	CAT His	GGT Gly 585	AAA Lys	TCT Ser	AGG Arg	ATT Ile	GCT Ala 590	TTA Leu	ACA Thr	,	1776
AAT Asn	TCT Ser	GTT Val 595	AAC Asn	GAA Glu	GCA Ala	TTA Leu	TTA Leu 600	AAT Asn	CCT	AGT Ser	CGT Arg	GTT Val 605	TAT Tyr	ACA Thr	TTT Phe		1824
TTT Phe	TCT Ser 610	TCA Ser	GAC Asp	TAT Tyr	GTA Val	AAG Lys 615	AAA Lys	GTT Val	AAT Asn	AAA Lys	GCT Ala 620	ACG Thr	GAG Glu	GCA Ala	GCT Ala		1872
ATG Met 625	TTT Phe	TTA Leu	GGC Gly	TGG Trp	GTA Val 630	GAA Glu	CAA Gln	TTA Leu	GTA Val	TAT Tyr 635	GAT Asp	TTT Phe	ACC Thr	GAT Asp	GAA Glu 640		1920
ACT Thr	AGC Ser	GAA Glu	GTA Val	AGT Ser 645	ACT Thr	ACG Thr	GAT Asp	AAA Lys	ATT Ile 650	GCG Ala	GAT Asp	ATA Ile	ACT Thr	ATA Ile 655	ATT Ile		1968
ATT Ile	CCA Pro	TAT Tyr	Ile	Gly	Pro	Ala	Leu	AAT Asn 665	Ile	Gly	AAT Asn	ATG Met	TTA Leu 670	TAT Tyr	AAA Lys		2016
GAT Asp	GAT Asp	TTT Phe 675	GTA Val	GGT Gly	GCT Ala	TTA Leu	ATA Ile 680	TTT Phe	TCA Ser	GGA Gly	GCT Ala	GTT Val 685	ATT. Ile	CTG Leu	TTA Leu		2064
GAA Glu	TTT Phe 690	ATA Ile	CCA Pro	GAG Glu	ATT Ile	GCA Ala 695	ATA Ile	CCT Pro	GTA Val	TTA Leu	GGT Gly 700	ACT Thr	TTT Phe	GCA Ala	CTT Leu		2112
GTA Val 705	TCA Ser	TAT Tyr	ATT Ile	GCG Ala	AAT Asn 710	AAG Lys	GTT Val	CTA Leu	ACC Thr	GTT Val 715	CAA Gln	ACA Thr	ATA Ile	GAT Asp	AAT Asn 720		2160
GCT Ala	TTA Leu	AGT Ser	Lys	AGA Arg 725	AAT Asn	GAA Glu	AAA Lys	TGG Trp	GAT Asp 730	GAG Glu	GTC Val	TAT Tyr	AAA Lys	TAT Tyr 735	ATA Ile		2208
GTA Val	ACA Thr	AAT Asn	TGG Trp 740	TTA Leu	GCA Ala	AAG Lys	GTT Val	AAT Asn 745	ACA Thr	CAG Gln	ATT Ile	GAT Asp	CTA Leu 750	ATA Ile	AGA Arg		2256

AAA Lys	AAA Lys	ATG Met 755	AAA Lys	GAA Glu	GCT Ala	TTA Leu	GAA Glu 760	AAT Asn	CAA Gln	GCA Ala	GAA Glu	GCA Ala 765	ACA Thr	AAG Lys	GCT Ala	2304
ATA Ile	ATA Ile 770	AAC Asn	TAT Tyr	CAG Gln	TAT Tyr	AAT Asn 775	CAA Gln	TAT Tyr	ACT Thr	GAG Glu	GAA Glu 780	GAG Glu	AAA Lys	AAT Asn	AAT Asn	2352
ATT Ile 785	AAT Asn	TTT Phe	AAT Asn	ATT Ile	GAT Asp 790	GAT Asp	TTA Leu	AGT Ser	TCG Ser	AAA Lys 795	CTT Leu	AAT Asn	GAG Glu	TCT Ser	ATA Ile 800	2400
AAT Asn	AAA Lys	GCT Ala	ATG Met	ATT Ile 805	AAT Asn	ATA Ile	AAT Asn	AAA Lys	TTT Phe 810	TTG Leu	AAT Asn	CAA Gln	TGC Cys	TCT Ser 815	GTT Val	2448
TCA Ser	TAT Tyr	TTA Leu	ATG Met 820	AAT Asn	TCT Ser	ATG Met	ATC Ile	CCT Pro 825	TAT Tyr	GGT Gly	GTT Val	AAA Lys	CGG Arg 830	TTA Leu	GAA Glu	2496
GAT Asp	TTT Phe	GAT Asp 835	GCT Ala	AGT Ser	CTT	AAA Lys	GAT Asp 840	GCA Ala	TTA Leu	TTA Leu	AAG Lys	TAT Tyr 845	ATA Ile	TAT Tyr	GAT Asp	2544
AAT Asn	AGA Arg 850	GGA Gly	ACT Thr	TTA Leu	ATT Ile	GGT Gly 855	CAA Gln	GTA Val	GAT Asp	AGA Arg	TTA Leu 860	AAA Lys	GAT Asp	AAA Lys	GTT Val	2592
AAT Asn 865	AAT Asn	ACA Thr	CTT Leu	AGT Ser	ACA Thr 870	GAT Asp	ATA Ile	CCT Pro	TTT Phe	CAG Gln 875	CTT Leu	TCC Ser	AAA Lys	TAC Tyr	GTA Val 880	2640
									ACT Thr 890					TAA 895		2685

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 895 amino acids
 - (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Gly Ser Pro Gly Ile His Met Thr Ser Thr Arg Leu Gln Lys Leu Leu

Glu Phe Glu Leu Pro Gly Thr Met Glu Phe Val Asn Lys Gln Phe Asn 20


Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro


Lys Tyr Gly Gln Met Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys

Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly 70

Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr

Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys





- 42 -Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 825 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys * 885 890 895

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2622 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1.. 2622
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GGA Gly 1	TCC Ser	ATG Met	GAG Glu	TTC Phe 5	GTG Val	AAC Asn	AAG Lys	CAG Gln	TTC Phe 10	AAC Asn	TAT	AAG Lys	GAC Asp	Pro 15	GTA Val	48
AAC Asn	GGT Gly	GTT Val	GAC Asp 20	ATT Ile	GCC Ala	TAC Tyr	ATC Ile	AAA Lys 25	ATT Ile	CCA Pro	AAG Lys	TAC Tyr	GGC Gly 30	CAG Gln	ATG Met	96
								CAT His								144
GAA Glu	CGC Arg 50	GAT Asp	ACA Thr	TTT	ACG Thr	AAC Asn 55	CCG Pro	GAA Glu	GAA Glu	GGA Gly	GAC Asp 60	TTG Leu	AAC Asn	CCG Pro	CCG Pro	192
CCG Pro 65	GAA Glu	GCA Ala	AAG Lys	CAG Gln	GTG Val 70	CCA Pro	GTT Val	TCA Ser	TAC Tyr	TAC Tyr 75	GAT Asp	TCA Ser	ACC Thr	TAT Tyr	CTG Leu 80	240
AGC Ser	ACA Thr	GAC Asp	AAC Asn	GAG Glu 85	AAG Lys	GAT Asp	AAC Asn	TAC Tyr	CTG Leu 90	AAG Lys	GGA Gly	GTG Val	ACC Thr	AAA Lys 95	TTA Leu	288
TTC Phe	GAG Glu	CGT Arg	ATT Ile 100	TAT Tyr	TCC Ser	ACT Thr	GAC Asp	CTG Leu 105	GGC Gly	CGT Arg	ATG Met	CTG Leu	CTG Leu 110	ACC Thr	TCA Ser	336
ATC Ile	GTC Val	CGC Arg 115	GGA Gly	ATC Ile	CCA Pro	TTT Phe	TGG Trp 120	GGT Gly	GGC Gly	AGT Ser	ACC Thr	ATT Ile 125	GAC Asp	ACG Thr	GAG Glu	384
TTG Leu	AAG Lys 130	GTT Val	ATT Ile	GAC Asp	ACT Thr	AAC Asn 135	TGC Cys	ATT Ile	AAC Asn	GTG Val	ATC Ile 140	CAA Gln	CCA Pro	GAC Asp	GGT Gly	432

						'											
AGC Ser 145	Tyr	AGA Arg	TCT Ser	GAA Glu	GAA Glu 150	Leu	AAC Asn	CTC Leu	GTA Val	ATC Ile 155	ATC Ile	GGG Gly	CCC Pro	TCC Ser	GCG Ala 160		480
GAC Asp	ATT Ile	ATC	CAG Gln	Phe	Glu	TGC Cys	AAG Lys	AGC Ser	TTT Phe 170	Gly	CAC His	GAA Glu	GTG Val	TTG Leu 175	AAC Asn		528
CTG Leu	ACG Thr	CGT Arg	AAC Asn 180	Gly	TAC	GGC Gly	TCT Ser	ACT Thr 185	CAG Gln	TAC Tyr	ATT Ile	CGT Arg	TTC Phe 190	AGC Ser	CCA Pro		576
GAC Asp	TTC Phe	ACG Thr 195	TTC Phe	GGT Gly	TTC Phe	GAG Glu	GAG Glu 200	AGC Ser	CTG Leu	GAG Glu	GTT Val	GAT Asp 205	ACC Thr	AAC Asn	CCG Pro		624
CTG Leu	TTG Leu 210	GGT Gly	GCA Ala	GGC Gly	AAG Lys	TTC Phe 215	GCA Ala	ACT Thr	GAT Asp	CCA Pro	GCG Ala 220	GTG Val	ACC Thr	CTG Leu	GCA Ala		672
CAC His 225	GAG Glu	CTG Leu	ATC Ile	CAC His	GCC Ala 230	GGT Gly	CAT His	CGT Arg	CTG Leu	TAT Tyr 235	GGC Gly	ATT	GCG Ala	ATT Ile	AAC Asn 240		720
CCG Pro	AAC Asn	CGC Arg	GTG Val	TTC Phe 245	AAG Lys	GTT Val	AAC Asn	ACC Thr	AAC Asn 250	GCC Ala	TAC Tyr	TAC Tyr	GAG Glu	ATG Met 255	AGT Ser		768
GGT Gly	TTA Leu	GAA Glu	GTA Val 260	AGC Ser	TTC Phe	GAG Glu	GAA Glu	CTG Leu 265	CGC Arg	ACG Thr	TTC Phe	GGT Gly	GGC Gly 270	CAT His	GAT Asp	•	816
GCG Ala	AAG Lys	TTT Phe 275	Ile	GAC Asp	AGC Ser	TTG Leu	CAG Gln 280	GAG Glu	AAC Asn	GAG Glu	TTC Phe	CGT Arg 285	CTG Leu	TAC Tyr	TAC Tyr		864
									ACA Thr								912
									TAT Tyr								960
GAG Glu	AAA Lys	Tyr	Leu	Leu	Ser	Glu	Asp	Thr	TCT Ser 330	Gly	Lys	Phe	Ser	GTA Val 335	Asp		1008
									ATG Met							-	1056
									GTA Val								1104
									ATA Ile			Val					1152
									TTA Leu								1200
									ATT Ile 410								1248

AAA Lys	CTA Leu	AAA Lys	AAT Asn 420	TTT Phe	ACT Thr	GGA Gly	TTG Leu	TTT Phe 425	GAA Glu	TTT Phe	TAT Tyr	AAG Lys	TTG Leu 430	CTA Leu	TGT Cys	129
Val	Arg	Gly 435	Ile	ATA Ile	Thr	Ser	Lys 440	Thr	Lys	Ser	Leu	Asp 445	Lys	Gly	Tyr	134
AAT Asn	AAG Lys 450	GCA Ala	TTA Leu	AAT Asn	GAT Asp	TTA Leu 455	TGT Cys	ATC Ile	AAA Lys	GTT Val	AAT Asn 460	AAT Asn	TGG Trp	GAC Asp	TTG Leu	139
Phe 465	Phe	Ser	Pro	TCA Ser	Glu 470	Asp	Asn	Phe	Thr	Asn 475	Asp	Leu	Asn	Lys	Gly 480	144
Glu	Glu	Ile	Thr	TCT Ser 485	Asp	Thr	Asn	Ile	Glu 490	Ala	Ala	Glu	Glu	Asn 495	Ile	148
AGT Ser	TTA Leu	GAT Asp	TTA Leu 500	ATA Ile	CAA Gln	CAA Gln	TAT Tyr	TAT Tyr 505	TTA Leu	ACC Thr	TTT Phe	AAT Asn	TTT Phe 510	GAT Asp	AAT Asn	153
GAA Glu	CCT Pro	GAA Glu 515	AAT Asn	ATT Ile	TCA Ser	ATA Ile	GAA Glu 520	AAT Asn	CTT Leu	TCA Ser	AGT Ser	GAC Asp 525	ATT Ile	ATA Ile	GGC Gly	158
CAA Gln	TTA Leu 530	GAA Glu	CTT Leu	ATG Met	CCT Pro	AAT Asn 535	ATA Ile	GAA Glu	AGA Arg	Phe	CCT Pro 540	AAT Asn	GGA Gly	AAA Lys	AAG Lys	163
TAT Tyr 545	GAG Glu	TTA Leu	GAT Asp	AAA Lys	TAT Tyr 550	ACT Thr	ATG Met	TTC Phe	CAT His	TAT Tyr 555	CTT Leu	CGT Arg	GCT Ala	CAA Gln	GAA Glu 560	168
TTT Phe	GAA Glu	CAT	GGT Gly	AAA Lys 565	TCT Ser	AGG Arg	ATT Ile	GCT Ala	TTA Leu 570	ACA Thr	AAT Asn	TCT Ser	GTT Val	AAC Asn 575	GAA Glu	172
GCA Ala	TTA Leu	TTA Leu	AAT Asn 580	CCT Pro	AGT Ser	CGT Arg	GTT Val	TAT Tyr 585	ACA Thr	TTT Phe	TTT Phe	TCT Ser	TCA Ser 590	GAC Asp	TAT Tyr	177
GTA Val	AAG Lys	AAA Lys 595	GTT Val	AAT Asn	AAA Lys	GCT Ala	ACG Thr 600	GAG Glu	GCA Ala	GCT Ala	ATG Met	TTT Phe 605	TTA Leu	GGC Gly	TGG Trp	182
				GTA Val												187
				ATT Ile												192
				ATA Ile 645												196
				TCA Ser												201
		Ile 675		GTA Val												206

															•		
AAT Asn	AAG Lys 690	Val	CTA Leu	ACC Thr	GTT Val	CAA Gln 695	ACA Thr	ATA Ile	GAT Asp	AAT Asn	GCT Ala 700	TTA Leu	AGT Ser	AAA Lys	AGA Arg		2112
AAT Asn 705	Glu	AAA Lys	TGG Trp	GAT Asp	GAG Glu 710	GTC Val	TAT Tyr	AAA Lys	TAT Tyr	ATA Ile 715	GTA Val	ACA Thr	AAT Asn	TGG Trp	TTA Leu 720		2160
GCA Ala	AAG Lys	GTT Val	AAT Asn	ACA Thr 725	CAG Gln	ATT Ile	GAT Asp	CTA Leu	ATA Ile 730	AGA Arg	AAA Lys	AAA Lys	ATG Met	AAA Lys 735	GAA Glu		2208
					GCA Ala										CAG Gln		2256
					GAG Glu												2304
GAT Asp	GAT Asp 770	TTA Lèu	AGT Ser	TCG Ser	AAA Lys	CTT Leu 775	AAT Asn	GAG Glu	TCT Ser	ATA Ile	AAT Asn 780	AAA Lys	GCT Ala	ATG Met	ATT		2352
AAT Asn 785	ATA Ile	AAT Asn	AAA Lys	TTT Phe	TTG Leu 790	AAT Asn	CAA Gln	TGC Cys	TCT Ser	GTT Val 795	TCA Ser	TAT Tyr	TTA Leu	ATG Met	AAT Asn 800		2400
					GGT Gly										Ser	•	2448
CTT Leu	AAA Lys	GAT Asp	GCA Ala 820	TTA Leu	TTA Leu	AAG Lys	TAT Tyr	ATA Ile 825	TAT Tyr	GAT Asp	AAT Asn	AGA Arg	GGA Gly 830	ACT Thr	TTA Leu		2496
					AGA Arg												2544
					CAG Gln												2592
					GAA Glu 870				TAA *								2622

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 874 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val

Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Lys Tyr Gly Gln Met 20 25 30

Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro 35

Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly 135 Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala 150 Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro 185 Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala 215 His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn 225 230 235 240 Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp 265 Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys 310 315 Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys-Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr 360 Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala 390 395

Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr 4.05 Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr. Asn Lys Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu 550 Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp 595 Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Pro Tyr Ile Gly 635 Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala 680 Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg 690 Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln

PCT/GB97/02273

Tyr	Asn	Gln 755	Tyr	Thr	Glu	Glu	Glu 760	Lys	Asn	Asr.	Ile	Asn 765	Phe	Asn	Ile	
Asp	Asp 770	Leu	Ser	Ser	Lys	Leu 775	Asn	Glu	Ser	Ile	Asn 780	Lys	Ala	Met	Ile	
Asn 785	Ile	Asn	Lys	Phe	Leu 790	Asn	Gln	Cys	Ser	Val 795	Ser	Tyr	Leu	Met	Asn 800	
Ser	Met	Ile	Pro	Tyr 805	Gly	Val	Lys	Arg	Leu 810	Glu	Asp	Phe	Asp	Ala 815	Ser	
Leu	Lys	Asp	Ala 820	Leu	Leu	Lys	Tyr	Ile 825	Tyr	Asp	Asn	Arg	Gly 830	Thr	Leu	
Ile	Gly	Gln 835	Val	Asp	Arg	Leu	Lys 840	Asp	Lys	Val	Asn	Asn 845	Thr	Leu	Ser	
Thr	Asp 850	Ile	Pro	Phe	Gln	Leu 855	Ser	Lys	Tyr	Val	Asp 860	Asn	Gln	Arg	Leu	
Leu 865	Ser	Thr	Phe	Thr	Glu 870	Tyr	Ile	Lys	* .							
(2)	INF	DRMAI	NOI	FOR	SEQ	ID 1	10:	7:								
		(C (I) MOI) FE	C) SI C) TO LECUI ATURE	(PE: TRANT OPOLO LE TY E: ME/I	DEDNE DGY: (PE:	ESS: line DNA CDS	douk ear (ger	ole	=)							
	(xi)	SEC	QUENC	E DE	SCRI	PTIC	ON: S	SEQ I	D NC): 7:	:					
				AAT Asn 5												48
GTT Val	GAT Asp	ATT Ile	GCT Ala 20	TAT Tyr	ATA Ile	AAA Lys	ATT Ile	CCA Pro 25	AAT Asn	GCA Ala	GGA Gly	CAA Gln	ATG Met 30	CAA Gln	CCA Pro	96
GTA Val	AAA Lys	GCT Ala 35	TTT Phe	AAA Lys	ATT Ile	CAT His	AAT Asn 40	AAA Lys	ATA Ile	TGG Trp	GTT Val	ATT Ile 45	CCA Pro	GAA Glu	AGA Arg	144
GAT Asp	ACA Thr 50	TTT Phe	ACA Thr	AAT Asn	CCT Pro	GAA Glu 55	GAA Glu	GGA Gly	GAT Asp	TTA Leu	AAT Asn 60	CCA Pro	CCA	CCA Pro	GAA Glu	192
GCA Ala 65	AAA Lys	CAA Gln	GTT Val	CCA Pro	GTT Val 70	TCA Ser	TAT Tyr	TAT Tyr	GAT Asp	TCA Ser 75	ACA Thr	TAT Tyr	TTA Leu	AGT Ser	ACA Thr 80	240
GAT Asp	AAT Asn	GAA Glu	AA A Lys	GAT Asp 85	AAT Asn	TAT	TTA Leu	AAG Lys	GGA Gly 90	GTT Val	ACA Thr	AAA Lys	TTA Leu	TTT Phe 95	GAG Glu	288

						,				. •		-					
					GAT Asp									Ile			336
AGG Arg	GGA Gly	ATA Ile 115	Pro	TTT Phe	TGG Trp	GGT Gly	GGA Gly 120	AGT Ser	ACA Thr	ATA Ile	GAT Asp	ACA Thr 125	GAA Glu	TTA Leu	AAA Lys	-	384
GTT Val	ATT Ile 130	GAT A sp	ACT Thr	AAT Asn	TGT Cys	ATT Ile 135	AAT Asn	GTG Val	ATA Ile	CAA Gln	CCA Pro 140	GAT Asp	GGT Gly	AGT	TAT Tyr		432
AGA Arg 145	Ser	GAA Glu	GAA Glu	CTT	AAT Asn 150	CTA Leu	GTA Val	ATA Ile	ATA Ile	GGA Gly 155	CCC Pro	TCA Ser	GCT Ala	GAT Asp	ATT Ile 160		480
ATA Ile	CAG Gln	TTT	GAA Glu	TGT Cys 165	AAA Lys	AGC Ser	TTT Phe	GGA Gly	CAT His 170	GAA Glu	GTT Val	TTG Leu	AAT Asn	CTT Leu 175	ACG Thr		528
CGA Arg	AAT Asn	GGT Gly	TAT Tyr 180	GGC	TCT	ACT	CAA Gln	TAC Tyr 185	ATT Ile	AGA Arg	TTT Phe	AGC Ser	CCA Pro 190	GAT Asp	TTT Phe		576
ACA Thr	TTT Phe	GGT Gly 195	Phe	GAG Glu	GAG Glu	TCA Ser	CTT Leu 200	GAA Glu	GTT Val	GAT Asp	ACA Thr	AAT Asn 205	CCT Pro	CTT Leu	TTA Leu		624
Gly	Ala 210	Gly	Lys	Phe	GCT Ala	Thr 215	Asp	Pro	Ala	Val	Thr 220	Leu	Ala	His	Glu	•	672
CTT Leu 225	ATA Ile	CAT	GCT Ala	GGA Gly	CAT His 230	Arg	TTA Leu	TAT Tyr	GGA Gly	ATA Ile 235	GCA Ala	ATT Ile	AAT Asn	CCA Pro	AAT Asn 240		720
					AAT Asn												768
GAA Glu	GTA Val	AGC Ser	TTT Phe 260	GAG Glu	GAA Glu	CTT Leu	AGA Arg	ACA Thr 265	TTT Phe	GGG Gly	GGA Gly	CAT His	GAT Asp 270	GCA Ala	AAG Lys		816
				Leu	CAG Gln	Glu	Àsn	Glu			Leu						864
Lys	TTT Phe 290	AAA Lys	GAT Asp	ATA Ile	GCA Ala	AGT Ser 295	ACA Thr	CTT Leu	AAT Asn	AAA Lys	GCT Ala 300	AAA Lys	TCA Ser	ATA Ile	GTA Val		912
GGT Gly 305	ACT	ACT Thr	GCT Ala	TCA Ser	TTA Leu 310	CAG Gln	TAT	ATG Met	AAA Lys	AAT Asn 315	GTT Val	TTT	AAA Lys	GAG Glu	AAA Lys 320		960
					GAT Asp											-	1008
					TAC Tyr												1056
					TTT Phe												1104

- 50 -

TTT Phe	GAT Asp 370	AAA Lys	GCC Ala	GTA Val	TTT Phe	AAG Lys 375	ATA Ile	AAT Asn	ATA Ile	GTA Val	CCT Pro 380	AAG Lys	GTA Val	AAT Asn	TAC Tyr		1152
ACA Thr 385	ATA Ile	TAT Tyr	GAT Asp	GGA Gly	TTT Phe 390	AAT Asn	TTA Leu	AGA Arg	AAT Asn	ACA Thr 395	AAT Asn	TTA Leu	GCA Ala	GCA Ala	AAC Asn 400		1200
TTT Phe	AAT Asn	GGT Gly	CAA Gln	AAT Asn 405	ACA Thr	GAA Glu	ATT Ile	AAT Asn	AAT Asn 410	ATG Met	AAT Asn	TTT Phe	ACT Thr	AAA Lys 415	CTA Leu	-	1248
								TTT Phe 425									1296
								TCA Ser									1344
								GTT Val									1392
								AAT Asn									1440
ATT Ile	ACA Thr	TCT Ser	GAT Asp	ACT Thr 485	AAT Asn	ATA Ile	GAA Glu	GCA Ala	GCA Ala 490	GAA Glu	GAA Glu	AAT Asn	ATT Ile	AGT Ser 495	TTA Leu		1488
								ACC Thr 505									1536
								TCA Ser									1584
								TTT Phe									1632
TTA Leu 545	GAT Asp	AAA Lys	TAT Tyr	ACT Thr	ATG Met 550	TTC Phe	CAT His	TAT Tyr	CTT Leu	CGT Arg 555	GCT Ala	CAA Gln	GAA Glu	TTT Phe	GAA Glu 560		1680
CAT His	GGT Gly	AAA Lys	TCT Ser	AGG Arg 565	ATT Ile	GCT Ala	TTA Leu	ACA Thr	AAT Asn 570	TCT Ser	GTT Val	AAC Asn	GAA Glu	GCA Ala 575	TTA Leu		1728
TTA Leu	AAT Asn	CCT Pro	AGT Ser 580	CGT Arg	GTT Val	TAT Tyr	ACA Thr	TTT Phe 585	TTT Phe	TCT Ser	TCA Ser	GAC Asp	TAT Tyr 590	GTA Val	AAG Lys		1776
AAA Lys	GTT Val	AAT Asn 595	AAA Lys	GCT Ala	ACG Thr	GAG Glu	GCA Ala 600	GCT Ala	ATG Met	TTT Phe	TTA Leu	GGC Gly 605	TGG Trp	GTA Val	GAA Glu		1824
CAA Gln	TTA Leu 610	GTA Val	TAT Tyr	GAT Asp	TTT Phe	ACC Thr 615	GAT Asp	GAA Glu	ACT Thr	AGC Ser	GAA Glu 620	GTA Val	AGT Ser	ACT Thr	ACG Thr		1872
GAT Asp 625	AAA Lys	ATT Ile	GCG Ala	GAT Asp	ATA Ile 630	ACT Thr	ATA Ile	ATT Ile	ATT Ile	CCA Pro 635	TAT Tyr	ATA Ile	GGA Gly	CCT Pro	GCT Ala 640		1920

TTA	AAT	ATA	GGT	AAT	ATG	TTA	TAT	. AAA	GAT	' GAT	TT T	СТА	GGT	GCT	TTA		1000
Leu	Asn	Ile	Gly	Asr 645	ı Met	Leu	Tyr	Lys	Asp 650	Asp	Phe	Val	Gly	Ala 655	Leu		1968
ATA Ile	TTT Phe	TCA Ser	GGA Gly 660	GCT Ala	GTT Val	ATT Ile	CTG Leu	Leu 665	Glu	TTT Phe	ATA Ile	CCA Pro	GAG Glu 670	Ile	GCA Ala		2016
ATA Ile	CCT Pro	GTA Val 675	TTA Leu	GGT Gly	ACT Thr	TTT	GCA Ala 680	Leu	GTA Val	TCA Ser	TAT	ATT Ile 685	GCG Ala	AAT Asn	AAG Lys		2064
GTT Val	CTA Leu 690	ACC Thr	GTT Val	CAA Gln	ACA Thr	ATA Ile 695	GAT Asp	AAT Asn	GCT Ala	TTA Leu	AGT Ser 700	AAA Lys	AGA Arg	AAT Asn	GAA Glu		2112
AAA Lys 705	TGG Trp	GAT Asp	GAG Glu	GTC Val	TAT Tyr 710	AAA Lys	TAT Tyr	ATA Ile	GTA Val	ACA Thr 715	AAT Asn	TGG	TTA Leu	GCA Ala	AAG Lys 720		2160
GTT Val	AAT Asn	ACA Thr	CAG Gln	ATT Ile 725	GAT Asp	CTA Leu	ATA Ile	AGA Arg	AAA Lys 730	AAA Lys	ATG Met	AAA Lys	GAA Glu	GCT Ala 735	TTA Leu		2208
GAA Glu	AAT Asn	CAA Gln	GCA Ala 740	GAA Glu	GCA Ala	ACA Thr	AAG Lys	GCT Ala 745	ATA Ile	ATA Ile	AAC Asn	TAT Tyr	CAG Gln 750	TAT Tyr	AAT Asn		2256
CAA Gln	TAT Tyr	ACT Thr 755	GAG Glu	GAA Glu	GAG Glu	AAA Lys	AAT Asn 760	AAT Asn	ATT Ile	AAT Asn	TTT Phe	AAT Asn 765	ATT Ile	GAT Asp	GAT Asp		2304.
TTA Leu	AGT Ser 770	TCG Ser	AAA Lys	CTT Leu	AAT Asn	GAG Glu 775	TCT	ATA Ile	AAT Asn	AAA Lys	GCT Ala 780	ATG Met	ATT Ile	AAT Asn	ATA Ile		2352
AAT Asn 785	AAA Lys	TTT Phe	TTG Leu	AAT Asn	CAA Gln 790	TGC Cys	TCT	GTT Val	TCA Ser	TAT Tyr 795	TTA Leu	ATG Met	AAT Asn	TCT Ser	ATG Met 800		2400
ATC Ile	CCT Pro	TAT Tyr	GGT	GTT Val 805	AAA Lys	CGG Arg	TTA Leu	GAA Glu	GAT Asp 810	TTT Phe	GAT Asp	GCT Ala	AGT Ser	CTT Leu 815	AAA Lys	. ·	2448
GAT Asp	GCA Ala	TTA Leu	TTA Leu 820	AAG Lys	TAT Tyr	ATA Ile	TAT Tyr	GAT Asp 825	AAT Asn	AGA Arg	GGA Gly	ACT Thr	TTA Leu 830	ATT Ile	GGT Gly		2496
	GTA Val																2544
	CCT Pro 850									Asn							2592
	TTT Phe							J	٠.								2613

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 871 amino acids
 (B) TYPE: amino acid

 - (D) TOPOLOGY: linear




- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 135 Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 200 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 295 Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305

Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu

330





					,										
Val	Leu 690	Thr	Val	Gln	Thr	Ile 695	Asp	Asn	Ala	Leu	Ser 700	Lys	Arg	Asn	Glu
Lys 705	Trp	Asp	Glu	Val	Tyr 710	Lys	Tyr	Ile	Val	Thr 715	Asn	Trp	Leu	Ala	Lys 720
Val	Asn	Thr	Gln	Ile 725	Asp	Leu	Ile	Arg	Lys 730	Lys	Met	Lys	Glu	Ala 735	Leu
Glu	Asn	Gln	Ala 740	Glu	Ala	Thr	Lys	Ala 745	Ile	Ile	Asn	Tyr	Gln 750	Tyr	Asn
Gln	Tyr	Thr 755	Glu	Glu	Glu	Lys	Asn 760	Asn	Ile	Asn	Phe	Asn 765	Ile	Asp	Asp
Leu	Ser 770	Ser	Lys	Leu	Asn	Glu 775	Ser	Ile	Asn	Lys	Ala 780	Met	Ile	Asn	Ile
Asn 785	Lys	Phe	Leu	Asn	Gln 790	Cys	Ser	Val	Ser	Tyr 795	Leu	Met	Asn	Ser	Met 800
Ile	Pro	Tyr	Gly	Val 805	Lys	Arg	Leu	Glu	Asp 810	Phe	Asp	Ala	Ser	Leu 815	Lys
Asp	Ala	Leu	Leu 820	Lys	Tyr	Ile	Tyr	Asp 825	Asn	Arg	Gly	Thr	Leu 830	Ile	Gly
Gln	Val	Asp 835	Arg	Leu	Lys	Asp	Lys 840	Val	Asn	Asn	Thr	Leu 845	Ser	Thr	Asp
Ile	Pro 850	Phe	Gln	Leu	Ser	Lys 855	Tyr	Val	Asp	Asn	Gln 860	Arg	Leu	Leu	Ser
Thr 865	Phe	Thr	Glu	Tyr	Ile 870	Lys									
(2)	INFO	RMAT	NOI	FOR	SEQ	ID N	10: 9	€:							
	(i)	(E	A) LE B) TY C) SI	ENGTH (PE : (RANI	IARAC I: 26 nucl EDNE OGY:	28 k eic SS:	ase acid	paiz i	:s						
	(ii)	MOI	ECUI	E TY	PE:	DNA	(ger	omic	2)						
	(ix)		TURE		ŒY:	CDS									

(B) LOCATION:1..2628

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

ATG Met 1	CAG Gln	TTC Phe	GTG Val	AAC Asn 5	AAG Lys	CAG Gln	TTC Phe	AAC Asn	TAT Tyr 10	AAG Lys	GAC Asp	CCT Pro	GTA Val	AAC Asn 15	GGT Gly	4.8
					ATC Ile											96
					ATT Ile											144
					CCG Pro											192

GCA Ala 65	Lys	CAG Gln	GTG Val	CCA	GTT Val	Ser	TAC	TAC	GAT Asp	TCA Ser 75	ACC Thr	TAT	CTG Leu	AGC Ser	ACA Thr 80	240	
GAC Asp	AAC Asn	GAG Glu	AAG Lys	GAT Asp 85	Asn	TAC	CTG Leu	AAG Lys	GGA Gly 90	GTG Val	ACC	AAA Lys	TTA Leu	TTC Phe 95	GAG Glu	288	
CGT Arg	ATT Ile	TAT	Ser 100	Thr	GAC Asp	CTG Leu	GGC	CGT Arg 105	Met	CTG Leu	CTG Leu	ACC Thr	TCA Ser 110	ATC Ile	GTC Val	336	
CGC Arg	GGA Gly	ATC Ile 115	Pro	TTT Phe	TGG	GGT Gly	GGC Gly 120	AGT	ACC Thr	ATT Ile	GAC Asp	ACG Thr 125	GAG Glu	TTG Leu	AAG Lys	384	
GTT Val	ATT Ile 130	GAC Asp	ACT Thr	AAC Asn	TGC Cys	ATT Ile 135	AAC Asn	GTG Val	ATC Ile	CAA Gln	CCA Pro 140	GAC Asp	GGT Gly	AGC Ser	TAC Tyr	432	
AGA Arg 145	TCT Ser	GAA Glu	GAA Glu	CTT	AAC Asn 150	CTC Leu	GTA Val	ATC Ile	Ile	GGG Gly 155	CCC Pro	TCC Ser	GCG Ala	GAC Asp	ATT Ile 160	480	
ATC Ile	CAG Gln	TTT Phe	GAG Glu	TGC Cys 165	AAG Lys	AGC Ser	TTT Phe	GGC Gly	CAC His 170	GAA Glu	GTG Val	TTG Leu	Asn	CTG Leu 175	ACG Thr	528	
												AGC Ser				576	
												AAC Asn 205				624	
GGT Gly	GCA Ala 210	GGC Gly	AAG Lys	TTC Phe	GCA Ala	ACT Thr 215	GAT Asp	CCA Pro	GCG Ala	GTG Val	ACC Thr 220	CTG Leu	GCA Ala	CAC His	GAG Glu	672	<i>2</i> -
												ATT				720	
CGC	GTG Val	TTC Phe	AAG Lys	GTT Val 245	AAC Asn	ACC Thr	AAC Asn	GCC Ala	TAC Tyr 250	TAC Tyr	GAG Glu	ATG Met	AGT Ser	GGT Gly 255	TTA Leu	768	
GAA Glu	GTA Val	AGC Ser	TTC Phe 260	GAG Glu	GAA Glu	CTG Leu	CGC Arg	ACG Thr 265	TTC Phe	GGT Gly	GGC Gly	CAT His	GAT Asp 270	GCG Ala	AAG Lys	816	
												TAC Tyr 285				864	
												AAG Lys				912	
												TTT Phe				960	
												GTA Val				1008	

E.G.	
- 56 -	

AA: Ly:	A TT s Pho	T GA' e As	T AAG p Ly: 340		A TAG	C AAA c Lys	ATC Met	349	1 IUI	A GAC	AT:	TAC Ty:	C AC	r Gl	G GAT u Asp	1056
AA: Asi	r TTT	GT: Va. 35	L LJ.	TT:	TTT	C AAA E Lys	GTA Val 360	. net	AAC Asr	AGA Arg	A AAA J Lys	A ACI	r Ty	TTC Let	G AAT 1 Asn	1104
FILE	370) Dys	, WI	a val	r Pile	375	TTE	Asr	ılle	· Val	380	Lys	Va]	Ası	TAC Tyr	1152
385	5	y.	. Asi	, GI	390	ASII	Leu	Arg	Asn	395	Asn	Leu	Ala	Ala	AAC ASD 400	1200
TTI Phe	AAT Asn	GG1	CAP Gln	AAT ASD 405	THE	GAA Glu	ATT Ile	AAT Asn	AAT Asn 410	Met	AAT Asn	TTT Phe	ACT Thr	AAA Lys 415	CTA Leu	1248
AAA Lys	AAT Asn	TTI Phe	Thr 420	GIY	TTG Leu	TTT Phe	GAA Glu	TTT Phe 425	TAT Tyr	AAG Lys	TTG Leu	CTA Leu	TGT Cys 430	GTA Val	AGA Arg	1296
GGG Gly	ATA Ile	ATA Ile 435	1117	TCT	AAA Lys	ACT Thr	AAA Lys 440	TCA Ser	TTA Leu	GAT Asp	AAA Lys	GGA Gly 445	TAC	AAT Asn	AAG Lys	1344
AGC Ser	GCT Ala 450	GAT Asp	GGG Gly	GCA Ala	TTA Leu	AAT Asn 455	GAT Asp	TTA Leu	TGT Cys	ATC Ile	AAA Lys 460	GTT Val	AAT Asn	AAT Asn	TGG Trp	1392
GAC Asp 465	TTG Leu	TTT Phe	TTT Phe	AGT	CCT Pro 470	TCA Ser	GAA Glu	GAT Asp	AAT Asn	TTT Phe 475	ACT Thr	AAT Asn	GAT Asp	CTA Leu	AAT Asn 480	1440
AAA Lys	GGA Gly	GAA Glu	GAA Glu	ATT Ile 485	ACA Thr	TCT Ser	GAT Asp	ACT Thr	AAT Asn 490	ATA Ile	GAA Glu	GCA Ala	GCA Ala	GAA Glu 495	GAA Glu	1488
AAT Asn	ATT Ile	AGT Ser	TTA Leu 500	GAT Asp	TTA Leu	ATA Ile	CAA Gln	CAA Gln 505	TAT Tyr	TAT Tyr	TTA Leu	ACC Thr	TTT Phe 510	AAT Asn	TTT Phe	1536
GAT Asp	AAT Asn	GAA Glu 515	CCT Pro	GAA Glu	AAT Asn	TIE	TCA Ser 520	ATA Ile	GAA Glu	AAT Asn	CTT Leu	TCA Ser 525	AGT Ser	GAC Asp	ATT Ile	1584
ATA Ile	GGC Gly 530	CAA Gln	TTA Leu	GAA Glu	CTT Leu	ATG Met 535	CCT Pro	AAT Asn	ATA Ile	GAA Glu	AGA Arg 540	TTT Phe	CCT Pro	AAT Asn	GGA Gly	1632
AAA Lys 545	AAG Lys	TAT Tyr	GAG Glu	TTA Leu	GAT Asp 550	AAA Lys	TAT Tyr	ACT Thr	Met	TTC Phe 555	CAT His	TAT Tyr	CTT Leu	CGT Arg	GCT Ala 560	1680
CAA Gln	GAA Glu	TTT Phe	GAA Glu	CAT His 565	GGT Gly	AAA Lys	TCT . Ser .	Arg	ATT Ile 570	GCT Ala	TTA Leu	ACA Thr	AAT Asn	TCT Ser 575	GTT Val	1728
AAC Asn	GAA Glu	GCA Ala	TTA Leu 580	TTA Leu	AAT Asn	CCT . Pro	Ser /	CGT Arg 585	GTT Val	TAT Tyr	ACA Thr	TTT Phe	TTT Phe 590	TCT Ser	TCA Ser	1776
GAC Asp	TAL	GTA Val 595	AAG Lys	AAA Lys	GTT . Val .	Asn .	AAA (Lys 1	GCT Ala	ACG (Thr (GAG (Glu /	Ala .	GCT Ala 605	ATG Met	TTT Phe	TTA Leu	1824

GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GIV TFP VAI GIU GIN Leu Vail Tyr Asp Phe Thr Asp Giu Thr Ser Giu 1920 GIA GAT ACT ACG GAT AAA ACT GCG GAT ATA ACT ATA ACT ATT ATT CCA TAT VAIS SET THR THR ASP Lys Ile Ala Asp Ile Thr Ile Ile Pro Tyr 625 635 635 11e ATT ACT CAT TAT VAIS SET THR THR ASP Lys Ile ALA ASP Ile Thr Ile Ile Pro Tyr 625 635 635 11e ATT ACT TAT TAT AAA GAT GAT TTT Ile GIV Pro Ala Leu Asn Ile GIV Asn Met Leu Tyr Lys Asp Asp Phe 656 635 635 635 635 635 635 635 635 635											٠.							
Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr 625 625 630 640 635 640 635 640 635 640 635 640 635 640 635 640 665 655 650 665 655 650 665 655 650 665 655 65	GG Gl	y ir	p va	A GA 1 Gl	A CA u Gl	A TT	n var	. Tyi	GA:	TTT Phe	Thr	Ast	o Gli	A ACT	I AG r Se	C GAA r Glu		1872
GETA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA Val Gly Ale Leu Ile Phe Ser Gly Ale Val Ile Leu Leu Glu Phe Ile 660 CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr 660 ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser 670 AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn 705 TGC TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA ATA CTT Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met 715 AAA GAA GCT TTA GAA AAT CAA GCA GAT GAT CTA ATA AGA AAA AAA ATG Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met 740 TAT CAG TAT AAT CAA TAT ACT GAG GAA GAA AAA AAT AAT ATT AAT ATA CAG TAT AAT CAA TAT ACT GAG GAA GAA AAA AAT AAT ATT AAT TTT Tyr Glu Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe 755 AAT ATT GAT GAT TATA AGA TAT ACT GAG GAA CAA AAA AAT AAT ATT AAT TTT Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe 755 AAT ATT GAT GAT TATA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAT AAT CTT AAT TAT GAT GAT TAT AGT TCG AAA CTT AAT GAG TCT ATA AAT ATT AAT TTT Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe 755 AAT ATT GAT GAT TAT AAT AAT AAA TTT TTG AAT CAA TCC TCT GTT TCA TAT TTA ASN Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala TTO ATT AAT AAT AAT AAA TAT AAT TTT TTG AAT CAA TCC TCT GTT TCA TAT TTA ATT GAT GAT TAT AGT GAT GTT AAA GGT TAT AAT A	Va	1 Se	T AC	T AC r Th	G GA	р Гуз	s Ile	GCC Ala	GAT Asp	T ATA	Thr	Ile	ATT	ATT	CC Pr	o Tyr		1920
Val Gly Ala Leu leu Rer Ser Gly Ala Val Ile Leu Leu Glu Phe Ile 660 CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr 670 ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser 670 AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn 705 TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATA CYS Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn 705 TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATA CYS ATA CYS Glu Ala Leu Glu Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met 730 AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn 745 TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAA AAT AAT ATT AAT TTT Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe 765 AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala T70 ATG ATT AAT ATA AAT AAA TAAA TTT TTG AAT CAA TCA TCA TT TTG GAT Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu 800 ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CAG TTA GAT GAT TTA AGA Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu 800 ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CAG TTA ATA TAT ACA GAG Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp 805 GCT AGT CTT AAA GAT GCA TTA TA AGT TA AAA GAT TAT TAT AAT ACA 801 BER GROWN ASS AND AND TATA 802 ACT TTA ATT GGT CAA GTA GAT ACA TTA ACA ATA AAA GAT AAT ACA 803 BER GROWN ASS AND AND TTR 804 CCT AGT CTT AAA GAT ACA TTA CCT GAT TTA AAA GAT AAA TAT AAA ACA 804 BER GROWN ASS AND AND TATA ACA ACA 805 BER GROWN AND TATA ACA TAT ACT TTA AAA GAT AAA GAT AAA 807 BER GROWN AND TATA ACA TAT ACT TTA AAA GAT AAA GAT AAA TAT 807 CTT ACT ACT AAA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA 807 BER GRO	AT:	A GG/ e Gly	A CC	T GC o Al	а ье	ı Aşr	T ATA	GGT Gly	'AAT	Met	Leu	TAT	AAA Lys	GAT Asp	As	Phe		1968
ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT 11e Ala Asn Lys Val Leu Thr Val Gln Thr 11e Asp Asn Ala Leu Ser 695 AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT 15c TTA AGT 17c Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr 11e Val Thr Asn 720 AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT 17c TACA TATA GCA AAT 17c Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr 11e Val Thr Asn 720 TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG TTP Leu Ala Lys Val Asn Thr Gln 11e Asp Leu I1e Arg Lys Lys Mct 735 AAA GAA GCT TTA GAA AAT CAA GCA GCA GAT GAT CTA ATA AGA AAA AAA ATG ATG TAG GCA ACA AGG GCT ATA ATA AAC Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala I1e I1e Asn 750 TAT CAG TAT AAT CAA TAT ACT GAG GAG GAA AAA AAT AAT ATT AAT TTT TYR Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn I1e Asn Phe 755 AAT ATT GAT GAT TATA ACT TGG AAA CTT AAT GAG TATA AAT AAA GCT 770 ATG ATT AAT AAT AAA ATT TTA GT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT 770 ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ASN 11e Asn Lys Ala 770 ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA GOO ATG TTT A GT TTA ASN Leu Asn Glu Ser Val Ser Tyr Leu 800 ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GAT GAT ANA ASN Leu Lys Asn Arg Leu Glu Asp Phe Asp 805 GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT TAT GAT AAT AGA GGA AAA AA	GT/ Va	A GGT	C GC' Ala	a Lei	n IIe	A TTT Phe	TCA Ser	GGA Gly	Ala	Val	ATT Ile	CTG Leu	TTA Leu	Glu	Phe	T ATA		2016
AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn 720 TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AAG AAA AAA ATG TTP Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met 735 AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC AAT ATA ACA CAG ATT GLU Ala Thr Lys Ala Ile Ile Asn 740 TAT CAG TAT AAT CAA TAT ACT GAG GAA GCA GAA AAA AAA ATA ATA TTT GAT ASN GLU Ser Leu Lys Asp Ale Leu Ser Tyr Ile Asn Cash Gar Gar Aca Aag GCT ATA ATA AAC Caga ATT GAT GAG GAA GAA AAA AAT AAT ATT TTT GAT GA	CC! Pro	A GAC	1 116	S ATS	A ATA	CCI Pro	' GTA Val	Leu	GGT Gly	ACT Thr	TTT Phe	GCA Ala	Leu	Val	TC! Sei	A TAT		2064
Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn 720 TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met 735 AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC CLys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn 740 TAT CAG TAT AAT CAA TAT ACT GAG GAA GAA GAA AAT AAT ATT AAT TTT 755 AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAT ATT ASN Ile Asn Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala 770 ATG ATT AAT ATA AAT AAA AAT AAA TTT TTT	ATT Ile	Ala	ASI	Lys	G GTI s Val	CTA Leu	Thr	GTT Val	CAA Gln	ACA Thr	ATA Ile	Asp	AAT Asn	GCT Ala	TTA Let	A AGT		2112
AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC CAA GC GAA GAA GCT ATA ATA AAC CAA GCT AAA GCT AAA AAT AAT AAT TTT CAG TATA AAT CAA TATA ACT GCT CATA CAA GCT AAA GCT AAA AAT AAT AAT AAT TTT CAG TATA AAT AAT AAT AAA GCT AAA AAT AAT AAT AAA GCT AAA AAT AAT AAT AAA GCT AAA AAT AAT AAT AAA AAA TATA AAA GCT AAA CTT AAT GAA GCT AAA CTT AAT GAA GCT AAA AAA AAT AAA AAA AAA AAA AAA AAA A	Lys	: Arg	AA1 Asr	GAA 1 Glu	AAA Lys	Trp	Asp	GAG Glu	GTC Val	TAT	Lys	Tyr	ATA Ile	GTA Val	ACA Thr	Asn		2160
TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT AAA GAT TAT TA	TGG	TTA Leu	GCA Ala	AAG Lys	Val	Asn	ACA Thr	CAG Gln	ATT Ile	Asp	CTA Leu	ATA Ile	AGA Arg	AAA Lys	Lys	Met		2208
TYP GIN TYP ASN GIN TYP Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe 755 AAT ATT GAT GAT GAT TTA AGT TCG Asn Ile Asn Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala 770 ATG ATT AAT ATA AAT AAA ATT TTG AAT CAA TGC TCT GTT TCA TAT TTA Met Ile Asn Ile Asn Lys 780 ATG ATT TATA ATT AAT AAA ATT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA Met Ile Asn Ile Asn Lys 780 ATG ATT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT Met Asn Ser Met Ile Pro 805 GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA ASP ASP Ala Leu Leu Lys 825 GCT AGT CTT AAA ASP Ala Leu Leu Lys 825 CTT ATT ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GAT AAA GTA AAA GTA AAA ASP ASP 835 CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT ACA 11e Gly Gln Val Asp Aag Leu Lys Asp Lys Val Asn Asn Thr 835 CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln 850 AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT ATT AAG TAA Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys * 2352 2352 2400 240	AAA Lys	GAA Glu	GCT Ala	Leu	Glu	AAT Asn	CAA Gln	GCA Ala	Glu	GCA Ala	ACA Thr	AAG Lys	GCT Ala	Ile	ATA Ile	AAC Asn		2256
ASS THE ASP ASP Leu Ser Ser Lys Leu Ass Glu Ser He Ass Lys Ala ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA Met He Ass He Ass He Ass Lys Phe Leu Ass Gln Cys Ser Val Ser Tyr Leu 800 ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT Met Ass Ser Met He Pro 805 GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAA ASP Phe 815 GCT AGT CTT AAA ASP Ala Leu Leu Lys Tyr He Tyr Asp Ass Arg Gly 820 ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GAT AAA GTT AAT AA	Tyr	Gin	Tyr 755	Asn	Gin	Tyr	Thr	Glu 760	Glu	Glu	Lys	Asn	Asn 765	Ile	Asn	Phe	٠	2304
Met Ile Asn Ile Asn Lys 790 ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT Asp 810 ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT Asp 810 GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly 820 ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AA	AAT Asn	lle	GAT Asp	GAT Asp	TTA Leu	AGT Ser	Ser	AAA Lys	CTT Leu	AAT Asn	GAG Glu	Ser	ATA Ile	AAT Asn	AAA Lys	GCT Ala		2352
Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp 815 GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly 825 ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AA	Met	He	Asn	Ile	Asn	Lys	Phe	Leu	Asn	Gln	Cys	TCT Ser	GTT Val	TCA Ser	TAT Tyr	Leu		2400
Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly 825 ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AA	ATG Met	AAT Asn	TCT Ser	ATG Met	Ile	CCT Pro	TAT Tyr	GGT	GTT Val	Lys	CGG Arg	TTA Leu	GAA Glu	GAT Asp	Phe	GAT Asp	,	2448
Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr 845 CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln 850 AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2628 Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys *	GCT Ala	AGT Ser	CTT Leu	Lys	GAT Asp	GCA Ala	TTA Leu	Leu	Lys	TAT Tyr	ATA Ile	TAT Tyr	GAT Asp	Asn	AGA Arg	GGA Gly		2496
Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln 850 860 AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys *	ACT Thr	TTA Leu	Ile	GGT Gly	CAA Gln	GTA Val	Asp .	Arg	TTA Leu	AAA Lys	GAT . Asp	Lys	Val	AAT Asn	AAT Asn	ACA Thr	٠	2544
Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys *	CTT Leu	Ser	ACA Thr	GAT Asp	ATA Ile	Pro	Phe (CAG (Gln)	CTT Leu	TCC ; Ser ;	Lys '	Tyr	GTA Val	GAT Asp	AAT Asn	CAA Gln		2592
	Arg	TTA Leu	TTA Leu	TCT Ser	ACA Thr	Phe '	ACT C	GAA :	rat . Fyr	Ile 1	Lys	AA1	•		,		•	2628

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 876 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 170 Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 200 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val

295

300

Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 310 315 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 390 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 410 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys Ser Ala Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn 470 Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu 490 Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala -550 Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe-Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe 645 650



Val	Gly	Ala	Leu 660	Ile	Phe	Ser	Gly	Ala 665	Val	Ile	Leu	Leu	Glu 670	Phe	Ile
Pro	Glu	Ile 675	Ala	Ile	Pro	Val	Leu 680	Gly	Thr	Phe	Ala	Leu 685	Val	Ser	Tyr
Ile	Ala 690	Asn	Lys	Val	Leu	Thr 695	Val	Gln	Thr	Ile	Asp 700	Asn	Ala	Leu	Ser
Lys 705	Arg	Asn	Glu	Lys	Trp 710	Asp	Glu	Val	Tyr	Lys 715	Tyr	Ile	Val	Thr	Asn 720
Trp	Leu	Ala	Lys	Val 725	Asn	Thr	Gln	Ile	Asp 730	Leu	Ile	Arg	Lys	Lys 735	Met
Lys	Glu	Ala	Leu 740	Glu	Asn	Gln	Ala	Glu 745	Ala	Thr	Lys	Ala	Ile 750	Ile	Asn
Tyr	Gln	Tyr 755	Asn	Gln	Tyr	Thr	Glu 760	Glu	Glu	Lys	Asn	Asn 765	Ile	Asn	Phe
Asn	Ile 770	Asp	Asp	Leu	Ser	Ser 775	Lys	Leu	Asn	Glu	Ser 780	Ile	Asn	Lys	Ala
Met 785	Ile	Asn	Ile	Asn	Lys 790	Phe	Leu	Asn	Gln	Cys 795	Ser	Val	Ser	Tyr	Leu 800
Met	Asn	Ser	Met	Ile 805	Pro	Tyr	Gly	Val	Lys 810	Arg	Leu	Glu	Asp	Phe 815	Asp
			820					825					Asn 830	_	-
		835					840					845	Asn		
Leu	Ser 850	Thr	Asp	Ile	Pro	Phe 855	Gln	Leu	Ser	Lys	Tyr 860	Val	Asp	Asn	Gln
Arg	Leu	Leu	Ser	Thr	Phe	Thr	Glu	Tyr	Ile	Lys	*				

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2637 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

870

- (ii) MOLECULE_TYPE: DNA (genomic)
- (ix) FEATURE:

 - (A) NAME/KEY: CDS
 (B) LOCATION:1..2637
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
- ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly

875

GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20

			•			,		•					•				
GTC Val	AAC Lys	GCT Ala 35	a Phe	C.AAC E.Lys	S AT	Γ CAT ≥ His	AA(AS)	n Lys	A ATO	TGC Tr	G GTT	T ATT	Pro	G GAZ	A CGC i Arg	•	144
GA1 Asp	ACA Thr	Phe	r ACC Thi	AA G ASI	CCC n Pro	G GAA O Glu 55	Gli	A GGA 2 Gly	A GAC	TTC Leu	AAG ASI 60	Pro	CCC Pro	CCC Pro	GAA Glu		192
GCA Ala 65	Lys	Glr	GTC 1 Val	CCA Pro	A GTT Val	. Ser	TAC Tyl	TAC	GAT Asp	TCA Ser 75	Thr	TAT	CTG Leu	AGC Ser	ACA Thr		240
GAC Asp	AAC Asn	GAC Glu	AAC Lys	GAT Asp 85	Asr	TAC Tyr	CTC Lev	AAG Lys	GGA Gly 90	' Val	ACC Thr	AAA Lys	TTA Leu	TTC Phe 95	GAG Glu		288
CGT Arg	ATT	TAT	TCC Ser 100	Thr	GAC Asp	CTG Leu	GGC	CGT Arg 105	Met	CTG Leu	CTG Leu	ACC Thr	TCA Ser 110	Ile	GTC Val		336
CGC	GGA Gly	ATC Ile 115	Pro	TTT Phe	TGG Trp	GGT Gly	GGC Gly 120	Ser	ACC Thr	ATT	GAC Asp	ACG Thr 125	GAG Glu	TTG Leu	AAG Lys		384
GTT Val	ATT Ile 130	GAC Asp	ACT	AAC Asn	TGC Cys	Ile 135	AAC Asn	GTG Val	ATC Ile	CAA Gln	CCA Pro 140	Asp	GGT Gly	AGC Ser	TAC Tyr		432
AGA Arg 145	TCT Ser	GAA Glu	GAA Glu	CTT Leu	AAC Asn 150	CTC Leu	GTA Val	ATC Ile	ATC Ile	GGG Gly 155	CCC Pro	TCC Ser	GCG Ala	GAC Asp	ATT Ile 160		480
ATC Ile	CAG Gln	TTT Phe	GAG Glu	TGC Cys 165	AAG Lys	AGC Ser	TTT Phe	GGC Gly	CAC His 170	GAA Glu	GTG Val	TTG Leu	AAC Asn	CTG Leu 175	ACG Thr		528
CGT Arg	AAC Asn	GGT Gly	TAC Tyr 180	GGC Gly	TCT Ser	ACT Thr	CAG Gln	TAC Tyr 185	ATT Ile	CGT Arg	TTC Phe	AGC Ser	CCA Pro 190	GAC Asp	TTC Phe		576
ACG Thr	TTC Phe	GGT Gly 195	TTC Phe	GAG Glu	GAG Glu	AGC Ser	CTG Leu 200	GAG Glu	GTT Val	GAT Asp	ACC Thr	AAC Asn 205	CCG Pro	CTG Leu	TTG Leu		624
GGT Gly	GCA Ala 210	GGC Gly	AAG Lys	TTC Phe	GCA Ala	ACT Thr 215	GAT Asp	Pro	GCG Ala	GTG Val	ACC Thr 220	CTG Leu	GCA Ala	CAC His	GAG Glu		672
CTG Leu 225	ATC Ile	CAC His	GCC Ala	GGT Gly	CAT His 230	CGT Arg	CTG Leu	TAT Tyr	GGC Gly	ATT Ile 235	GCG Ala	ATT Ile	AAC Asn	CCG Pro	AAC Asn 240	·	720
CGC Arg	GTG Val	TTC Phe	AAG Lys	GTT Val 245	AAC Asn	ACC Thr	AAC Asn	GCC Ala	TAC Tyr 250	TAC Tyr	GAG Glu	ATG Met	AGT Ser	GGT Gly 25 5	TTA Leu		768
GAA Glu	GTA Val	AGC Ser	TTC Phe 260	Glu	GAA Glu	CTG Leu	CGC Arg	ACG Thr 265	TTC Phe	GGT Gly	GGC Gly	CAT	GAT Asp 270	GCG Ala	AAG Lys		816
TTT Phe	ATC Ile	GAC Asp 275	AGC Ser	TTG Leu	CAG Gln	GA G Glu	AAC Asn 280	GAG Glu	TTC Phe	CGT Arg	CTG Leu	TAC Tyr 285	TAC Tyr	TAC Tyr	AAC Asn		864
Lys	TTT Phe 290	AAA Lys	GAT Asp	ATT Ile	Ala	AGT Ser 295	ACA Thr	CTG Leu	AAC Asn	AAG Lys	GCT Ala 300	AA G Lys	TCC Ser	ATT Ile	GTG Val		912

- 62 -

GGT Gly 305	Thr	ACT Thr	GCT Ala	TCA Ser	TTA Leu 310	CAG Gln	TAT	ATG Met	AAA Lys	AAT Asn 315	GTT Val	TTT Phe	AAA Lys	GAG Glu	AAA Lys 320	960
TAT Tyr	CTC Leu	CTA Leu	TCT Ser	GAA Glu 325	Asp	ACA Thr	TCT Ser	GGA Gly	AAA Lys 330	TTT Phe	TCG Ser	GTA Val	GAT Asp	AAA Lys 335	TTA Leu	1008
AAA Lys	TTT Phe	GAT Asp	AAG Lys 340	Leu	TAC	AAA Lys	ATG Met	TTA Leu 345	ACA Thr	GAG Glu	ATT Ile	TAC Tyr	ACA Thr 350	GAG Glu	GAT Asp	1056
Asn	Phe	Val 355	Lys	Phe	Phe	Lys	Val 360	Leu	AAC Asn	Arg	Lys	Thr 365	Tyr	Leu	Asn	1104
TTT Phe	GAT Asp 370	AAA Lys	GCC Ala	GTA Val	TTT Phe	AAG Lys 375	ATA Ile	AAT Asn	ATA Ile	GTA Val	CCT Pro 380	AAG Lys	GTA Val	AAT Asn	TAC Tyr	1152
ACA Thr 385	ATA Ile	TAT	GAT Asp	GGA Gly	TTT Phe 390	AAT Asn	TTA Leu	AGA Arg	AAT Asn	ACA Thr 395	AAT Asn	TTA Leu	GCA Ala	GCA Ala	AAC Asn 400	1200
TTT Phe	AAT Asn	GGT Gly	CAA Gln	AAT Asn 405	ACA Thr	GAA Glu	ATT Ile	AAT Asn	AAT Asn 410	ATG Met	AAT Asn	TTT Phe	ACT Thr	AAA Lys 415	CTA Leu	1248
AAA Lys	AAT Asn	TTT Phe	ACT Thr 420	GGA Gly	TTG Leu	TTT Phe	GAA Glu	TTT Phe 425	TAT Tyr	AAG Lys	TTG Leu	CTA Leu	TGT Cys 430	GTA Val	AGA Arg	1296
GGG Gly	ATA Ile	ATA Ile 435	ACT Thr	TCT	AAA Lys	ACT Thr	AAA Lys 440	TCA Ser	TTA Leu	GAT Asp	AAA Lys	GGA Gly 445	TAC Tyr	AAT Asn	AAG Lys	1344
ATC Ile	GAA Glu 450	GGT Gly	CGT Arg	TGC Cys	GAT Asp	GGG Gly 455	GCA Ala	TTA Leu	AAT Asn	GAT Asp	TTA Leu 460	TGT Cys	ATC Ile	AAA Lys	GTT Val	1392
AAT Asn 465	AAT Asn	TGG Trp	GAC Asp	TTG Leu	TTT Phe 470	TTT Phe	AGT Ser	CCT Pro	TCA Ser	GAA Glu 475	GAT Asp	AAT Asn	TTT Phe	ACT Thr	AAT Asn 480	1440
GAT Asp	CTA Leu	AAT Asn	AAA Lys	GGA Gly 485	GAA Glu	GAA Glu	ATT Ile	ACA Thr	TCT Ser 490	GAT Asp	ACT Thr	AAT Asn	ATA Ile	GAA Glu 495	GCA Ala	1488
GCA Ala	GAA Glu	GAA Glu	AAT Asn 500	ATT Ile	AGT Ser	TTA Leu	GAT Asp	TTA Leu 505	ATA Ile	CAA Gln	CAA Gln	TAT Tyr	TAT Tyr 510	TTA Leu	ACC Thr	1536
TTT Phe	AAT Asn	TTT Phe 515	GAT Asp	TAA Asn	GAA Glu	CCT Pro	GAA Glu 520	AAT Asn	ATT	TCA Ser	ATA Ile	GAA Glu 525	AAT Asn	CTT Leu	TCA Ser	1584
AGT Ser	GAC Asp 530	ATT Ile	ATA Ile	GGC Gly	CAA Gln	TTA Leu 535	GAA Glu	CTT Leu	ATG Met	CCT Pro	AAT Asn 540	ATA Ile	GAA Glu	AGA Arg	TTT Phe	1632
CCT Pro 545	AAT Asn	GGA Gly	AAA Lys	AAG Lys	TAT Tyr 550	GAG Glu	TTA Leu	GAT Asp	AAA Lys	TAT Tyr 555	ACT Thr	ATG Met	TTC Phe	CAT His	TAT Tyr 560	1680
CTT Leu	CGT Arg	GCT Ala	CAA Gln	GAA Glu 565	TTT Phe	GAA Glu	CAT His	GGT Gly	AAA Lys 570	TCT Ser	AGG Arg	ATT Ile	GCT Ala	TTA Leu 575	ACA Thr	1728

ANT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT ASIS SEY VAI ASIN GIU AIA LEU LEU ASIN PYO SEY ARG VAI TYP THY PHE \$80 TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA ACT ACG GAG GCA GCT Phe Ser's Ser Asp Tyr Val Lys Lys Val Asin Lys Ala Thr Giu Ala Ala \$605 ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA Met Phe Leu Gly Trp Vai Gly Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCC GAT ATA ACT ATA ATT Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 625 ATT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCC GAT ATA ACT ATA ATT THE SER Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 645 645 GAT GAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TATA TA																		
ATG TIT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TIT ACC GAT GAA MET POR Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu 610 ATG AGC GAA GTA AGT ACT ACC GAT AAA ATT GCG GAT ATA ACT ATA ATT Thr Ser Glu Val Ser Thr Thr ASP Lys Ile Ala Asp Ile Thr Ile Ile 635 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA ILE PRO Tyr Ile Gly Pro Ala Leu Asn Ile GIY Asn Met Leu Tyr Lys 645 GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA ASP ASP ASP PHE Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 670 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GU Phe Ala Leu GIY Fire Val Leu Gly Thr Phe Ala Leu Composition of 675 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA ASP ASP PHE Val Gly Ala Leu Thr Val Ghn Thr Ile ASP Asn 695 GTA TCA TAT ATT CCG AAT AGG GTT CTA ACC GTT CAA ACCA ATA GAT AAT CCA GAS TTY ILE ASP ASN 695 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA ANA ILE EVE VAL Ser Tyr Ile Ala ASN Lys Val Leu Thr Val Ghn Thr Ile ASP ASN 695 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA ANA ILE Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Tle 710 GTA ACA AAT TGG TAA GCA AGG GTT AAT ACA CAG ATT GAT CTA ATA AGA Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg. 720 GTA ACA AAT TGG TTA GCA AAG GCT TTA GAA ACC AGA ACC ACA AAG GCT Lys Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 740 ATA AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT Lys Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 740 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAA GAA AAA AAA TAT TAT ATA GAA CAA AAG GCT TTA ASN TTP Glu Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn 740 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAA GAA AAA AAT AAT TAT ATT GAT GA	AA As	T TC	CT G	al A	sn G	AA GO lu Al	CA TI la Le	A TT	u As	n Pr	T AG o Se	T CG	T GT g Va	1 Ty	r Th	CA TTT ir Phe	17	776
### Pipe Leu Giy firp val Giu Gin Leu Val Tyr Asp 620 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT THR Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 625 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT THR Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 625 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys 645 GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 665 GAA TAT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu 675 GAT TA TATA CCA GAG ATT GCA ATA CCT GTA TTA GCT ACT TTT GCA CTT GLY Phe Ala Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 695 GAT TA TATA ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT ATA ATA 6690 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA AGA ALA ATA GAT AAT GAT ATA GAT AAT ATA AGA AAA FAG AAT GAA AAA TGG AAT GAG GTC TAT AAA TAT ATA AGA AAA ATA GAA AAT GAA ATA GAA ATA GAA ATA TAT ATA AGA AAA ATA GAA AAT GAA ATA GAA ATA GAA ATA GAA ATA GAA ATA GAA ATA TAT ATA AGA AAA ATA GAA AAT GAA AAT GAA GAT TAT ATA AGA CAA ATA GAT ATA AGA CAA ATA GAA GAT ATA AGA CAA ATA GAA CAA ATA GAA GAA ATA GAA GAA ATA GAA GAA ATA GAA ATA GAA ATA GAA GA	TI Ph	T TC e Se	er se	er As	AC TI	AT GI yr Va	TA AA il Ly	s Lys	s Va	T AA l As	T AA n Ly	A GC s Al	a Th	r Gl	G GC u Al	CA GCT .a Ala	18	124
ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA AAA	AT Me	t Pn	e Le	TA GO	SC TO	GG G1 cp Va	I GI	u Glr	A TT	A GT u Va.	A ТА' 1 Ту:	r Ası	p Ph	T AC e Th	C GA r As	T GAA p Glu	18	72
GAT GAT TIT GTA GGT GCT TTA ATA TIT TCA GGA GCT GTT ATT CTG TTA ASP ASP Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 665 GAA TIT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA G65 GAA TIT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA G67 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA G67 GAA TTT ATA TATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT G70 GAA TTT ATA TT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT CVA Ser Tyr Ile Ala ASS Lys Val Leu Thr Val Gln Thr Ile Asp Ass 695 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA ATA AIA Leu Ser Lys Arg Ass Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 720 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA CVAl Thr Ass TTP Leu Ala Lys Val Ass Thr Gln Ile Asp Leu Ile Arg 735 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ACA CVAL THR ASS TYR GIN ALA CU GLU ALA GIN ALA CTA GAG ATA COT ATA AGA CVAL THR Lys Glu Ala Leu Glu Ass Gln Ala Glu Ala Thr Lys Ala 740 ATA ATA AAC TAT CAG TAT AAT CAA CAA TAT ACT GAG GAA GAA AAA AAT AAT ATA TAT CAG TAT AAT CAA GCA GAA GAA AAA AAT TAT CAG TAT AAT CAA TAT ACT GAG GAA GAA AAA AAT TAT CAG TAT AAT CAA TAT ACT GAG GAA GAA AAA AAT TAT CAG TAT AAT CAA TAT ACT GAG GAA GAA AAA AAT AAT AAT AAT AAT AA	62	r se 5	r G1	u Va	il Se	63	r Th:	r Asp	Ly:	s Ile	e Ala 635	a Asp	o Ile	e Th	r Il	e Ile 640	19	20
ASP ASP Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 665 665 665 665 665 665 665 665 665 66	11	e Pr	о ту	. 11	.e G1 64	y Pr 5	O Ala	a Leu	Asr	1 Ile	e Gly	/ Asr	n Met	Le:	1 Ty	r Lys 5	19	68
GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT ATA AAT AAT AAT AAT AAT AA	Asį	O AS	p Ph	e Va 66	0 1 G1	A AT	a Lei	ı Ile	Phe 665	e Ser	Gly	Ala	a Val	1 Ile 670	e Le	u Leu	20	16
Ser Tyr Ile Ala Ash Lys Val Leu Thr Val Ghn Thr Ile Asp Ash 695 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA ALA Leu Ser Lys Arg Ash Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 720 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAG GCT 725 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GCA ACA ACA AAG GCT 735 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GCA GAA GCA ACA AAG GCT Lys Lys Met Lys Glu Ala Leu Glu Ash Gln Ala Glu Ala Thr Lys Ala 750 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GCA AAA AAT AAT ASh Tyr Gln Tyr Ash Gln Tyr Thr Glu Glu Glu Lys Ash Ash 750 ATT AAT TTT AAT ATT GAT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 11e Ash Phe Ash Ile Asp Asp Leu Ser Ser Lys Leu Ash Glu Ser Ile 770 AAT AAA GCT ATG ATT AAT ATA AAT AAA TATA AAA TTT TTG AAT CAA TGC TCT GTT 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 780 AAT AAA GCT ATG ATT AAT ATA ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 780 CTCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA CST TYR Leu Met Ash Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 815 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAA CAG TTA AAA GAT AAA GAT TAT AAA GAT CAA TGC TTA TAT TAT GAT ASh Phe Ash Ala Ser Leu Lys Ash Ala Leu Leu Lys Tyr Ile Tyr Ash 820 AAT AGA CGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAA AAA	GI	ı Phe	67	e Pr 5	o GI	u II	e Ala	680	Pro	Val	. Leu	Gly	7 Thr 685	Phe	Al.	a Leu	200	64
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 705 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg 725 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GCA GCA GCA ACA AAG GCT Lys Lys Met Lys Glu Ala Leu Glu Asn Cln Ala Glu Ala Thr Lys Ala 740 ATA ATA ATA CAT CAG TAT AAT CAA TAT ACT GAG GAA GCA GLU ASN ASN ATI ATA ATA ATA CAT TYR ASN TYR Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn ASS TYR Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn ATT AAT TTT AAT ATT GAT GAT GAT TAT AGT TCG AAA CTT AAT GAG TCT ATA Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile 770 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT ASN Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val 785 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 GAT TTT GAT GAT GCT CTT AAA GAT GCA TTA TATA AAA GAT TATA TATA	Val	690	r Ty:	r II	e Al	a Ası	695	Val	Leu	Thr	Val	Gln 700	Thr	Ile	: Ası) Asn	213	LŻ
AAA AAA ATG AAA GAA GAT TTA GAT AAT AAA AAA	705	Leu	ı Şei	r Ly:	s Ar	g Asr 710	ı Glu	Lys	Trp	Asp	Glu 715	Val	Tyr	Lys	Туг	720	216	50
ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA CTT AAT GAG TCT ATA ASS Leu Ass Lys Phe Ass Lys Ala Met Ass Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 815 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTT AAA GAT AAA CGG TTA GAA CGA TAT AAT TTT GAT GAT ASS Ser Leu Lys Ass Ala Ser Leu Lys Ass Ala Leu Leu Lys Tyr Ile Tyr Ass 820 AAT AAA GGA ACT TTA AAT GGT CAA GTA GAT AAA GAT AAA GAT AAA GTT AAT GAT G	vai	Thr	ASI	ı Tr	729	a Ala	Lys	Val	Asn	730	Gln	Ile	Asp	Leu	735	Arg.	220	8
ATT AAT TTT AAT ATT GAT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT ASS GIN Tyr Thr Glu Glu Glu Lys Ass Ass Ass 760 ATT AAT TTT AAT ATT GAT GAT GAT TA AGT TCG AAA CTT AAT GAG TCT ATA 11e Ass 11e As	Lys	rys	Met	740	GIU	ı Ala	Leu	Glu	Asn 745	Gln	Ala	Glu	Ala	Thr 750	Ļys	Ala	225	6
AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT AAA Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Glu Ser Val 795 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT ASP ASP ARG GIY THR Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val	iie	ile	755	тут	. Glr	Tyr	Asn	760	Tyr	Thr	Glu	Glu	Glu 765	Lys	Asn	Asn	230	4
Ash Lys Ala Met lie Ash Ile Ash Lys Phe Leu Ash Gln Cys Ser Val 795 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Ash Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT Ash Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val	Ite	770	Phe	: Asņ	lle	. Asp	775	Leu	Ser	Ser	Lys	Leu 780	Asn	Glu	Ser	Ile	235	2
GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT ASP Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT ASP ASP ARG ARG GIY THE Leu Ile Gly Gin Val Asp Arg Leu Lys Asp Lys Val	Asn 785	Lys	Ala	Met	He	790	Ile	Asn	Lys	Phe	Leu 795	Asn	Gln	Cys	Ser	Val 800	240	O .
Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 825 830 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val	TCA Ser	TAT Tyr	TTA Leu	ATG Met	Asn	Ser	ATG Met	ATC Ile	CCT Pro	Tyr	GGT	GTT Val	AAA Lys	CGG Arg	Leu	GAA Glu	244	8
Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val	GAT Asp	TTT Phe	GAT Asp	Ala	AGT Ser	CTT	AAA Lys	Asp .	Ala	TTA Leu	TTA Leu	AAG Lys	TAT Tyr	Ile	TAT Tyr	GAT Asp	249	6
	AAT Asn	AGA Arg	Gly	ACT Thr	TTA Leu	ATT Ile	GGT Gly	Gln '	GTA Val	GAT Asp	AGA Arg	TTA Leu	Lys	GAT Asp	AAA Lys	GTT Val	2544	1

- 64 -

AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val 855 GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2637 Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys 870 875

- (2) INFORMATION FOR SEQ ID NO: 12:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 879 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 105 Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 155 Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 205

Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu

Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn

Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 250 255

Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 395 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 410 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 425 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 470 475 Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser 520 Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 600

- 66 -

Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 695 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 745 Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys 865 870

- (2) INFORMATION FOR SEQ ID NO: 13:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2862 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION:1..2862
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

•										_								
AT Me	G CAG	G TI n Ph	CC G1 ne Va	TG AA	AC AA sn Ly 5	AG CA /s Gl	G TI n Ph	C AA e As	C TA n Ty 1	T ÅA T Ly 0	G GA s As	C CC	T GT	al As	AC (sn (GGT Gly		48
GT Va	T GAG	C AT	E MI	C TA	C AT	C AA .e Ly	A AT	T CC. e Pro 2	o As	C GC	C GG a Gl	C CA y Gl	n Me	G CZ et Gl	AG (CCG Pro		96
GT(Va)	AAC L Lys	S MI	T TT a Ph 5	C AA e Ly	G AT	T CA e Hi	T AA s As:	n Lys	A ATO	C TGG e Tr	G∘GT p∘Va	T AT 1 11 4	e Pr	G GA	NA C	GC Yrg		144
GA] Asp	ACA Thr	. PII	T AC e Th	G AA r As	C CC n Pr	G GA o Gl 5	u GII	A GG/ u Gl _}	A GA(/ Asi	C TTC p Lev	S AA AS:	n Pr	G CC o Pr	G CC	G G	AA lu		192
GCA Ala 65	r nys	Gl:	G GT n Va	G CC 1 Pr	A GT o Va 7	r se	A TAC	TAC Tyr	GAT Asi	TCF Ser 75	: Thi	TA'	T CT r Le	G AG u Se	r T	CA hr 80		240
GAC Asp	AAC Asn	GA(G AAG u Ly:	G GA s Ası 8	P AS	C TAC	C CTC	AAG Lys	GGA Gly 90	A GTG Val	ACC Thi	AA Lys	A TT	u Ph	C G e G 5	AG lu		288
CGT Arg	ATT	TA?	TCC Ser 100	1111	r Asi	C CTC	G GGC	CGT Arg 105	Met	CTG Leu	CTC Lev	ACO Thi	TC: F Se:	r Il	C G e V	TC al		336
CGC Arg	GGA Gly	ATC Ile	PIC	A TTT	TGC Trp	G GGT	GGC Gly 120	Ser	ACC	ATT	GAC Asp	ACC Thr	: Glı	G TT(G A	AG Ys		384
GTT Val	ATT Ile 130	GAC Asp	ACT Thr	AAC Asn	TGC Cys	Ile 135	Asn	GTG Val	ATC Ile	CAA Gln	CCA Pro	Asp	GG1 Gly	AG(Sei	T)	AC /I		432
AGA Arg 145	TCT	GAA Glu	GAA Glu	CTI Leu	AAC Asn 150	Leu	GTA Val	ATC Ile	ATC Ile	GGG Gly 155	CCC Pro	TCC	GCG Ala	GAC Asp	A1	.e		480
ATC Ile	CAG Gln	TTT	GAG Glu	TGC Cys 165	AAG Lys	AGC Ser	TTT Phe	GGC Gly	CAC His 170	GAA Glu	GTG Val	TTG Leu	AAC Asn	CTC Leu 175	Th	:G ir		528
CGT	AAC Asn	GGT Gly	TAC Tyr 180	GIY	Ser	Inr	CAG Gln	Tyr	He	CGT Arg	TTC Phe	AGC Ser	CCA Pro 190	GAC Asp	TT	C e		576
ACG Thr	Pne	GGT Gly 195	TTC Phe	GAG Glu	GAG Glu	AGC Ser	CTG Leu 200	GAG Glu	GTT Val	GAT Asp	ACC Thr	AAC Asn 205	CCG Pro	CTG Leu	TT Le	G u	••	624
GIY	GCA Ala 210	GGC Gly	AAG Lys	TTC Phe	GCA Ala	ACT Thr 215	GAT Asp	CCA Pro	GCG Ala	GTG Val	ACC Thr 220	CTG Leu	GCA Ala	CAC His	GA Gl	G u		672
CTG Leu 225	ATC	CAC His	GCC Ala	GGT Gly	CAT His 230	CGT Arg	CTG Leu	TAT Tyr	GGC Gly	ATT Ile 235	GCG Ala	ATT Ile	AAC Asn	CCG Pro	AA Asi 24	n.		720
CGC (GTG 1	Phe	AAG Lys	GTT Val 245	AAC Asn	ACC Thr	AAC Asn	Ala '	TAC Tyr 250	TAC (GAG Glu	ATG Met	AGT Ser	GGT Gly 255	TT	A		768
GAA (GTA A	er	TTC Phe 260	GAG Glu	GAA Glu	CTG Leu	Arg '	ACG : Thr 1 265	TTC (Phe (GGT (GGC Gly	CAT	GAT Asp 270	GCG Ala	AAC Lys	5		816
														_				

- 68 -

TTT Phe	ATC	GAC Asp 275	ser	TTC Lev	CAG Gln	GAG Glu	AAC Asn 280	Glu	TTC Phe	CGT	CTG Leu	TAC Tyr 285	TAC	TAC	AAC Asn	864
AAG Lys	Phe 290	rys	GAI Asp	ATI Ile	GCA Ala	AGT Ser 295	ACA Thr	CTG Leu	AAC Asn	AAG Lys	GCT Ala 300	Lys	TCC Ser	ATT Ile	GTG Val	912
GGT Gly 305	Inr	ACT Thr	GCT Ala	TCA Ser	TTA Leu 310	Gin	TAT Tyr	ATG Met	AAA Lys	AAT Asn 315	GTT Val	TTT Phe	AAA Lys	GAG Glu	AAA Lys 320	960
Tyr	Leu	rea	Ser	325	Asp	Thr	Ser	Gly	1330	Phe	Ser	Val	Asp	AAA Lys 335	Leu	1008
AAA Lys	TTT Phe	GAT Asp	AAG Lys 340	Leu	TAC	AAA Lys	ATG Met	TTA Leu 345	ACA Thr	GAG Glu	ATT Ile	TAC Tyr	ACA Thr 350	GAG Glu	GAT Asp	1056
AAT Asn	TTT Phe	GTT Val 355	AAG Lys	TTT Phe	TTT Phe	AAA Lys	GTA Val 360	CTT Leu	AAC Asn	AGA Arg	AAA Lys	ACA Thr 365	TAT	TTG Leu	AAT Asn	1104
TTT Phe	GAT Asp 370	AAA Lys	GCC Ala	GTA Val	TTT Phe	AAG Lys 375	ATA Ile	AAT Asn	ATA Ile	GTA Val	CCT Pro 380	AAG Lys	GTA Val	AAT Asn	TAC Tyr	1152
ACA Thr 385	ATA Ile	TAT Tyr	GAT Asp	GGA Gly	TTT Phe 390	AAT Asn	TTA Leu	AGA Arg	AAT Asn	ACA Thr 395	AAT Asn	TTA Leu	GCA Ala	GCA Ala	AAC Asn 400	1200
TTT Phe	AAT Asn	GGT Gly	CAA Gln	AAT Asn 405	ACA Thr	GAA Glu	ATT Ile	AAT Asn	AAT Asn 410	ATG Met	AAT Asn	TTT Phe	ACT Thr	AAA Lys 415	CTA Leu	1248
AAA Lys	AAT Asn	TTT Phe	ACT Thr 420	GGA Gly	TTG Leu	TTT Phe	GAA Glu	TTT Phe 425	TAT Tyr	AAG Lys	TTG Leu	CTA Leu	TGT Cys 430	GTA Val	AGA Arg	1296
GGG Gly	ATA Ile	ATA Ile 435	ACT Thr	TCT Ser	AAA Lys	ACT Thr	AAA Lys 440	TCA Ser	TTA Leu	GAT Asp	AAA Lys	GGA Gly 445	TAC Tyr	AAT Asn	AAG Lys	1344
ATC Ile	GAA Glu 450	GGT Gly	CGT Arg	TGC Cys	GAT Asp	GGG Gly 455	GCA Ala	TTA Leu	AAT Asn	GAT Asp	TTA Leu 460	TGT Cys	ATC Ile	AAA Lys	GTT Val	1392
AAT Asn 465	AAT Asn	TGG Trp	GAC Asp	TTG Leu	TTT Phe 470	TTT Phe	AGT Ser	CCT Pro	TCA Ser	GAA Glu 475	GAT Asp	AAT Asn	TTT Phe	ACT Thr	AAT Asn 480	1440
GAT Asp	CTA Leu	AAT Asn	AAA Lys	GGA Gly 485	GAA Glu	GAA Glu	ATT Ile	ACA Thr	TCT Ser 490	GAT Asp	ACT Thr	AAT Asn	ATA Ile	GAA Glu 495	GCA Ala	1488
GCA Ala	GAA Glu	GAA Glu	AAT Asn 500	ATT Ile	AGT Ser	TTA Leu	GAT Asp	TTA Leu 505	ATA Ile	CAA Gln	CAA Gln	TAT Tyr	TAT Tyr 510	TTA Leu	ACC Thr	1536
TTT Phe	AAT Asn	TTT Phe 515	GAT Asp	AAT Asn	GAA Glu	Pro	GAA Glu 520	AAT Asn	ATT Ile	TCA Ser	ATA Ile	GAA Glu 525	AAT Asn	CTT Leu	TCA Ser	1584
AGT Ser	GAC Asp 530	ATT Ile	ATA Ile	GGC Gly	CAA Gln	TTA Leu 535	GAA Glu	CTT Leu	ATG Met	CCT Pro	AAT Asn 540	ATA Ile	GAA Glu	AGA Arg	TTT Phe	1632

- 69 -

																. *		
CC Pro	O Asi	r GG : Gl	À AÁ y Ly	A AA s Ly	G TA' s Ty: 55	r Glu	TTA Leu	GAT L Asp	Lys	TA: 5 Ty: 555	Thi	r ATC	G TT	C CA' e Hi	T TAT s Tyr 560		1680	
CT'	r cg: u Arq	GC Al	T CA a Gl:	A GA n Gli 56	u Phe	T GAA e Glu	CAT His	GG1 Gly	AAA Lýs 570	Ser	AGC Arg	G ATT	GC:	T TT	A ACA u Thr 5		1728	
AA Asi	r TC1 n Sei	GT Va	T AAG 1 Ass 580	n Gli	A GC/ L Ala	A TTA a Leu	TTA Leu	AAT Asn 585	Pro	AGT Ser	CG1	GTT Val	TA: Ty:	r Thi	A TTT r Phe		1776	
TTT	TC1	TC: Se: 599	r Ası	C TAT	r GTA	A AAG L Lys	AAA Lys 600	Val	'AAT Asn	Lys	GCT Ala	ACC Th: 605	Glu	G GCA	A GCT a Ala		1824	
ATC Met	TTT Phe	: Le	A GGG	TGC Trp	GTA Val	A GAA L Glu 615	CAA Gln	TTA Leu	GTA Val	TAT Tyr	GAT Asp 620	Phe	ACC Thr	GAT Asp	GAA Glu		1872	
ACT Thr 625	Ser	GAZ Glu	A GTA ı Val	A AG1 L Ser	ACT Thr 630	C ACG Thr	GAT Asp	AAA Lys	ATT	GCG Ala 635	Asp	ATA	ACI Thr	ATA	A ATT		1920	
ATI Ile	CCA Pro	TAT	T ATA	GGA Gly 645	Pro	GCT Ala	TTA	AAT Asn	ATA Ile 650	Gly	AAT Asn	ATG Met	Leu	TAT Tyr 655	Lys		1968	
GAT Asp	GAT Asp	TTT Phe	GTA Val 660	. Gly	GCT Ala	TTA Leu	ATA Ile	TTT Phe 665	TCA Ser	GGA Gly	GCT	GTT Val	ATT Ile 670	Leu	TTA Leu	-	2016	
GAA Glu	TTT Phe	ATA Ile 675	Pro	GAG Glu	ATT Ile	GCA Ala	ATA Ile 680	CCT Pro	GTA Val	TTA Leu	GGT Gly	ACT Thr 685	Phe	GCA Ala	CTT		2064	
GTA Val	TCA Ser 690	TAT	ATT	GCG Ala	AAŤ Asn	AAG Lys 695	GTT Val	CTA Leu	ACC Thr	GTT Val	CAA Gln 700	ACA Thr	ATA	GAT Asp	AAT Asn		2112	
GCT Ala 705	TTA Leu	AGT Ser	AAA Lys	AGA Arg	AAT Asn 710	GAA Glu	AAA Lys	TGG Trp	GAT Asp	GAG Glu 715	GTC Val	TAT	AAA Lys	TAT Tyr	ATA Ile 720		2160	
GTA Val	ACA Thr	AAT Asn	TCG	TTA Leu 725	GCA Ala	AAG Lys	GTT Val	AAT Asn	ACA Thr 730	CAG Gln	ATT Ile	GAT Asp	CTA Leu	ATA Ile 735	Arg		2208	
AAA Lys	AAA Lys	ATG Met	AAA Lys 740	GAA Glu	GCT Ala	TTA Leu	GAA Glu	AAT Asn 745	CAA Gln	GCA Ala	GAA Glu	GCA Ala	ACA Thr 750	AAG Lys	GCT Ala		2256	
ATA Ile	ATA. Ile	AAC Asn 755	TAT Tyr	CAG Gln	TAT Tyr	AAT Asn	CAA Gln 760	TAT Tyr	ACT Thr	GAG Glu	GAA Glu	GAG Glu 765	AAA Lys	AAT Asn	AAT Asn		2304	
ATT Ile	AAT Asn 770	TTT Phe	AAT Asn	ATT Ile	GAT Asp	GAT Asp 775	TTA . Leu	AGT Ser	TCG Ser	AAA Lys	CTT Leu 780	AAT Asn	GAG Glu	TCT Ser	ATA Ile		2352	
AAT Asn 785	AAA Lys	GCT Ala	ATG Met	ATT Ile	AAT Asn 790	ATA . Ile .	AAT . Asn :	AAA Lys	TTT Phe	TTG Leu 795	AAT Asn	CAA Gln	TGC Cys	TCT Ser	GTT Val 800	•	2400	
TCA Ser	TAT Tyr	TTA Leu	ATG Met	AAT Asn 805	TCT Ser	ATG A	ATC (CCT Pro	TAT Tyr 810	GGT Gly	GTT Val	AAA Lys	CGG Arg	TTA Leu 815	GAA Glu		2448	

GAT Asp	TTT Phe	GAT Asp	GCT Ala 820	AGT Ser	CTT Leu	AAA Lys	GAT Asp	GCA Ala 825	TTA Leu	TTA Leu	AAG Lys	TAT Tyr	ATA Ile 830	TAT Tyr	GAT Asp	2496
AAT Asn	AGA Arg	GGA Gly 835	ACT Thr	TTA Leu	ATT Ile	GGT Gly	CAA Gln 840	GTA Val	GAT Asp	AGA Arg	TTA Leu	AAA Lys 845	GAT Asp	AAA Lys	GTT Val	2544
AAT Asn	AAT Asn 850	ACA Thr	CTT Leu	AGT Ser	ACA Thr	GAT Asp 855	ATA Ile	CCT Pro	TTT Phe	CAG Gln	CTT Leu 860	TCC Ser	AAA Lys	TAC Tyr	GTA Val	2592
GAT Asp 865	AAT Asn	CAA Gln	AGA Arg	TTA Leu	TTA Leu 870	TCT Ser	ACA Thr	TTT Phe	ACT Thr	GAA Glu 875	TAT Tyr	ATT Ile	AAG Lys	TCT Ser	AGG Arg 880	2640
CCT Pro	GGA Gly	CCG Pro	GAG Glu	ACG Thr 885	CTC Leu	TGC Cys	GGG Gly	GCT Ala	GAG Glu 890	CTG Leu	GTG Val	GAT Asp	GCT Ala	CTT Leu 895	CAG Gln	2688
TTC Phe	GTG Val	TGT Cys	GGA Gly 900	GAC Asp	AGG Arg	GGC Gly	TTT Phe	TAT Tyr 905	TTC Phe	AAC Asn	AAG Lys	CCC Pro	ACA Thr 910	GGG Gly	TAT Tyr	2736
GGC Gly	TCC Ser	AGC Ser 915	AGT Ser	CGG Arg	AGG Arg	GCG Ala	CCT Pro 920	CAG Gln	ACA Thr	GGT Gly	ATC Ile	GTG Val 925	GAT Asp	GAG Glu	TGC Cys	2784
TGC Cys	TTC Phe 930	CGG Arg	AGC Ser	TGT Cys	GAT Asp	CTA Leu 935	AGG Arg	AGG Arg	CTG Leu	GAG Glu	ATG Met 940	TAT Tyr	TGC Cys	GCA Ala	CCC Pro	2832
				AAG Lys					TAG *							2862

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 954 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly

Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro

Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg


Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu

Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr

Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 90

Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 105

Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Ard Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 265 Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 360 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val 455 460



											•					
Asp	Phe	e Ası	P Ala 820	Ser	: Leu	Lys	Asp	Ala 829	a Le	ı Leı	Ly:	з Ту	83		r Asp	ı
Asr	a Arg	61 839	y Thi	Leu	Ile	e Gly	Glr 840	val	l Ası	o Arg	g Le	1 Lys		p Ly:	s Val	
Asr	850	The	r Leu	Ser	Thr	Asp 855	Ile	Pro	Phe	€ Glr	Let 860		Ly	з Туг	r Val	
Asr 865	Asn	Glr	n Arg	Leu	Leu 870	Ser	Thr	Phe	Thi	Glu 875		Ile	Lys	s Sei	Arg 880	
Pro	Gly	Pro	Glu	Thr 885	Leu	Cys	Gly	Ala	Gl: 890		val	. Asp	Ala	a Leu 899	ı Gln	
Phe	. Val	Cys	900	Asp	Arg	Gly	Phe	Tyr 905		Asn	Lys	Pro	Thr 910		' Tyr	
Gly	Ser	Ser 915	Ser	Arg	Arg	Ala	Pro 920	Gln	Thr	Gly	Ile	Val 925		Glu	Cys	
Cys	Phe 930	Arg	Ser	Cys	Asp	Leu 935	Arg	Arg	Leu	Glu	Met 940		Cys	Ala	Pro	
Leu 945		Pro	Ala	Lys	Ser 950	Ala	Glu	Ala	•							
(2)	INF	ORMA	TION	FOR	SEQ	ID 1	NO:	15:								
	(i)	(; (;	QUENCA) LI B) TY C) ST D) TC	ENGTI (PE : [RAN]	nuc. DEDNI	724 l leic ESS:	acio doul	pai:	rs				-			
	/iii	MO	LECUI	E 17%	/DF.	DATA	(_ \							•
	(11)	140	LECUI	JE 11	if£;	DNA	(ger	10111	= 1					٠.		
	(ix)	(2	ATURE A) NA B) LO	ME/K			24									
	(xi)	SEC	QUENC	E DE	SCRI	PTIC	N: S	EQ 1	יא סו	D: 19	5:					
ATG Met 1	CAG Gln	TTC Phe	GTG Val	AAC Asn 5	AAG Lys	CAG Gln	TTC Phe	AAC Asn	TAT Tyr 10	AAG Lys	GAC Asp	CCT Pro	GTA Val	AAC Asn 15	GGT	4 8
GTT Val	GAC Asp	ATT Ile	GCC Ala 20	TAC Tyr	ATC Ile	AAA Lys	ATT Ile	CCA Pro 25	AAC Asn	GCC Ala	GGC Gly	CAG Gln	ATG Met 30	CAG Gln	CCG Pro	96
GTG Val	AAG Lys	GCT Ala 35	TTC Phe	AAG . Lys	ATT Ile	CAT . His .	AAC Asn 40	AAA Lys	ATC Ile	TGG Trp	GTT Val	ATT Ile 45	CCG Pro	GAA Glu	CGC Arg	144
GAT Asp	ACA Thr 50	TTT Phe	ACG .	AAC (Asn)	CCG (GAA (Glu (55	GAA Glu	GGA Gly	GAC Asp	TTG Leu	AAC Asn 60	CCG Pro	CCG [.] Pro	CCG Pro	GAA Glu	192
GCA Ala 65	Lys (CAG Gln	GTG (Val	CCA (Pro 1	GTT 'Val :	TCA ' Ser '	TAC Tyr	TAC Tyr	GAT Asp	TCA Ser 75	ACC Thr	TAT Tyr	CTG Leu	AGC Ser	ACA Thr 80	240
SAC .	AAC (Asn (GAG Glu	AAG (GAT A Asp A 85	AAC ' Asn '	TAC (Tyr 1	CTG Leu	AAG Lys	GGA Gly 90	GTG Val	ACC Thr	AAA Lys	TTA Leu	TTC Phe 95	GAG Glu	288

95

CG' Arg	r Art	TA:	r TCC r Ser 100		C Asp	CTG Leu	GG Gly	CGT Arg	y Met	G CTO	G CTO	G ACC	TCA Ser	: Ile	C GTC ≥ Val		336
CGG	GG, Gly	A ATO		TTT Phe	TGG Trp	GGT Gly	GGC Gly 120	Ser	ACC Thi	: ATT	GAC Asp	ACG Thr	· Glu	TTC Let	G AAG 1 Lys		384
GTT Val	T ATT		ACT Thr	AAC Asr	TGC Cys	Ile 135	ASI	GTG Val	ATC Ile	CAA Gln	CCA Pro	Asp	GGT	AGC Ser	TAC		432
AGA Arg 145	, ser	GAA Glu	GAA Glu	CTI Leu	AAC Asn 150	Leu	GTA Val	ATC Ile	ATC Ile	GGG Gly 155	Pro	TCC Ser	GCG Ala	GAC Asp	ATT Ile 160		480
ATC	CAG Gln	TTT Phe	GAG Glu	TGC Cys 165	Lys	AGC Ser	TTT Phe	GGC Gly	CAC His 170	Glu	GTG Val	TTG Leu	AAC Asn	CTG Leu 175	ACG Thr		528
CG1 Arg	AAC Asn	GGT Gly	TAC Tyr 180	GGC Gly	TCT Ser	ACT Thr	CAG Gln	TAC Tyr 185	ATT Ile	CGT Arg	TTC Phe	AGC Ser	CCA Pro 190	GAC Asp	TTC Phe	٠.	576
ACG Thr	TTC Phe	GGT Gly 195	Pile	GAG Glu	GAG Glu	AGC Ser	CTG Leu 200	GAG Glu	GTT Val	GAT Asp	ACC Thr	AAC Asn 205	CCG Pro	CTG Leu	TTG Leu		624
GGT Gly	GCA Ala 210	GGC Gly	AAG Lys	TTC Phe	GCA Ala	ACT Thr 215	GAT Asp	CCA Pro	GCG Ala	GTG Val	ACC Thr 220	CTG Leu	GCA Ala	CAC His	GAG Glu		672
CTG Leu 225	ATC Ile	CAC His	GCC Ala	GGT Gly	CAT His 230	CGT Arg	CTG Leu	TAT Tyr	GGC Gly	ATT Ile 235	GCG Ala	ATT Ile	AAC Asn	CCG Pro	AAC Asn 240		720
CGC Arg	GTG Val	TTC Phe	AAG Lys	GTT Val 245	AAC Asn	ACC Thr	AAC Asn	GCC Ala	TAC Tyr 250	TAC Tyr	GAG Glu	ATG Met	AGT Ser	GGT Gly 255	TTA Leu		768
GAA Glu	GTA Val	AGC Ser	TTC Phe 260	GAG Glu	GAA Glu	CTG Leu	CGC Arg	ACG Thr 265	TTC Phe	GGT Gly	GGC Gly	CAT His	GAT Asp 270	GCG Ala	AAG Lys		816
TTT Phe	ATC Ile	GAC Asp 275	AGC Ser	TTG Leu	CAG Gln	GAG Glu	AAC Asn 280	GAG Glu	TTC Phe	CGT Arg	CTG Leu	TAC Tyr 285	TAC Tyr	TAC Tyr	AAC Asn	,	864
AAG Lys	TTT Phe 290	AAA Lys	GAT Asp	ATT Ile	GCA Ala	AGT Ser 295	ACA Thr	CTG Leu	AAC Asn	AAG Lys	GCT Ala 300	AAG Lys	TCC Ser	ATT Ile	GTG Val		912
GGT Gly 305	ACC Thr	ACT Thr	GCT Ala	TCA Ser	TTA Leu 310	CAG Gln	TAT Tyr	ATG Met	AAA Lys	AAT Asn 315	GTT Val	TTT Phe	AAA Lys	GAG Glu	AAA Lys 320	:	960
TAT Tyr	CTC Leu	CTA Leu	Ser	GAA Glu 325	GAT Asp	ACA Thr	TCT Ser	GGA Gly	AAA Lys 330	TTT Phe	TCG Ser	GTA Val	GAT Asp	AAA Lys 335	TTA Leu	10	800
AAA Lys	TTT Phe	GAT Asp	AAG Lys 340	TTA Leu	TAC Tyr	AAA . Lys :	Met	TTA Leu 345	ACA Thr	GAG Glu	ATT Ile	Tyr	ACA Thr 350	GAG Glu	GAT Asp	10	056
AAT Asn	Pne	GTT Val 355	AAG Lys	TTT Phe	TTT . Phe	AAA (GTA Val 360	CTT Leu	AAC Asn	AGA Arg	AAA Lys	ACA Thr 365	TAT Tyr	TTG Leu	AAT Asn	11	104

Į,

TTT Phe	GA' Asj	b rå	A GC s Al	C GT. a Va	A TT	r AAG E Lys	s Ile	A AA: e Asi	r ATZ	A GTA	A CC L Pro 380	o Ly	G GT/ s Val	A AA' L Asi	TAC Tyr		1152
ACA Thi	: Ile	A TA e Ty	T GA	T GG/ p Gl	A TTT y Phe 390	Asr	TT/	A AGA	A AAT g Asi	T ACA Tha	: Ası	r TT/ n Lei	A GCA A Ala	A GCA A Ala	A AAC A Asn 400		1200
TTT Phe	AA:	r GG n Gl	T CA	A AAC 1 Asi 409	ı Thr	GAA Glu	ATT	T AA1 ⊇ Asr	AAT AST 410	ı Met	AA1 : Asi	r TTT	C ACT	Lys 415	A CTA Leu		1248
AAA Lys	AA A	r TT i Ph	T ACT e Thi 420	c Gly	Leu	TTT Phe	GAA Glu	TTT Phe 425	Tyr	AAG Lys	TTC Let	CTA Leu	TGT Cys 430	Va]	AGA Arg		1296
GGG Gly	ATA Ile	A AT	e Thi	TC1	AAA Lys	ACT Thr	Lys 440	Ser	TTA	GAT Asp	AAA Lys	GGA Gly 445	Tyr	AAT Asn	AAG Lys		1344
ATC Ile	GAA Glu 450	ı G13	r cgi / Arg	TGC GCys	GAT Asp	GGG Gly 455	GCA Ala	TTA Leu	AAT Asn	GAT Asp	Leu 460	Cys	ATC	AAA Lys	GTT Val		1392
AAT Asn 465	AAT Asn	TGC	G GAC Asp	TTG Leu	Phe 470	TTT	AGT Ser	CCT Pro	TCA Ser	GAA Glu 475	GAT Asp	AAT Asn	TTT Phe	ACT	AAT Asn 480		1440
Asp	Leu	Asn	Lys	Gly 485	•	Glu	Ile	Thr	Ser 490	Asp	Thr	Asn	Ile	Glu 495	Ala	•	1488
Ala	Glu	Ģlu	SOO	Ile	AGT Ser	Leu	Asp	Leu 505	Ile	Gln	Gln	Tyr	Tyr 510	Leu	Thr	٠	1536
Phe	Asn	Phe 515	Asp	Asn	GAA Glu	Pro	Glu 520	Asn	Ile	Ser	Ile	Glu 525	Asn	Leu	Ser		1584
Ser	530	Ile	Ile	Gly	CAA Gln	Leu 535	Glu	Leu	Met	Pro	Asn 540	Ile	Glu	Arg	Phe		1632
Pro 545	Asn	GIA	Lys	Lys	TAT Tyr 550	Glu	Leu	Asp	Lys	Tyr 555	Thr	Met	Phe	His	Tyr 560		1680
Leu	Arg	Ala	Gln	Glu 565	TTT Phe	Glu	His	Gly	Lys 570	Ser	Arg	Ile	Ala	Leu 575	Thr	·	1728
Asn	Ser	Val	Asn 580	Glu	GCA Ala	Leu	Leu	Asn 585	Pro	Ser	Arg	Val	Tyr 590	Thr	Phe		1776
Phe	Ser	Ser 595	Asp	Tyr	GTA Val	Lys	Lys 600	Val	Asn	Lys	Ala	Thr 605	Glu	Ala	Ala		1824
Met	Phe 610	Leu	Gly	Trp		Glu 615	Gln	Leu	Val	Tyr	Asp 620	Phe	Thr	Asp	Glu		1872
ACT Thr 625	AGC Ser	GAA Glu	GTA Val	Ser	ACT A Thr 6	ACG Thr	GAT Asp	AAA Lys	Ile	GCG (Ala , 635	GAT Asp	ATA Ile	ACT Thr	ATA Ile	ATT Ile 640		1920

ATT	CCA Pro	TAT Tyr	ATA	GIA	Pro	GCT Ala	TTA Leu	AAT Asn	ATA	GGT Gly	AAT Asn	ATG Met	TTA Leu	TAT	AAA Lvs	1968
GAT	GAT	TTT	GTA	GGT	GCT	TTA	ATA	TTT	650 TCA	ദോ	GCT	ستن	አ ጉጥ	655	TT A	2016
Asp	Asp	Pne	660	GIŸ	Ala	Leu	Ile	Phe 665	Ser	Gly	Ala	Val	Ile 670	Leu	Leu	2010
Glu	Pne	675	Pro	GIu	Ile	Ala	11e 680	Pro	Val	Leu	Gly	Thr 685	Phe	GCA Ala	Leu	2064
GTA Val	Ser 690	TAT Tyr	ATT Ile	GCG Ala	AAT Asn	AAG Lys 695	GTT Val	CTA Leu	ACC Thr	GTT Val	CAA Gln 700	ACA Thr	ATA Ile	GAT Asp	AAT Asn	2112
GCT Ala 705	Leu	AGT Ser	AAA Lys	AGA Arg	AAT Asn 710	GAA Glu	AAA Lys	TGG Trp	GAT Asp	GAG Glu 715	GTC Val	TAT Tyr	AAA Lys	TAT Tyr	ATA Ile 720	2160
GTA Val	ACA Thr	AAT Asn	TGG Trp	TTA Leu 725	GCA Ala	AAG Lys	GTT Val	AAT Asn	ACA Thr 730	CAG Gln	ATT Ile	GAT Asp	CTA Leu	ATA Ile 735	AGA Arg	2208
AAA Lys	AAA Lys	ATG Met	AAA Lys 740	GAA Glu	GCT Ala	TTA Leu	GAA Glu	AAT Asn 745	CAA Gln	GCA Ala	GAA Glu	GCA Ala	ACA Thr 750	AAG Lys	GCT Ala	2256
ATA Ile	ATA Ile	AAC Asn 755	TAT	CAG Gln	TAT Tyr	AAT Asn	CAA Gln 760	TAT Tyr	ACT Thr	GAG Glu	GAA Glu	GAG Glu 765	AAA Lys	AAT Asn	AAT Asn	2304
ATT Ile	AAT Asn 770	TTT Phe	AAT Asn	ATT Ile	GAT Asp	GAT Asp 775	TTA Leu	AGT Ser	TCG Ser	AAA Lys	CTT Leu 780	AAT Asn	GAG Glu	TCT Ser	ATA Ile	2352
AAT Asn 785	AAA Lys	GCT Ala	ATG Met	ATT Ile	AAT Asn 790	ATA Ile	AAT Asn	AAA Lys	TTT Phe	TTG Leu 795	AAT Asn	CAA Gln	TGC Cys	TCT Ser	GTT Val 800	2400
TCA Ser	TAT Tyr	TTA Leu	ATG Met	AAT Asn 805	TCT Ser	ATG Met	ATC Ile	CCT Pro	TAT Tyr 810	GGT Gly	GTT Val	AAA Lys	CGG Arg	TTA Leu 815	GAA Glu	2448
GAT Asp	TTT Phe	GAT Asp	GCT Ala 820	AGT Ser	CTT Leu	AAA Lys	GAT Asp	GCA Ala 825	TTA Leu	TTA Leu	AAG Lys	TAT Tyr	ATA Ile 830	TAT Tyr	GAT Asp	2496
AAT Asn	AGA Arg	GGA Gly 835	ACT Thr	TTA Leu	ATT Ile	Gly	CAA Gln 840	GTA Val	GAT Asp	AGA Arg	TTA Leu	AAA Lys 845	GAT Asp	AAA Lys	GTT Val	2544
AAT Asn	AAT Asn 850	ACA Thr	CTT Leu	AGT Ser	ACA Thr	GAT Asp 855	ATA Ile	CCT Pro	TTT Phe	CAG Gln	CTT Leu 860	TCC Ser	AAA Lys	TAC Tyr	GTA Val	2592
GAT Asp 865	AAT Asn	CAA Gln	AGA Arg	TTA Leu	TTA Leu 870	TCT Ser	ACA Thr	TTT Phe	ACT Thr	GAA Glu 875	TAT Tyr	ATT Ile	AAG Lys	TCT Ser	AGG Arg 880	2640
CCT Pro	CAA Gln	TCT Ser	AAA Lys	GTT Val 885	AAA Lys	AGA Arg	CAA Gln	ATA Ile	TTT Phe 890	TCA Ser	GGC Gly	TAT Tyr	CAA Gln	TCT Ser 895	GAT Asp	2688
ATT Ile	GAT Asp	ACA Thr	CAT His 900	AAT Asn	AGA Arg	ATT Ile	AAG Lys	GAT Asp 905	GAA Glu	TTA Leu	TGA *					2724

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 908 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro

Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg

Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Glu 50 60

Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80

Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95

Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110

Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
115 120 125

Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140

Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160

Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175

Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190

Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205

Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220


Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240

Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255

Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270

Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Asn 275 280 285

Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300



Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 695 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg 730 Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val 790 Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys Ser Arg 875 Pro Gln Ser Lys Val Lys Arg Gln Ile Phe Ser Gly Tyr Gln Ser Asp 890 Ile Asp Thr His Asn Arg Ile Lys Asp Glu Leu

(2) INFORMATION FOR SEQ ID NO: 17:

900

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3042 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION:1..3042
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly

- 80 -

GTT Val	GAC Asp	ATT	GCC Ala 20	TAC Tyr	ATC Ile	AAA Lys	ATT Ile	CCA Pro 25	AAC Asn	GCC Ala	GGC Gly	CAG Gln	ATG Met 30	CAG Gln	CCG Pro	96
GTG Val	AAG Lys	GCT Ala 35	TTC Phe	AAG Lys	ATT Ile	CAT His	AAC Asn 40	AAA Lys	ATC Ile	TGG Trp	GTT Val	ATT Ile 45	CCG Pro	GAA Glu	CGC Arg	144
GAT Asp	ACA Thr 50	TTT Phe	ACG Thr	AAC Asn	CCG Pro	GAA Glu 55	GAA Glu	GGA Gly	GAC Asp	TTG Leu	AAC Asn 60	CCG Pro	CCG Pro	CCG Pro	GAA Glu	192
GCA Ala 65	AAG Lys	CAG Gln	GTG Val	CCA Pro	GTT Val 70	TCA Ser	TAC Tyr	TAC Tyr	GAT Asp	TCA Ser 75	ACC Thr	TAT Tyr	CTG Leu	AGC Ser	ACA Thr 80	240
GAC Asp	AAC Asn	GAG Glu	AAG Lys	GAT Asp 85	AAC Asn	TAC Tyr	CTG Leu	AAG Lys	GGA Gly 90	Val	ACC Thr	AAA Lys	TTA Leu	TTC Phe 95	GAG Glu	288
CGT Arg	ATT Ile	TAT Tyr	TCC Ser 100	ACT Thr	GAC Asp	CTG Leu	GGC Gly	CGT Arg 105	ATG Met	CTG Leu	CTG Leu	ACC Thr	TCA Ser 110	ATC Ile	GTC Val	336
CGC Arg	GGA Gly	ATC Ile 115	CCA Pro	TTT Phe	TGG Trp	GGT Gly	GGC Gly 120	AGT Ser	ACC Thr	ATT Ile	GAC Asp	ACG Thr 125	GAG Glu	TTG Leu	AAG Lys	384
GTT Val	ATT Ile 130	GAC Asp	ACT Thr	AAC Asn	TGC Cys	ATT Ile 135	AAC Asn	GTG Val	ATC Ile	CAA Gln	CCA Pro 140	GAC Asp	GGT Gly	AGC Ser	TAC Tyr	432
AGA Arg 145	TCT Ser	GAA Glu	GAA Glu	CTT Leu	AAC Asn 150	CTC Leu	GTA Val	ATC Ile	ATC Ile	GGG Gly 155	CCC Pro	TCC Ser	GCG Ala	GAC Asp	ATT Ile 160	480
ATC Ile	CAG Gln	TTT Phe	GAG Glu	TGC Cys 165	AAG Lys	AGC Ser	TTT Phe	GGC Gly	CAC His 170	GAA Glu	GTG Val	TTG Leu	AAC Asn	CTG Leu 175	ACG Thr	528
CGT Arg	AAC Asn	GGT Gly	TAC Tyr 180	GGC Gly	TCT Ser	ACT Thr	CAG Gln	TAC Tyr 185	ATT Ile	CGT Arg	TTC Phe	AGC Ser	CCA Pro 190	GAC Asp	TTC Phe	576
ACG Thr	TTC Phe	GGT Gly 195	TTC Phe	GAG Glu	GAG Glu	AGC Ser	CTG Leu 200	GAG Glu	GTT Val	GAT Asp	ACC Thr	AAC Asn 205	CCG Pro	CTG Leu	TTG Leu	624
GGT Gly	GCA Ala 210	GGC Gly	AAG Lys	TTC Phe	GCA Ala	ACT Thr 215	GAT Asp	CCA Pro	GCG Ala	GTG Val	ACC Thr 220	CTG Leu	GCA Ala	CAC His	GAG Glu	672
CTG Leu 225	ATC Ile	CAC His	GCC Ala	GGT Gly	CAT His 230	CGT Arg	CTG Leu	TAT Tyr	GGC Gly	ATT Ile 235	GCG Ala	ATT Ile	AAC Asn	CCG Pro	AAC Asn 240	720
		TTC Phe														768
GAA Glu	GTA Val	AGC Ser	TTC Phe 260	GAG Glu	GAA Glu	CTG Leu	CGC Arg	ACG Thr 265	TTC Phe	GGT Gly	GGC Gly	CAT His	GAT Asp 270	GCG Ala	AAG Lys	816
TTT Phe	ATC Ile	GAC Asp 275	AGC Ser	TTG Leu	CAG Gln	GAG Glu	AAC Asn 280	GAG Glu	TTC Phe	CGT Arg	CTG Leu	TAC Tyr 285	TAC Tyr	TAC Tyr	AAC Asn	864

AA Ly	G TT s Ph 29	ie ri	AA G /s A	AT AT sp I:	rr Go le Al	CA AG La Se 29	r Th	A CT	G AA	C AAO n Lys	G GC S Al-	a Ly	G TC s Se	C AT	T GTG e Vai	912
GG G1 30	у тп	C AC	or A	CT TO la Se	CA TI er Le 31	in GT	G TA n Ty	T ATO	G AAI t Lys	A AA? 5 As: 315	ı Va	T TT	T AA e Ly:	A GA s Gl	G AAA u Lys 320	•
TA: Ty:	r CT	C CI u Le	TA TO	CT GA er Gl	.u As	T AC	A TC' r Se	T GG/ r Gl/	A AAI Y Lys 330	s Phe	C TCC	G GT r Va	A GA: l Ası	T AA D Ly: 33	A TTA s Leu s	1008
AA) Lys	A TT	T GA e As	T AASP Ly	's Le	'A TA u Ty	C AA	A ATO	G TTA Leu 345	ı Thr	A GAG	ATT	TAC Tyr	C ACA	Gl	G GAT	1056
AA7 Asr	TT'	T GT e Va 35	TTA	G TT 's Ph	T TT e Ph	T AAJ e Lys	A GT/ 5 Val 360	L Let	C AAC 1 Asn	AGA Arg	AAA Lys	A ACA Thr 365	Tyr	TTC	G AAT 1 Asn	1104
TT1 Phe	GAT Asp 370	о гу	A GC s Al	C GT a Va	A TT	T AAC e Lys 375	: Ile	A AAT Asn	ATA Ile	GTA Val	CCT Pro	Lys	GTA Val	AA1 Asr	TAC Tyr	1152
ACA Thr 385	TIE	A TA	I GA r As	T GG p Gl	A TT	e Asn	TTA Leu	AGA LArg	AAT Asn	ACA Thr 395	Asn	TTA Leu	GCA Ala	GCA Ala	A AAC A Asn 400	1200
TTT Phe	AAT Asr	GG Gl	T CA y Gl	A AA n As: 40	נמד ח	A GAA r Glu	ATT Ile	AAT Asn	AAT Asn 410	ATG	AAT Asn	TTT Phe	ACT	AAA Lys 415	CTA	1248
AAA Lys	AAT Asn	TT:	Th:	r Gly	A TTO	TTT Phe	GAA Glu	Phe	TAT Tyr	AAG Lys	TTG Leu	CTA Leu	TGT Cys 430	GTA Val	AGA Arg	1296
GGG Gly	ATA	ATA 116 439	Th	r TC: r Sei	Lys	ACT Thr	AAA Lys 440	TCA Ser	TTA Leu	GAT Asp	AAA Lys	GGA Gly 445	TAC Tyr	AAT Asn	AAG Lys	1344
ATC Ile	GAA Glu 450	GG1 Gly	CG7	r TGC g Cys	GAT Asp	GGG Gly 455	GCA Ala	TTA Leu	AAT Asn	GAT Asp	TTA Leu 460	TGT Cys	ATC Ile	AAA Lys	GTT Val	1392
AAT Asn 465	AAT Asn	Tro	GAC Asp	TTG Leu	Phe 470	TTT Phe	AGT Ser	CCT Pro	TCA Ser	GAA Glu 475	GAT Asp	AAT Asn	TTT Phe	ACT Thr	AAT Asn 480	1440
GAT Asp	CTA Leu	TAA	Lys	GGA Gly 485	Glu	GAA Glu	ATT	ACA Thr	TCT Ser 490	GAT Asp	ACT Thr	AAT Asn	ATA Ile	GAA Glu 495	GCA Ala	.1488
GCA Ala	GAA Glu	GAA Glu	AAT Asn 500	TTE	AGT Ser	TTA Leu	GAT Asp	TTA Leu 505	ATA Ile	CAA Gln	CAA Gln	TAT Tyr	TAT Tyr 510	TTA Leu	ACC Thr	1536
TTT Phe	AAT Asn	TTT Phe 515	GAT Asp	AAT Asn	GAA Glu	CCT Pro	GAA Glu 520	AAT Asn	ATT Ile	TCA Ser	ATA Ile	GAA Glu 525	AAT Asn	CTT Leu	TCA Ser	1584
Ser	GAC Asp 530	ATT Ile	ATA Ile	GGC Gly	CAA Gln	TTA Leu 535	GAA Glu	CTT Leu	ATG Met	Pro .	AAT Asn 540	ATA Ile	GAA Glu	AGA Arg	TTT Phe	1632
CCT Pro 545	AAT Asn	GGA Gly	AAA Lys	AAG Lys	TAT Tyr 550	GAG Glu	TTA Leu	GAT Asp	Lys	TAT / Tyr '	ACT Thr	ATG Met	TTC Phe	CAT His	TAT Tyr 560	1680

- 82 -

CTT Leu	CGT Arg	GCT Ala	CAA Gln	GAA Glu 565	TTT Phe	GAA Glu	CAT His	GGT Gly	AAA Lys 570	TCT Ser	AGG Arg	ATT Ile	GCT Ala	TTA Leu 575	ACA Thr	1728
AAT Asn	TCT Ser	GTT Val	AAC Asn 580	GAA Glu	GCA Ala	TTA Leu	TTA Leu	AAT Asn 585	CCT Pro	AGT Ser	CGT Arg	GTT Val	TAT Tyr 590	ACA Thr	TTT Phe	1776
TTT Phe	TCT Ser	TCA Ser 595	GAC Asp	TAT Tyr	GTA Val	AAG Lys	AAA Lys 600	GTT Val	AAT Asn	AAA Lys	GCT Ala	ACG Thr 605	GAG Glu	GCA Ala	GCT Ala	1824
ATG Met	TTT Phe 610	TTA Leu	GGC	TGG Trp	GTA Val	GAA Glu 615	CAA Gln	TTA Leu	GTA Val	TAT	GAT Asp 620	TTT Phe	ACC Thr	GAT Asp	GAA Glu	1872
ACT Thr 625	AGC Ser	GAA Glu	GTA Val	AGT Ser	ACT Thr 630	ACG Thr	GAT Asp	AAA Lys	ATT	GCG Ala 635	GAT Asp	ATA Ile	ACT Thr	ATA Ile	ATT Ile 640	1920
ATT Ile	CCA Pro	TAT Tyr	ATA Ile	GGA Gly 645	CCT Pro	GCT Ala	TTA Leu	AAT Asn	ATA Ile 650	GGT Gly	AAT Asn	ATG Met	TTA Leu	TAT Tyr 655	AAA Lys	1968
GAT Asp	GAT Asp	TTT Phe	GTA Val 660	GGT Gly	GCT Ala	TTA Leu	ATA Ile	TTT Phe 665	TCA Ser	GGA Gly	GCT Ala	GTT Val	ATT Ile 670	CTG Leu	TTA Leu	2016
GAA Glu	TTT Phe	ATA Ile 675	CCA Pro	GAG Glu	ATT Ile	GCA Ala	ATA Ile 680	CCT Pro	GTA Val	TTA Leu	GGT Gly	ACT Thr 685	TTT Phe	GCA Ala	CTT Leu	2064
GTA Val	TCA Ser 690	TAT Tyr	ATT Ile	GCG Ala	AAT Asn	AAG Lys 695	GTT Val	CTA Leu	ACC Thr	GTT Val	CAA Gln 700	ACA Thr	ATA Ile	GAT Asp	AAT Asn	2112
GCT Ala 705	TTA Leu	AGT Ser	AAA Lys	AGA Arg	AAT Asn 710	GAA Glu	AAA Lys	TGG Trp	GAT Asp	GAG Glu 715	GTC Val	TAT	AAA Lys	TAT Tyr	ATA Ile 720	2160
GTA Val	ACA Thr	AAT Asn	TGG Trp	TTA Leu 725	GCA Ala	AAG Lys	GTT Val	AAT Asn	ACA Thr 730	CAG Gln	ATT Ile	GAT Asp	CTA Leu	ATA Ile 735	AGA Arg	2208
AAA Lys	AAA Lys	ATG Met	AAA Lys 740	GAA Glu	GCT Ala	TTA Leu	GAA Glu	AAT Asn 745	CAA Gln	GCA Ala	GAA Glu	GCA Ala	ACA Thr 750	AAG Lys	GCT Ala	2256
ATA Ile	ATA Ile	AAC Asn 755	TAT Tyr	CAG Gln	TAT Tyr	AAT Asn	CAA Gln 760	TAT Tyr	ACT Thr	GAG Glu	GAA Glu	GAG Glu 765	AAA Lys	AAT Asn	AAT Asn	2304
ATT Ile	AAT Asn 770	TTT Phe	AAT Asn	ATT Ile	GAT Asp	GAT Asp 775	TTA Leu	AGT Ser	TCG Ser	AAA Lys	CTT Leu 780	AAT Asn	GAG Glu	TCT Ser	ATA Ile	2352
AAT Asn 785	AAA Lys	GCT Ala	ATG Met	ATT Ile	AAT Asn 790	ATA Ile	AAT Asn	AAA Lys	TTT Phe	TTG Leu 795	AAT Asn	CAA Gln	TGC Cys	TCT Ser	GTT Val 800	2400
										GGT Gly						2448
										TTA Leu						2496

AAT Asn	AGA Arg	GGA Gly 835	Thr	TTA Leu	ATT	GGT Gly	CAA Gln 840	GTA Val	GAT Asp	AGA Arg	TTA Leu	AAA Lys 845	GAT Asp	AAA Lys	GTT Val	2544
AAT Asn	AAT Asn 850	Thr	CTT Leu	AGT Ser	ACA Thr	GAT Asp 855	ATA Ile	CCT Pro	TTT Phe	CAG Gln	CTT Leu 860	TCC Ser	AAA Lys	TAC Tyr	GTA Val	2592
GAT Asp 865	AAT Asn	CAA Gln	AGA Arg	TTA Leu	TTA Leu 870	TCT Ser	ACA Thr	TTT	ACT Thr	GAA Glu 875	Tyr	ATT Ile	AAG Lys	TCA Ser	GGC Gly 880	2640
CTG Leu	AAT Asn	TCC	CCG Pro	GGT Gly 885	Ala	GCT Ala	CAT His	TAT	GCG Ala 890	CAA Gln	CAC His	GAT Asp	GAA Glu	GCC Ala 895	GTA Val	2688
GAC Asp	AAC Asn	AAA Lys	TTC Phe 900	AAC Asn	AAA Lys	GAA Glu	CAA Gln	CAA Gln 905	AAC Asn	GCG Ala	TTC Phe	TAT Tyr	GAG Glu 910	ATC Ile	TTA Leu	2736
CAT His	TTA Leu	CCT Pro 915	AAC Asn	TTA Leu	AAC Asn	GAA Glu	GAA Glu 920	CAA Gln	CGA Arg	AAC Asn	GCC Ala	TTC Phe 925	ATC Ile	CAA Gln	AGT Ser	2784
TTA Leu	AAA Lys 930	GAT Asp	GAC Asp	CCA Pro	AGC Ser	CAA Gln 935	AGC Ser	GCT Ala	AAC Asn	CTT Leu	TTA Leu 940	GCA Ala	GAA Glu	GCT Ala	AAA Lys	2832
AAG Lys 945	CTA Leu	AAT Asn	GAT Asp	GCT Ala	CAG Gln 950	GCG Ala	CCG Pro	AAA Lys	GTA Val	GAC Asp 955	AAC Asn	AAA Lys	TTC Phe	AAC Asn	AAA Lys 960	2880
GAA Glu	CAA Gln	CAA Gln	AAC Asn	GCG Ala 965	TTC Phe	TAT Tyr	GAG Glu	ATC Ile	TTA Leu 970	CAT His	TTA Leu	CCT Pro	AAC Asn	TTA Leu 975	AAC Asn	2928
GAA Glu	GAA Glu	CAA Gln	CGA Arg 980	AAC Asn	GCC Ala	TTC Phe	ATC Ile	CAA Gln 985	AGT Ser	TTA Leu	AAA Lys	GAT Asp	GAC Asp 990	CCA Pro	AGC Ser	2976
CAA Gln	AGC Ser	GCT Ala 995	AAC Asn	CTT Leu	TTA Leu	GCA Ala	GAA Glu 1000	Ala	AAA Lys	AAG Lys	CTA Leu	AAT Asn 1005	Asp	GCT Ala	CAG Gln	3024
	CCG Pro 1010	Lys			TAG						•					 3042


(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1014 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly

Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20

Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 40



Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 425 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 475 Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr 505 Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu 615 Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 630 Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys 650 Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu 680 Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala

- 86 -

Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 825 Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val 855 Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys Ser Gly Leu Asn Ser Pro Gly Ala Ala His Tyr Ala Gln His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Asn Lys Phe Asn Lys 950 Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser 985 Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln 995 1000 Ala Pro Lys Val Asp *

- (2) INFORMATION FOR SEQ ID NO: 19:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3509 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:

1010

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..3509
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ATC Met	Pro	A GT	r ACA l Thr	ATA Ile	A AA:	T AAT n Asr	TTI Phe	`AAI : Asr	TAT	Ası	GAI Asp	CC1	ATT Ile	GA:	TAAT Asn	48
AA 18A	AA 1 ASI	T ATT	r ATT e Ile 20	Met	ATO	G GAC	CCT Pro	CCA Pro 25	Phe	GCC Ala	AGA Arg	GG1 Gl;	ACC Thr	: G1}	G AGA / Arg	96
TAT Tyr	TAT	Lys	Ala	TTI Phe	Lys	A ATC	ACA Thr 40	Asp	CGI Arg	ATT Ile	TGG	ATA Ile	Ile	CCC Pro	GAA Glu	144
AGA Arg	TAT A	Thi	TTT Phe	GGA Gly	TAT	Lys 55	Pro	GAG Glu	GAT Asp	TTI Phe	AAT Asn 60	Lys	AGT Ser	TCC	GGT Gly	192
ATT Ile	Phe	AAT Asn	AGA Arg	GAT Asp	GTT Val 70	. Cys	GAA Glu	TAT Tyr	TAT	GAT Asp 75	CCA Pro	GAT Asp	TAC	TTA Leu	AAT Asn 80	240
ACT Thr	'AAT Asn	GAT Asp	AAA Lys	AAG Lys 85	Asn	ATA Ile	TTT Phe	TTA Leu	CAA Gln 90	Thr	ATG Met	ATC	AAG Lys	TTA Leu 95	Phe	288
AAT Asn	AGA Arg	ATC	AAA Lys 100	Ser	AAA Lys	CCA Pro	TTG Leu	GGT Gly 105	GAA Glu	AAG Lys	TTA Leu	TTA Leu	GAG Glu 110	ATG Met	ATT	336
ATA Ile	AAT Asn	GGT Gly 115	Ile	CCT Pro	TAT	CTT Leu	GGA Gly 120	GAT Asp	AGA Arg	CGT Arg	GTT Val	CCA Pro 125	CTC Leu	GAA Glu	GAG Glu	384
TTT Phe	AAC Asn 130	ACA Thr	AAC Asn	ATT Ile	GCT Ala	AGT Ser 135	GTA Val	ACT Thr	GTT Val	AAT Asn	AAA Lys 140	TTA Leu	ATC Ile	AGT Ser	AAT Asn	432
CCA Pro 145	GGA Gly	GAA Glu	GTG Val	GAG Glu	CGA Arg 150	AAA Lys	AAA Lys	GGT Gly	ATT Ile	TTC Phe 155	GCA Ala	AAT Asn	TTA Leu	ATA Ile	ATA Ile 160	480
TTT Phe	GGA Gly	CCT Pro	GGG Gly	CCA Pro 165	GTT Val	TTA Leu	AAT Asn	GAA Glu	AAT Asn 170	GAG Glu	ACT Thr	ATA Ile	GAT Asp	ATA Ile 175	GGT Gly	528
ATA Ile	CAA Gln	AAT Asn	CAT His 180	TTT Phe	GCA Ala	TCA Ser	AGG Arg	GAA Glu 185	GGC Gly	TTC Phe	GGG Gly	GGT Gly	ATA Ile 190	ATG Met	CAA Gln	576
ATG Met	AAG Lys	TTT Phe 195	TGC Cys	CCA Pro	GAA Glu	TAT	GTA Val 200	AGC Ser	GTA Val	TTT Phe	AAT Asn	AAT Asn 205	GTT Val	CAA Gln	GAA Glu	624
AAC Asn	AAA Lys 210	GGC Gly	GCA Ala	AGT Ser	ATA Ile	TTT Phe 215	AAT Asn	AGA Arg	CGT Arg	GGA Gly	TAT Tyr 220	TTT Phe	TCA Ser	GAT Asp	CCA Pro	672
GCC Ala 225	TTG Leu	ATA Ile	TTA Leu	ATG Met	CAT His 230	GAA Glu	CTT . Leu	ATA Ile	CAT His	GTT Val 235	TTA Leu	CAT	GGA Gly	TTA. Leu	TAT Tyr 240	720
GGC	ATT Ile	AAA Lys	Val	GAT Asp 245	GAT Asp	TTA Leu	CCA . Pro	Ile	GTA Val 250	CCA Pro	AAT Asn	GAA Glu	AAA Lys	AAA Lys 255	TTT Phe	768
TTT Phe	ATG Met	Gln	TCT Ser 260	ACA Thr	GAT Asp	GCT Ala	Ile (CAG Gln 265	GCA Ala	GAA Glu	GAA Glu	CTA Leu	TAT Tyr 270	ACA Thr	TTT Phe	816

- 88 -

GGA Gly	GGA Gly	CAA Gln 275	GAT Asp	CCC Pro	AGC Ser	ATC Ile	ATA Ile 280	ACT Thr	CCT Pro	TCT Ser	ACG Thr	GAT Asp 285	AAA Lys	AGT Ser	ATC Ile	864
TAT Tyr	GAT Asp 290	AAA Lys	GTT Val	TTG Leu	CAA Gln	AAT Asn 295	TTT Phe	AGA Arg	GGG Gly	ATA Ile	GTT Val 300	GAT Asp	AGA Arg	CTT Leu	AAC Asn	912
AAG Lys 305	GTT Val	TTA Leu	GTT Val	TGC Cys	ATA Ile 310	TCA Ser	GAT Asp	CCT Pro	AAC Asn	ATT Ile 315	AAT Asn	ATT Ile	AAT Asn	ATA Ile	TAT Tyr 320	960
AAA Lys	AAT Asn	AAA Lys	TTT Phe	AAA Lys 325	GAT Asp	AAA Lys	TAT Tyr	AAA Lys	TTC Phe 330	GTT Val	GAA Glu	GAT Asp	TCT Ser	GAG Glu 335	GGA Gly	1008
AAA Lys	TAT Tyr	AGT Ser	ATA Ile 340	GAT Asp	GTA Val	GAA Glu	AGT Ser	TTT Phe 345	GAT Asp	AAA Lys	TTA Leu	TAT Tyr	AAA Lys 350	AGC Ser	TTA Leu	1056
ATG Met	TTT Phe	GGT Gly 355	TTT Phe	ACA Thr	GAA Glu	ACT Thr	AAT Asn 360	ATA Ile	GCA Ala	GAA Glu	AAT Asn	TAT Tyr 365	AAA Lys	ATA Ile	AAA Lys	1104
ACT Thr	AGA Arg 370	GCT Ala	TCT Ser	TAT Tyr	TTT Phe	AGT Ser 375	GAT Asp	TCC Ser	TTA Leu	CCA Pro	CCA Pro 380	GTA Val	AAA Lys	ATA Ile	AAA Lys	1152
AAT Asn 385	TTA Leu	TTA Leu	GAT Asp	AAT Asn	GAA Glu 390	ATC Ile	TAT Tyr	ACT Thr	ATA Ile	GAG Glu 395	GAA Glu	GGG Gly	TTT Phe	AAT Asn	ATA Ile 400	1200
TCT Ser	GAT Asp	AAA Lys	GAT Asp	ATG Met 405	GAA Glu	AAA Lys	GAA Glu	TAT Tyr	AGA Arg 410	GGT Gly	CAG Gln	AAT Asn	AAA Lys	GCT Ala 415	Ile	1248
AAT Asn	AAA Lys	CAA Gln	GCT Ala 420	TAT Tyr	GAA Glu	GAA Glu	ATT	AGC Ser 425	AAG Lys	GAG Glu	CAT His	TTG Leu	GCT Ala 430	GTA Val	TAT Tyr	1296
AAG Lys	ATA Ile	CAA Gln 435	ATG Met	TGT Cys	AAA Lys	AGT Ser	GTT Val 440	AAA Lys	GCT Ala	CCA Pro	GGA Gly	ATA Ile 445	TGT Cys	ATT Ile	GAT Asp	1344
GTT Val	GAT Asp 450	AAT Asn	GAA Glu	GAT Asp	TTG Leu	TTC Phe 455	TTT Phe	ATA Ile	GCT Ala	GAT Asp	AAA Lys 460	AAT Asn	AGT Ser	TTT Phe	TCA Ser	1392
GAT Asp 465	GAT Asp	TTA Leu	TCT Ser	AAA Lys	AAC Asn 470	GAA Glu	AGA Arg	ATA Ile	GAA Glu	TAT Tyr 475	AAT Asn	ACA Thr	CAG Gln	AGT Ser	AAT Asn 480	1440
TAT Tyr	ATA Ile	GAA Glu	AAT Asn	GAC Asp 485	TTC Phe	CCT Pro	ATA Ile	AAT Asn	GAA Glu 490	TTA Leu	ATT	TTA Leu	GAT Asp	ACT Thr 495	GAT Asp	1488
TTA Leu	ATA Ile	AGT Ser	AAA Lys 500	ATA Ile	GAA Glu	TTA Leu	CCA Pro	AGT Ser 505	GAA Glu	AAT Asn	ACA Thr	GAA Glu	TCA Ser 510	CTT Leu	ACT Thr	1536
						CCA Pro										1584
AAA Lys	ATT Ile 530	TTT Phe	ACA Thr	GAT Asp	GAA Glu	AAT Asn 535	ACC Thr	ATC Ile	TTT Phe	CAA Gln	TAT Tyr 540	TTA Leu	TAC Tyr	TCT Ser	CAG Gln	1632

- 89 -

ACA Thr 545	. bpe	CC.	r CT/	TAD A	T ATA	: Arc	GAT Asp	ATA	A AGI Ser	TTA Leu 555	ı Thi	TCI Ser	TCA Ser	TTT Phe	GAT Asp 560	168	80
GAT Asp	GCA Ala	TT#	TT/	A TTT 1 Phe 565	: Ser	AAC Asn	Lys	GTI Val	TAT Tyr 570	Ser	TTT Phe	TTT Phe	TCI Ser	Met 575	GAT Asp	17:	28
TAT Tyr	ATT	AAA Lys	ACT Thr 580	: Ala	AAT Asn	AAA Lys	GTG Val	GTA Val 585	Glu	GCA Ala	GGA Gly	TTA Leu	TTT Phe 590	Ala	GGT	17	76
TGG Trp	GTG Val	Lys 595	Glr	ATA lle	GTA Val	AAT Asn	GAT Asp 600	Phe	GTA Val	ATC	GAA Glu	GCT Ala 605	Asn	AAA Lys	AGC Ser	182	24
AAT Asn	ACT Thr 610	Met	GAT Asp	AAA Lys	ATT Ile	GCA Ala 615	GAT Asp	ATA Ile	TCT	CTA Leu	ATT Ile 620	Val	CCT Pro	TAT	ATA Ile	187	72
GGA Gly 625	TTA Leu	GCT Ala	TTA Leu	AAT Asn	GTA Val 630	GGA Gly	AAT Asn	GAA Glu	ACA Thr	GCT Ala 635	AÀA Lys	GGA Gly	AAT Asn	TTT Phe	GAA Glu 640	192	<u> 2</u> O
AAT Asn	GCT Ala	TTT Phe	GAG Glu	ATT Ile 645	GCA Ala	GGA Gly	GCC Ala	AGT Ser	ATT Ile 650	CTA Leu	CTA Leu	GAA Glu	TTT Phe	ATA Ile 655	CCA Pro	196	8 6
GAA Glu	CTT Leu	TTA Leu	ATA Ile 660	CCT Pro	GTA Val	GTT Val	GGA Gly	GCC Ala 665	TTT	TTA Leu	TTA	GAA Glu	TCA Ser 670	TAT Tyr	ATT Ile	201	. 6.
Asp	Asn	Lys 675	Asn	Lys	Ile	Ile	Lys 680	Thr	ATA Ile	Asp	Asn	Ala 685	Leu	Thr	Lys	206	4
AGA Arg	AAT Asn 690	Glu	AAA Lys	TGG Trp	AGT Ser	GAT Asp 695	ATG Met	TAC Tyr	GGA Gly	TTA Leu	ATA Ile 700	GTA Val	GCG Ala	CAA Gln	TGG Trp	211	2
Leu 705	Ser	Thr	Val	Asn	Thr 710	Gln	Phe	Tyr	ACA Thr	11e 715	Lys	Glu	Gly	Met	Tyr 720	216	o
Lys	Ala	Leu	Asn	Tyr 725	Gln	Ala	Gln	Ala	TTG Leu 730	Glu	Glu.	Ile	Ile	Lys 735	Tyr	. 220	8
Arg	Tyr	Asn	11e 740	Tyr	Ser	Glu	Lys	Glu 745	AAG Lys	Ser	Asn	Ile	Asn 750	Ile	Asp	225	6
TTT Phe	AAT Asn	GAT Asp 755	ATA Ile	AAT Asn	TCT Ser	AAA Lys	CTT Leu 760	AAT Asn	GAG Glu	GGT Gly	ATT Ile	AAC Asn 765	CAA Gln	GCT Ala	ATA Ile	230	4
GAT Asp	AAT Asn 770	ATA Ile	AAT Asn	AAT Asn	TTT Phe	ATA Ile 775	AAT Asn	GGA Gly	TGT Cys	TCT Ser	GTA Val 780	TCA Ser	TAT Tyr	TTA Leu	ATG Met	235	2
AAA Lys 785	AAA Lys	ATG Met	ATT Ile	Pro	TTA Leu 790	GCT Ala	GTA Val	GAA Glu	AAA Lys	TTA Leu 795	CTA Leu	GAC Asp	TTT Phe	GAT Asp	AAT Asn 800	240	0
ACT Thr	CTC Leu	AAA Lys	Lys	AAT Asn 805	TTG Leu	TTA Leu	AAT Asn	TAT Tyr	ATA Ile 810	GAT Asp	GAA Glu	AAT Asn	AAA Lys	TTA Leu 815	TAT Tyr	244	8

reu	. 116	GGA Gly	820	Ala	GLU	Tyr	GIu	Lys 825	Ser	Lys	Val	Asn	Lys 830	Tyr	Leu		2496
гÀг	Inr	Ile 835	мес	Pro	Pne	Asp	Leu 840	Ser	Ile	Tyr	Thr	Asn 845	Asp	Thr	Ile		2544
Leu	850		MEC	Pne	ASN	855	Tyr	Asn	Ser	Glu	Ile 860	Leu	Asn	Asn	Ile		2592
865	Leu	AAT Asn	Leu	Arg	870	Lys	Asp	Asn	Asn	Leu 875	Ile	Asp	Leu	Ser	Gly 880		2640
Tyr	GIÀ	GCA Ala	Lys	Va1 885	GIU	Val	Tyr	Asp	Gly 890	Val	Glu	Leu	Asn	Asp 895	Lys		2688
ASN	GIN	TTT Phe	900	Leu	Thr	Ser	Ser	Ala 905	Asn	Ser	Lys	Ile	Arg 910	Val	Thr	:	2736
GIn	Asn	CAG Gln 915	Asn	Ile	Ile	Phe	920	Ser	Val	Phe	Léu	Asp 925	Phe	Ser	Val	:	2784
Ser	930	TGG Trp	Ile	Arg	Ile	935	Lys	Tyr	Lys	Asn	Asp 940	Gly	Ile	Gln	Asn	:	2832
1yr 945	He	CAT His	Asn	Glu	79 2 950	Thr	Ile	Ile	Asn	Cys 955	Met	Lys	Asn	Asn	Ser 960	:	2880
GIA	Trp	AAA Lys	Ile	965	Ile	Arg	Gly	Asn	Arg 970	Ile	Ile	Trp	Thr	Leu 975	Ile		2928
GAT Asp	ATA Ile	AAT Asn	GGA Gly 980	AAA Lys	ACC Thr	AAA Lys	TCG Ser	GTA Val 985	TTT Phe	TTT Phe	GAA Glu	TAT Tyr	AAC Asn 990	ATA Ile	AGA Arg	2	2976
Glu	Asp	ATA Ile 995	Ser	Glu	Tyr	Ile	Asn 1000	Arg	Trp	Phe	Phe	Val 1005	Thr	Ile	Thr	3	3024
AAT Asn	AAT Asn 1010	TTG Leu	AAT Asn	AAC Asn	Ala	AAA Lys 1015	Ile	TAT Tyr	ATT Ile	AAT Asn	GGT Gly 1020	Lys	CTA Leu	GAA Glu	TCA Ser	3	3072
AAT Asn 1025	Thr	GAT Asp	ATT Ile	AAA Lys	GAT Asp 1030	Ile	AGA Arg	GAA Glu	GTT Val	ATT Ile 1035	Ala	AAT Asn	GGT Gly	GAA Glu	ATA Ile 1040	3	120
ATA Ile	TTT Phe	AAA Lys	TTA Leu	GAT Asp 1045	Gly	GAT Asp	ATA Ile	GAT Asp	AGA Arg 1050	Thr	CAA Gln	TTT Phe	ATT Ile	TGG Trp 1055	Met	3	168
AAA Lys	TAT Tyr	TTC Phe	AGT Ser 1060	Ile	TTT Phe	AAT Asn	Thr	GAA Glu 1065	Leu	AGT Ser	CAA Gln	TCA Ser	AAT Asn 1070	Ile	GAA Glu	3	216
GAA Glu	AGA Arg	TAT Tyr 1075	Lys	ATT Ile	CAA Gln	Ser	TAT Tyr 1080	Ser	GAA Glu	TAT Tyr	TTA Leu	AAA Lys 1085	Asp	TTT Phe	TGG Trp	3	264

- 91 -

GGA AAT Gly Asn 109	Pro L	TA ATG eu Met	TAC AAT Tyr Asn 109	Lys G	AA TAT	TAT ATG Tyr Met	TTT AAT Phe Asn	GCG Ala	GGG Gly	3312
AAT AAA Asn Lys 1105	AAT TO	CA TAT er Tyr	ATT AAA Ile Lys 1110	CTA A Leu L	ys Lys	GAT TCA Asp Ser 1115	CCT GTA Pro Val	GGT Gly	GAA Glu 1120	3360
ATT TTA Ile Leu	ACA CO	GT AGC rg Ser 1125	Lys Tyr	AAT C	AA AAT In Asn 1130	Ser Lys	TAT ATA	AAT Asn 1135	Tyr	3408
AGA GAT Arg Asp	Leu Ty	AT ATT	GGA GAA Gly Glu	Lys Pl	he Ile	ATA AGA Ile Arg	AGA AAG Arg Lys	TCA Ser	AAT Asn	3456
		140		Δ.	145					
TCT CAA Ser Gln	TCT AT	TA AT	GAT GAT Asp Asp	ATA G	TT AGA	AAA GAA) ATA	TAT	3504

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1169 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn 1 le Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 25 Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu 45

Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 60

Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80

Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe 85 90 95


Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile 100 105 110

Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125

Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn 130 135 140

Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile 145 150 155 160

Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly
165 170 175



Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu Asn Ala Phe Giu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro 650 Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr 730 Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 790 Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr 810 Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 825 Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile 840 Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser Glu Ile Leu Asn Asn Ile Ile Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu Ile Asp Leu Ser Gly

- 94 -

Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys 885 890 Asn Gln Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys Ile Arg Val Thr Gln Asn Gln Asn Ile Ile Phe Asn Ser Val Phe Leu Asp Phe Ser Val 920 Ser Phe Trp Ile Arg Ile Pro Lys Tyr Lys Asn Asp Gly Ile Gln Asn Tyr Ile His Asn Glu Tyr Thr Ile Ile Asn Cys Met Lys Asn Asn Ser Gly Trp Lys Ile Ser Ile Arg Gly Asn Arg Ile Ile Trp Thr Leu Ile Asp Ile Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn Ile Arg Glu Asp Ile Ser Glu Tyr Ile Asn Arg Trp Phe Phe Val Thr Ile Thr 1000 Asn Asn Leu Asn Asn Ala Lys Ile Tyr Ile Asn Gly Lys Leu Glu Ser 1015 1010 Asn Thr Asp Ile Lys Asp Ile Arg Glu Val Ile Ala Asn Gly Glu Ile 1025 1030 Ile Phe Lys Leu Asp Gly Asp Ile Asp Arg Thr Gln Phe Ile Trp Met 1050 Lys Tyr Phe Ser Ile Phe Asn Thr Glu Leu Ser Gln Ser Asn Ile Glu 1065 Glu Arg Tyr Lys Ile Gln Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp 1075 1080 1085 Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly 1095 Asn Lys Asn Ser Tyr Ile Lys Leu Lys Lys Asp Ser Pro Val Gly Glu 1110 1115 Ile Leu Thr Arg Ser Lys Tyr Asn Gln Asn Ser Lys Tyr Ile Asn Tyr 1125 1130 1135 Arg Asp Leu Tyr Ile Gly Glu Lys Phe Ile Ile Arg Arg Lys Ser Asn

1145

Ser Gln Ser Ile Asn Asp Asp Ile Val Arg Lys Glu Asp Tyr Ile Tyr 1155 1160 1165

Leu

- (2) INFORMATION FOR SEQ ID NO: 21:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2574 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)

- 95 -

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..2574

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

			_														
ATG Met 1	Pro	GTI Val	ACA Thr	ATA Ile	Asn	AAT Asn	TTT Phe	AAT Asn	TAT Tyr 10	Asn	GAT Asp	CCT Pro	ATT Ile	GAT Asp 15	AAT Asn		48
AAT Asn	AAT Asn	ATT	ATT Ile 20	Met	ATG Met	GAG Glu	CCT Pro	CCA Pro 25	Phe	GCG Ala	AGA Arg	GGT Gly	ACG Thr 30	Gly	AGA Arg		96
TAT Tyr	TAT	AAA Lys 35	Ala	TTT Phe	AAA Lys	ATC Ile	ACA Thr 40	GAT Asp	CGT Arg	ATT Ile	TGG	ATA Ile 45	ATA Ile	CCG Pro	GAA Glu		144
AGA Arg	TAT Tyr 50	Thr	TTT Phe	GGA Gly	TAT	AAA Lys 55	CCT Pro	GAG Glu	GAT Asp	TTT Phe	AAT Asn 60	AAA Lys	AGT Ser	TCC Ser	GGT Gly		192
ATT Ile 65	TTT	AAT Asn	AGA Arg	GAT Asp	GTT Val 70	TGT Cys	GAA Glu	TAT Tyr	TAT Tyr	GAT Asp 75	CCA Pro	GAT Asp	TAC Tyr	TTA Leu	TAA nsA 08		240
ACT Thr	AAT Asn	GAT Asp	AAA Lys	AAG Lys 85	AAT Asn	ATA Ile	TTT Phe	TTA Leu	CAA Gln 90	ACA Thr	ATG Met	ATC Ile	AAG Lys	TTA Leu 95	TTT Phe		288
AAT Asn	AGA Arg	ATC Ile	AAA Lys 100	TCA Ser	AAA Lys	CCA Pro	TTG Leu	GGT Gly 105	GAA Glu	AAG Lys	TTA Leu	TTA Leu	GAG Glu 110	ATG Met	ATT Ile		336
ATA Ile	AAT Asn	GGT Gly 115	ATA Ile	CCT Pro	TAT	CTT	GGA Gly 120	GAT Asp	AGA Arg	CGT Arg	GTT Val	CCA Pro 125	CTC Leu	GAA Glu	GAG Glu	, <u>.</u>	384
TTT Phe	AAC Asn 130	ACA Thr	AAC Asn	ATT Ile	GCT Ala	AGT Ser 135	GTA Val	ACT Thr	GTT Val	AAT Asn	AAA Lys 140	TTA Leu	ATC Ile	AGT Ser	AAT Asn		432
CCA Pro 145	GGA Gly	GAA Glu	GTG Val	GAG Glu	CGA Arg 150	AAA Lys	AAA Lys	GGT Gly	ATT	TTC Phe 155	GCA Ala	AAT Asn	TTA Leu	ATA Ile	ATA Ile 160		480
TTT Phe	GGA Gly	CCT Pro	GGG Gly	CCA Pro 165	GTT Val	TTA Leu	AAT Asn	GAA Glu	AAT Asn 170	GAG Glu	ACT Thr	ATA Ile	GAT Asp	ATA Ile 175	GGT Gly		528
ATA Ile	CAA Gln	AAT Asn	CAT His 180	Phe	Ala	Ser	Arg	Glu	Gly	Phe	Gly	GGT Gly	Ile	Met	CAA Gln		576
ATG Met	AAG Lys	TTT Phe 195	TGC Cys	CCA Pro	GAA Glu	TAT Tyr	GTA Val 200	AGC Ser	GTA Val	TTT Phe	AAT Asn	AAT Asn 205	GTT Val	CAA Gln	GAA Glu		624
AAC Asn	AAA Lys 210	GGC Gly	GCA Ala	AGT Ser	ATA Ile	TTT Phe 215	AAT Asn	AGA Arg	CGT Arg	GGA Gly	TAT Tyr 220	TTT Phe	TCA Ser	GAT Asp	CCA Pro		672
GCC Ala 225	TTG Leu	ATA Ile	TTA Leu	ATG Met	CAT His 230	GAA Glu	CTT Leu	ATA Ile	His	GTT Val 235	TTA Leu	CAT His	GGA Gly	TTA Leu	TAT Tyr 240		720

GG(ATT	AAA Lys	A GTA Val	GAT Asp 245	Asp	TTA Leu	CCA Pro	ATT	GTA Val 250	Pro	AAT Asn	GAA Glu	AAA Lys	AAA Lys 255	TTT Phe	768
TTT Phe	ATG Met	CAA Gln	TCT Ser 260	inr	GAT Asp	GCT Ala	ATA Ile	CAG Gln 265	GCA Ala	GAA Glu	GAA Glu	CTA Leu	TAT Tyr 270	ACA Thr	TTT Phe	816
GGA Gly	GGA Gly	CAA Gln 275	Asp	CCC	AGC Ser	ATC Ile	ATA Ile 280	Thr	CCT Pro	TCT Ser	ACG Thr	GAT Asp 285	AAA Lys	AGT Ser	ATC Ile	864
TAT	GAT Asp 290	∟ys	GTT Val	TTG Leu	CAA Gln	AAT Asn 295	TTT Phe	AGA Arg	GGG Gly	ATA Ile	GTT Val 300	GAT Asp	AGA Arg	CTT	AAC Asn	912
AAG Lys 305	GTT Val	TTA Leu	GTT Val	TGC Cys	ATA Ile 310	TCA Ser	GAT Asp	CCT Pro	AAC Asn	ATT Ile 315	AAT Asn	ATT Ile	AAT Asn	ATA Ile	TAT Tyr 320	960
AAA Lys	AAT Asn	AAA Lys	TTT	AAA Lys 325	GAT Asp	AAA Lys	TAT Tyr	AAA Lys	TTC Phe 330	GTT Val	GAA Glu	GAT Asp	TCT	GAG Glu 335	GGA Gly	1008
AAA Lys	TAT Tyr	AGT Ser	ATA Ile 340	GAT Asp	GTA Val	GAA Glu	AGT Ser	TTT Phe 345	GAT Asp	AAA Lys	TTA Leu	TAT Tyr	AAA Lys 350	AGC Ser	TTA Leu	1056
ATG Met	TTT Phe	GGT Gly 355	TTT Phe	ACA Thr	GAA Glu	ACT Thr	AAT Asn 360	ATA Ile	GCA Ala	GAA Glu	AAT Asn	TAT Tyr 365	AAA Lys	ATA Ile	AAA Lys	1104
ACT Thr	AGA Arg 370	GCT Ala	TCT Ser	TAT Tyr	TTT Phe	AGT Ser 375	GAT Asp	TCC Ser	TTA Leu	CCA Pro	CCA Pro 380	GTA Val	AAA Lys	ATA Ile	AAA Lys	1152
AAT Asn 385	TTA Leu	TTA Leu	GAT Asp	AAT Asn	GAA Glu 390	ATC Ile	TAT Tyr	ACT Thr	ATA Ile	GAG Glu 395	GAA Glu	GGG Gly	TTT Phe	AAT Asn	ATA Ile 400	1200
TCT Ser	GAT Asp	AAA Lys	GAT Asp	ATG Met 405	GAA Glu	AAA Lys	GAA Glu	TAT Tyr	AGA Arg 410	GGT Gly	CAG Gln	AAT Asn	AAA Lys	GCT Ala 415	ATA Ile	1248
AAT Asn	AAA. Lys	CAA Gln	Ala	Tyr	Glu	GAA Glu	Ile	Ser	Lys	Glu	CAT His	TTG Leu	GCT Ala 430	GTA Val	TAT Tyr	1296
AAG Lys	ATA Ile	CAA Gln 435	ATG Met	TGT Cys	AAA Lys	AGT Ser	GTT Val 440	AAA Lys	GCT Ala	CCA Pro	GGA Gly	ATA Ile 445	TGT Cys	ATT Ile	GAT Asp	1344
GTT Val	GAT Asp 450	AAT Asn	GAA Glu	GAT Asp	TTG Leu	TTC Phe 455	TTT Phe	ATA Ile	GCT Ala	GAT Asp	AAA Lys 460	AAT Asn	AGT Ser	TTT Phe	TCA Ser	1392
GAT Asp 465	GAT Asp	TTA Leu	TCT Ser	AAA Lys	AAC Asn 470	GAA Glu	AGA Arg	ATA Ile	GAA Glu	TAT Tyr 475	AAT Asn	ACA Thr	CAG Gln	AGT Ser	AAT Asn 480	1440
TAT Tyr	ATA Ile	GAA Glu	AAT Asn	GAC Asp 485	TTC Phe	CCT Pro	ATA Ile	AAT Asn	GAA Glu 490	TTA Leu	ATT Ile	TTA Leu	GAT Asp	ACT Thr 495	GAT Asp	1488
TTA Leu	ATA Ile	AGT Ser	AAA Lys 500	ATA Ile	GAA Glu	TTA Leu	CCA Pro	AGT Ser 505	GAA Glu	AAT Asn	ACA Thr	GAA Glu	TCA Ser 510	CTT Leu	ACT Thr	1536

GAT Asp	TTT	AAT Asn 515	GTA Val	GAT Asp	GTT Val	CCA Pro	GTA Val 520	TAT Tyr	GAA Glu	AAA Lys	CAA Gln	CCC Pro 525	GCT Ala	ATA Ile	AAA Lys		1584
		TTT Phe															1632
	Phe	CCT Pro															1680
GAT Asp	GCA Ala	TTA Leu	TTA Leu	TTT Phe 565	TCT Ser	AAC Asn	AAA Lys	GTT Val	TAT Tyr 570	TCA Ser	TTT Phe	TTT Phe	TCT Ser	ATG Met 575	GAT Asp	· .	1728
TAT Tyr	ATT Ile	AAA Lys	ACT Thr 580	GCT Ala	AAT Asn	AAA Lys	GTG Val	GTA Val 585	GAA Glu	GCA Ala	GGA Gly	TTA Leu	TTT Phe 590	GCA Ala	GGT Gly		1776
		AÀA Lys 595															1824
		ATG Met															1872
	Leu	GCT Ala															1920
		TTT Phe															1968
		TTA Leu		Pro													2016
		AAA Lys 675				Ile											2064
AGA Arg	AAT Asn 690	GAA Glu	AAA Lys	TGG Trp	AGT Ser	GAT Asp 695	ATG Met	TAC Tyr	GGA Gly	TTA Leu	ATA Ile 700	GTA Val	GCG Ala	CAA Gln	TGG Trp	:	2112
CTC Leu 705	TCA Ser	ACA Thr	GTT Val	AAT Asn	ACT Thr 710	CAA Gln	TTT Phe	TAT Tyr	ACA Thr	ATA Ile 715	AAA Lys	GAG Glu	GGA Gly	ATG Met	TAT Tyr 720		2160
		TTA Leu			Gln											٠.	2208
		AAT Asn															2256
		GAT Asp 755															2304
Asp		ATA Ile															2352

- 98 -

AAA Lys 785	AAA Lys	ATG Met	ATT Ile	CCA Pro	TTA Leu 790	GCT Ala	GTA Val	GAA Glu	AAA Lys	TTA Leu 795	CTA Leu	GAC Asp	TTT Phe	GAT Asp	AAT Asn 800	2400
ACT Thr	CTC Leu	AAA Lys	AAA Lys	AAT Asn 805	TTG Leu	TTA Leu	AAT Asn	TAT Tyr	ATA Ile 810	GAT Asp	GAA Glu	AAT Asn	AAA Lys	TTA Leu 815	TAT Tyr	2448
TTG Leu	ATT Ile	GGA Gly	AGT Ser 820	GCA Ala	GAA Glu	TAT Tyr	GAA Glu	AAA Lys 825	TCA Ser	AAA Lys	GTA Val	AAT Asn	AAA Lys 830	TAC Tyr	TTG Leu	2496
AAA Lys	ACC Thr	ATT Ile 835	ATG Met	CCG Pro	TTT Phe	GAT Asp	CTT Leu 840	TCA Ser	ATA Ile	TAT Tyr	ACC Thr	AAT Asn 845	GAT Asp	ACA Thr	ATA Ile	2544
		GAA Glu														2574

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 858 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

180

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

 Met
 Pro
 Val
 Thr
 Ile
 Asn
 Asn
 Phe
 Asn
 Tyr
 Asn
 Asp
 Pro
 Ile
 Asn
 Asn
 Asn
 Asn
 Asn
 Asn
 Ile
 Asn
 Asn
 Asn
 Asn
 Ile
 Asn
 Asn</th

Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln

185

Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 215 Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 330 Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile 390 395 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp 440 Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp 490 Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys 520 Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln 535 540

- 100 -

Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp 560 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu Asn Ala Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile 840 Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser

- (2) INFORMATION FOR SEQ ID NO: 23:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1644 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- 101 -

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..1644

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

	1.44	, 52	Q02.				••••			· ·	J .		•			
ATG Met 1	Pro	GTT Val	ACA Thr	ATA Ile 5	AAT Asn	AAT Asn	TTT	AAT Asn	TAT Tyr 10	AAT Asn	GAT Asp	CCT Pro	ATT	GAT Asp 15	AAT Asn	48
AAT Asn	AAT Asn	ATT Ile	ATT Ile 20	ATG Met	ATG Met	GAG Glu	CCT Pro	CCA Pro 25	TTT Phe	GCG Ala	AGA Arg	GGT Gly	ACG Thr 30	GGG Gly	AGA Arg	96
TAT Tyr	TAT Tyr	AAA Lys 35	Ala	TTT Phe	AAA Lys	ATC Ile	ACA Thr 40	GAT Asp	CGT	ATT Ile	TGG Trp	ATA Ile 45	Ile	CCG Pro	GAA Glu	144
AGA Arg	TAT Tyr 50	ACT Thr	TTT Phe	GGA Gly	TAT	AAA Lys 55	CCT	GAG Glu	GAT Asp	TTT Phe	AAT Asn 60	AAA Lys	AGT Ser	TCC Ser	GGT Gly	192
ATT Ile 65	TTT Phe	AAT Asn	AGA Arg	GAT Asp	GTT Val 70	TGT Cys	GAA Glu	TAT	TAT	GAT Asp 75	CCA Pro	GAT Asp	TAC	TTA Leu	AAT Asn 80	240
				AAG Lys 85												288
				TCA Ser												336
				CCT												3.8.4:
TTT Phe	AAC Asn 130	ACA Thr	AAC Asn	ATT Ile	GCT Ala	AGT Ser 135	GTA Val	ACT Thr	GTT Val	AAT Asn	AAA Lys 140	TTA Leu	ATC Ile	AGT Ser	AAT Asn	432
				GAG Glu												 480
				CCA Pro 165												528
ATA Ile	CAA Gln	Asn	His	TTT Phe	Ala	Ser	Arg	Glu	Gly	Phe	Gly	Gly	Ile	Met	CAA Gln	5 76
				CCA Pro												624
AAC Asn	AAA Lys 210	GGC Gly	GCA Ala	AGT Ser	ATA Ile	TTT Phe 215	AAT Asn	AGA Arg	CGT Arg	GGA Gly	TAT Tyr 220	TTT Phe	TCA Ser	GAT Asp	CCA Pro	672 -

- 102 -

GCC Ala 225	TTG Leu	ATA Ile	TTA Leu	ATG Met	CAT His 230	GAA Glu	CTT Leu	ATA Ile	CAT His	GTT Val 235	TTA Leu	CAT His	GGA Gly	TTA Leu	TAT Tyr 240	720
GGC Gly	ATT	AAA Lys	GTA Val	GAT Asp 245	GAT Asp	TTA Leu	CCA Pro	ATT Ile	GTA Val 250	CCA Pro	AAT Asn	GAA Glu	AAA Lys	AAA Lys 255	TTT Phe	768
TTT Phe	ATG Met	CAA Gln	TCT Ser 260	ACA Thr	GAT Asp	GCT Ala	ATA Ile	CAG Gln 265	GCA Ala	GAA Glu	GAA Glu	CTA Leu	TAT Tyr 270	ACA Thr	TTT Phe	816
GGA Gly	GGA Gly	CAA Gln 275	GAT Asp	CCC Pro	AGC Ser	ATC Ile	ATA Ile 280	ACT Thr	CCT Pro	TCT Ser	ACG Thr	GAT Asp 285	AAA Lys	AGT Ser	ATC Ile	864
TAT Tyr	GAT Asp 290	AAA Lys	GTT Val	TTG Leu	CAA Gln	AAT Asn 295	TTT Phe	AGA Arg	GGG Gly	ATA Ile	GTT Val 300	GAT Asp	AGA Arg	CTT Leu	AAC Asn	912
AAG Lys 305	GTT Val	TTA Leu	GTT Val	TGC Cys	ATA Ile 310	TCA Ser	GAT Asp	CCT Pro	AAC Asn	ATT Ile 315	AAT Asn	ATT Ile	AAT Asn	ATA Ile	TAT Tyr 320	960
AAA Lys	AAT Asn	AAA Lys	TTT Phe	AAA Lys 325	GAT Asp	AAA Lys	TAT Tyr	AAA Lys	TTC Phe 330	GTT Val	GAA Glu	GAT Asp	TCT Ser	GAG Glu 335	GGA Gly	1008
AAA Lys	TAT Tyr	AGT Ser	ATA Ile 340	GAT Asp	GTA Val	GAA Glu	AGT Ser	TTT Phe 345	GAT Asp	AAA Lys	TTA Leu	TAT Tyr	AAA Lys 350	AGC Ser	TTA Leu	1056
ATG Met	TTT Phe	GGT Gly 355	TTT Phe	ACA Thr	GAA Glu	ACT Thr	AAT Asn 360	ATA Ile	GCA Ala	GAA Glu	AAT Asn	TAT Tyr 365	AAA Lys	ATA Ile	AAA Lys	1104
ACT Thr	AGA Arg 370	GCT Ala	TCT Ser	TAT Tyr	TTT Phe	AGT Ser 375	GAT Asp	TCC Ser	TTA Leu	CCA Pro	CCA Pro 380	GTA Val	AAA Lys	ATA Ile	AAA Lys	1152
AAT Asn 385	TTA Leu	TTA Leu	GAT Asp	AAT Asn	GAA Glu 390	ATC Ile	TAT Tyr	ACT Thr	ATA Ile	GAG Glu 395	GAA Glu	GGG Gly	TTT Phe	AAT Asn	ATA Ile 400	1200
TCT Ser	GAT Asp	AAA Lys	GAT Asp	ATG Met 405	GAA Glu	AAA Lys	GAA Glu	TAT Tyr	AGA Arg 410	GGT Gly	CAG Gln	AAT Asn	AAA Lys	GCT Ala 415	ATA Ile	1248
AAT Asn	AAA Lys	CAA Gln	GCT Ala 420	TAT Tyr	GAA Glu	GAA Glu	ATT Ile	AGC Ser 425	AAG Lys	GAG Glu	CAT His	TTG Leu	GCT Ala 430	GTA Val	TAT Tyr	1296
AAG Lys	Ile	CAA Gln 435	ATG Met	TGT Cys	AAA Lys	AGT Ser	GTT Val 440	AAA Lys	GCT Ala	CCA Pro	GGA Gly	ATA Ile 445	TGT Cys	ATT Ile	GAT Asp	1344
GTT Val	GAT Asp 450	AAT Asn	GAA Glu	GAT Asp	TTG Leu	TTC Phe 455	TTT Phe	ATA Ile	GCT Ala	GAT Asp	AAA Lys 460	AAT Asn	AGT Ser	TTT Phe	TCA Ser	1392
GAT Asp 465	GAT Asp	TTA Leu	TCT Ser	AAA Lys	AAC Asn 470	GAA Glu	AGA Arg	ATA Ile	GAA Glu	TAT Tyr 475	AAT Asn	ACA Thr	CAG Gln	AGT Ser	AAT Asn 480	1440
		GAA Glu														1488

- 103 -

TTA Leu	ATA Ile	AGT Ser	AAA Lys 500	ATA Ile	GAA Glu	TTA Leu	CCA Pro	AGT Ser 505	GAA Glu	AAT Asn	ACA Thr	GAA Glu	TCA Ser 510	CTT Leu	ACT Thr	1536
GAT Asp	TTT Phe	AAT Asn 515	GTA Val	GAT Asp	GTT Val	CCA Pro	GTA Val 520	TAT Tyr	GAA Glu	AAA Lys	CAA Gln	CCC Pro 525	GCT Ala	ATA Ile	AAA Lys	1584
			ACA Thr		Glu											1632
		CCT Pro		-												1644

- (2) INFORMATION FOR SEQ ID NO: 24:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 548 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile 150 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu 195 200 205

Asn	Lys 210	Gly	Ala	Ser	Ile	Phe 215	Asn	Arg	Arg	Gly	Tyr 220	Phe	Ser	Asp	Pro
Ala 225	Leu	Ile	Leu	Met	His 230	Glu	Leu	Ile	His	Val 235	Leu	His	Gly	Leu	Tyr 240
Gly	Ile	Lys	Val	Asp 245	Asp	Leu	Pro	Ile	Val 250	Pro	Asn	Glu	Lys	Lys 255	Phe
Phe	Met	Gln	Ser 260	Thr	Asp	Ala	Ile	Gln 265	Ala	Glu	Glu	Leu	Tyr 270	Thr	Phe
Gly	Gly	Gln 275	Asp	Pro	Ser	Ile	Ile 280	Thr	Pro	Ser	Thr	Asp 285	Lys	Ser	Ile
Tyr	Asp 290	Lys	Val	Leu	Gln	Asn 295	Phe	Arg	Gly	Ile	Val 300	Asp	Arg	Leu	Asn
Lys 305	Val	Leu	Val	Cys	Ile 310	Ser	Asp	Pro	Asn	Ile 315	Asn	Ile	Asn	Ile	Tyr 320
Lys	Asn	Lys	Phe	Lys 325	Asp	Lys	Tyr	Lys	Phe 330	Val	Glu	Asp	Ser	Glu 335	Gly
Lys	Tyr	Ser	Ile 340	Asp	Val	Glu	Ser	Phe 345	Asp	Lys	Leu	Tyr	Lys 350	Ser	Leu
Met	Phe	Gly 355	Phe	Thr	Glu	Thr	Asn 360	Ile	Ala	Glu	Asn	Tyr 365	Lys	Ile	Lys
Thr	Arg 370	Ala	Ser	Tyr	Phe	Ser 375	Asp	Ser	Leu	Pro	Pro 380	Val	Lys	Ile	Lys
Asn 385		Leu	Asp	Asn	Glu 390	Ile	Tyr	Thr	Ile	Glu 395	Glu	Gly	Phe	Asn	Ile 400
Ser	Asp	Lys	Asp	Met 405	Glu	Lys	Glu	Tyr	Arg 410	Gly	Gln	Asn	Lys	Ala 415	Ile
Asn	Lys	Gln	Ala 420	Tyr	Glu	Glu	Ile	Ser 425	Lys	Glu	His	Leu	Ala 430	Val	Tyr
Lys	Ile	Gln 435		Cys	Lys	Ser	Val 440	Lys	Ala	Pro	Gly	Ile 445	Cys	Ile	Asp
Val	Asp 450		Glu	Asp	Leu	Phe 455		Ile	Ala	Asp	Lys 460	Asn	Ser	Phe	Ser
Asp 465	-	Leu	Ser	Lys	Asn 470	Glu	Arg	Ile	Glu	Tyr 475	Asn	Thr	Gln	Ser	Asn 480
Tyr	Ile	Glu	Asn	Asp 485		Pro	Ile	Asn	Glu 490	Leu	Ile	Leu	Asp	Thr 495	Asp
Leu	Ile	Ser	Lys 500		Glu	Leu	Pro	Ser S05		Asn	Thr	Glu	Ser 510	Leu	Thr
Asp	Phe	Asn 515		Asp	Val	Pro	Val 520		Glu	Lys	Gln	Pro 525	Ala	Ile	Lys
Lys	1le 530		Thr	Asp	Glu	Asn 535		Ile	Phe	Gln	Tyr 540		Tyr	Ser	Gln
Thr 545		Pro	Leu	ı											

- 105 -

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2616 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:

 - (A) NAME/KEY: CDS
 (B) LOCATION:1..2616

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

			GTG Val													48
GTT Val	GAC Asp	ATT Ile	GCC Ala 20	Tyr	ATC	AAA Lys	ATT	CCA Pro 25	AAC Asn	GCC Ala	GGC Gly	CAG Gln	ATG Met 30	CAG Gìn	CCG Pro	96
			TTC Phe													144
			ACG Thr													192
	Lys		GTG Val													240
			AAG Lys													288
			TCC Ser 100													336
			CCA Pro												AAG Lys	384
			ACT Thr													432
			GAA Glu													480
			GAG Glu													528
			TAC Tyr 180													576

- 106 - -

ACG Thr	TTC Phe	GGT Gly 195	TTC Phe	GAG Glu	GAG Glu	AGC Ser	CTG Leu 200	GAG Glu	GTT Val	GAT Asp	ACC Thr	AAC Asn 205	CCG Pro	CTG Leu	TTG Leu	624
GGT Gly	GCA Ala 210	GGC Gly	AAG Lys	TTC Phe	GCA Ala	ACT Thr 215	GAT Asp	CCA Pro	GCG Ala	GTG Val	ACC Thr 220	CTG Leu	GCA Ala	CAC His	GAG Glu	672
CTG Leu 225	ATC Ile	CAC His	GCC Ala	GGT Gly	CAT His 230	CGT Arg	CTG Leu	TAT Tyr	GGC Gly	ATT Ile 235	GCG Ala	ATT Ile	AAC Asn	CCG Pro	AAC Asn 240	720
CGC Arg	GTG Val	TTC Phe	AAG Lys	GTT Val 245	AAC Asn	ACC Thr	AAC Asn	GCC Ala	TAC Tyr 250	TAC Tyr	GAG Glu	ATG Met	AGT Ser	GGT Gly 255	TTA Leu	768
GAA Glu	GTA Val	AGC Ser	TTC Phe 260	GAG Glu	GAA Glu	CTG Leu	CGC Arg	ACG Thr 265	TTC Phe	GGT Gly	GGC Gly	CAT His	GAT Asp 270	GCG Ala	AAG Lys	816
TTT Phe	ATC Ile	GAC Asp 275	AGC Ser	TTG Leu	CAG Gln	GAG Glu	AAC Asn 280	GAG Glu	TTC Phe	CGT Arg	CTG Leu	TAC Tyr 285	TAC Tyr	TAC Tyr	AAC Asn	864
AAG Lys	TTT Phe 290	AAA Lys	GAT Asp	ATT Ile	GCA Ala	AGT Ser 295	ACA Thr	CTG Leu	AAC Asn	AAG Lys	GCT Ala 300	AAG Lys	TCC Ser	ATT	GTG Val	912
GGT Gly 305	ACC Thr	ACT Thr	GCT Ala	TCA Ser	TTA Leu 310	CAG Gln	TAT Tyr	ATG Met	AAA Lys	AAT Asn 315	GTT Val	TTT Phe	AAA Lys	GAG Glu	AAA Lys 320	960
TAT Tyr	CTC Leu	CTA Leu	TCT Ser	GAA Glu 325	GAT Asp	ACA Thr	TCT Ser	GGA Gly	AAA Lys 330	TTT Phe	TCG Ser	GTA Val	GAT Asp	AAA Lys 335	TTA Leu	1008
AAA Lys	TTT Phe	GAT Asp	AAG Lys 340	TTA Leu	TAC Tyr	AAA Lys	ATG Met	TTA Leu 345	ACA Thr	GAG Glu	ATT	TAC Tyr	ACA Thr 350	GAG Glu	GAT Asp	1056
AAT Asn	TTT Phe	GTT Val 355	AAG Lys	TTT Phe	TTT Phe	AAA Lys	GTA Val 360	CTT Leu	AAC Asn	AGA Arg	AAA Lys	ACA Thr 365	TAT Tyr	TTG Leu	AAT Asn	1104
TTT Phe	GAT Asp 370	AAA Lys	GCC Ala	GTA Val	TTT Phe	AAG Lys 375	ATA Ile	AAT Asn	ATA Ile	GTA Val	CCT Pro 380	AAG Lys	GTA Val	AAT Asn	TAC Tyr	1152
ACA Thr 385	ATA Ile	TAT Tyr	GAT Asp	GGA Gly	TTT Phe 390	AAT Asn	TTA Leu	AGA Arg	AAT Asn	ACA Thr 395	AAT Asn	TTA Leu	GCA Ala	GCA Ala	AAC Asn 400	1200
TTT Phe	AAT Asn	GGT Gly	CAA Gln	AAT Asn 405	ACA Thr	GAA Glu	ATT Ile	AAT Asn	AAT Asn 410	ATG Met	AAT Asn	TTT Phe	ACT Thr	AAA Lys 415	CTA Leu	1248
AAA Lys	AAT Asn	TTT Phe	ACT Thr 420	GGA Gly	TTG Leu	TTT Phe	GAA Glu	TTT Phe 425	TAT Tyr	AAG Lys	TTG Leu	CTA Leu	TGT Cys 430	GTA Val	AGA Arg	1296
GGG Gly	ATA Ile	ATA Ile 435	ACT Thr	TCT Ser	AAA Lys	ACT Thr	AAA Lys 440	TCA Ser	TTA Leu	GAT Asp	AAA Lys	GGA Gly 445	TAC Tyr	AAT Asn	AAG Lys	1344
											TGG Trp 460					1392

- 107 -

AGT Ser 465	Pro	TC/ Sei	GAZ Glu	A GAT 1 Asp	AAT AST 470) Phe	ACT Thr	AAT Asn	GAT Asp	CTA Leu 475	AAT Asn	AAA Lys	GGA Gly	GAA Glu	GAA Glu 480		1440
ATI	ACA Thr	TCI Ser	GAT Asp	TACT Thr 485	Asn	ATA Ile	GAA Glu	GCA Ala	GCA Ala 490	GAA Glu	GAA Glu	AAT Asn	ATT Ile	AGT Ser 495			1488
GAT Asp	TTA Leu	ATA Ile	CAA Gln 500	CAA Gln	TAT	TAT Tyr	TTA Leu	ACC Thr 505	Phe	AAT Asn	TTT Phe	GAT Asp	AAT Asn 510	GAA Glu	CCT Pro		1536
Glu	Asn	11e 515	Ser	ATA Ile	Glu	Asn	Leu 520	Ser	Ser	Asp	Ile	Ile 525	Gly	Gln	Leu		1584
GAA Glu	Leu 530	Met	Pro	AAT Asn	ATA Ile	GAA Glu 535	AGA	TTT Phe	CCT Pro	AAT Asn	GGA Gly 540	AAA Lys	AAG Lys	TAT	GAG Glu		1632
Leu 545	Asp	Lys	Tyr	ACT	Met 550	Phe	His	Tyr	Leu	Arg 555	Ala	Gln	Glu	Phe	Glu 560		1680
His	Gly	Lys	Ser	AGG Arg 565	Ile	Ala	Leu	Thr	Asn 570	Ser	Val	Asn	Glu	Ala 575	Leu		1728
TTA Leu	AAT Asn	Pro	AGT Ser 580	CGT	GTT Val	TAT	ACA Thr	TTT Phe 585	TTT Phe	TCT Ser	TCA Ser	GAC Asp	TAT Tyr 590	GTA Val	AAG Lys		1776
Lys	Val	Asn 595	Lys	GCT Ala	Thr	Glu	Ala 600	Ala	Met	Phe	Leu	Gly 605	Trp	Val	Glu	•	L824
Gln	Leu 610	Val	Tyr	GAT Asp	Phe	Thr 615	Asp	Glu	Thr	Ser	Glu 620	Val	Ser	Thr	Thr	:	L872
Asp 625	Lys	Ile	Ala	GAT Asp	Ile 630	Thr	Ile	Ile	Ile	Pro 635	Tyr	Ile	Gly	Pro	Ala: 640		.920
Leu	Asn	Ile	Gly	AAT Asn 645	Met	Leu	Tyr	Lys	Asp 650	Asp	Phe	Val	Gly	Ala 655	Leu	1	.968
Ile	Phe	Ser	Gly 660	GCT Ala	Val	Ile	Leu	Leu 665	Glu	Phe	<u>Į</u> le	Pro	Glu 670	Ile	Ala	, 2	016
Ile	Pro	Val 675	Leu	GGT Gly	Thr	Phe	Ala 680	Leu	Val	Ser	Tyr	Ile 685	Ala	Asn	Lys	2	064
GTT Val	CTA Leu 690	ACC Thr	GTT Val	CAA Gln	ACA Thr	ATA Ile 695	GAT Asp	AAT Asn	GCT Ala	TTA Leu	AGT Ser 700	AAA Lys	AGA Arg	AAT Asn	GAA Glu	2	112
AAA Lys 705	TGG Trp	GAT Asp	GAG Glu	GTC Val	TAT Tyr 710	AAA Lys	TAT Tyr	ATA Ile	Val	ACA Thr 715	AAT Asn	TGG Trp	TTA Leu	Ala	AAG Lys 720	2	160
GTT Val	AAT Asn	ACA Thr	Gln	ATT Ile 725	GAT Asp	CTA Leu	ATA . Ile .	Arg	AAA Lys 730	AAA Lys	ATG Met	AAA Lys	GAA Glu	GCT Ala 735	Leu	2	208

- 108 -

GAA Glu	AAT Asn	CAA Gln	GCA Ala 740	GAA Glu	GCA Ala	ACA Thr	AAG Lys	GCT Ala 745	ATA Ile	ATA Ile	AAC Asn	TAT Tyr	CAG Gln 750	TAT Tyr	AAT Asn		2256
CAA Gln	TAT Tyr	ACT Thr 755	GAG Glu	GAA Glu	GAG Glu	AAA Lys	AAT Asn 760	AAT Asn	ATT Ile	AAT Asn	TTT Phe	AAT Asn 765	ATT	GAT Asp	GAT Asp		2304
TTA Leu	AGT Ser 770	TCG Ser	AAA Lys	CTT Leu	AAT Asn	GAG Glu 775	TCT Ser	ATA Ile	AAT Asn	AAA Lys	GCT Ala 780	ATG Met	ATT Ile	AAT Asn	ATA Ile		2352
AAT Asn 785	AAA Lys	TTT Phe	TTG Leu	AAT Asn	CAA Gln 790	TGC Cys	TCT Ser	GTT Val	TCA Ser	TAT Tyr 795	TTA Leu	ATG Met	AAT Asn	TCT Ser	ATG Met 800		2400
ATC Ile	CCT Pro	TAT Tyr	GGT Gly	GTT Val 805	AAA Lys	CGG Arg	TTA Leu	Glu	GAT Asp 810	TTT Phe	GAT Asp	GCT Ala	AGT Ser	CTT Leu 815	AAA Lys		2448
GAT Asp	GCA Ala	TTA Leu	TTA Leu 820	AAG Lys	TAT Tyr	ATA Ile	TAT Tyr	GAT Asp 825	AAT Asn	AGA Arg	GGA Gly	ACT Thr	TTA Leu 830	ATT Ile	GGT Gly	-	2496
CAA Gln	GTA Val	GAT Asp 835	AGA Arg	TTA Leu	AAA Lys	GAT Asp	AAA Lys 840	GTT Val	AAT Asn	AAT Asn	ACA Thr	CTT Leu 845	AGT Ser	ACA Thr	GAT Asp		2544
ATA Ile	CCT Pro 850	TTT Phe	CAG Gln	CTT Leu	TCC Ser	AAA Lys 855	TAC Tyr	GTA Val	GAT Asp	AAT Asn	CAA Gln 860	AGA Arg	TTA Leu	TTA Leu	TCT Ser		2592
					ATT Ile 870		TAA									•	2616

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 872 amino acids
 - (B) TYPE: amino acid(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly

Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro

Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg

Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu

Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr

Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu

Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val

Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 150 Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 215 Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 230 Arg Val Phe Lys Val Asm Thr Asm Ala Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 265 Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 310 315 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn Phe Vai Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 410 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 425 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe 455

Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu 550 His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 615 Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met 795 Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 81C

Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly

Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 845

Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser 855

Thr Phe Thr Glu Tyr Ile Lys

- (2) INFORMATION FOR SEQ ID NO: 27:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2574 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

ATGCCGGTTA CCATCAACAA CTTCAACTAC AACGACCCGA TCGACAAGAA CAACATCATC	60
TGATGGAAC CGCCGTTCGC ACGTGGTACC GGTCGTTACT ACAAGGCTTT CAAGATCACC	120
ACCGTATCT GGATCATCCC GGAACGTTAC ACCTTCGGTT ACAAACCTGA GGACTTCAAC	180
AGAGTAGCG GGATTTTCAA TCGTGACGTC TGCGAGTACT ATGATCCAGA TTATCTGAAT	240
CCAACGATA AGAAGAACAT ATTCCTTCAG ACTATGATCA AGTTATTTAA TAGAATCAAA	300
CAAAACCAT TGGGTGAAAA GTTATTAGAG ATGATTATAA ATGGTATACC TTATCTTGGA	360
ATAGACGTG TTCCACTCGA AGAGTTTAAC ACAAACATTG CTAGTGTAAC TGTTAATAAA	420
TAATCAGTA ATCCAGGAGA AGTGGAGCGA AAAAAAGGTA TTTTCGCAAA TTTAATAATA	480
TTGGACCTG GGCCAGTTTT AAATGAAAAT GAGACTATAG ATATAGGTAT ACAAAATCAT	540
TTGCATCAA GGGAAGGCTT CGGGGGTATA ATGCAAATGA AGTTTTGCCC AGAATATGTA	600
GCGTATTTA ATAATGTTCA AGAAAACAAA GGCGCAAGTA TATTTAATAG ACGTGGATAT	660
TTTCAGATC CAGCCTTGAT ATTAATGCAT GAACTTATAC ATGTTTTACA TGGATTATAT	720
GCATTAAAG TAGATGATTT ACCAATTGTA CCAAATGAAA AAAAATTTTT TATGCAATCT	780
CAGATGCTA TACAGGCAGA AGAACTATAT ACATTTGGAG GACAAGATCC CAGCATCATA	840
STECTICTA CGGATAAAAG TATCTATGAT AAAGTTTTGC AAAATTTTAG AGGGATAGTT	900
ATAGACTTA ACAAGGTTTT AGTTTGCATA TCAGATCCTA ACATTAATAT TAATATATAT	960
AAAATAAAT TTAAAGATAA ATATAAATTC GTTGAAGATT CTGAGGGAAA ATATAGTATA	1020
ATGTAGAAA GTTTTGATAA ATTATATAAA AGCTTAATGT TTGGTTTTAC AGAAACTAAT	1080
TAGCAGAAA ATTATAAAAT AAAAACTAGA GCTTCTTATT TTAGTGATTC CTTACCACCA	1140
TAAAAATAA AAAATTTATT AGATAATGAA ATCTATACTA TAGAGGAAGG GTTTAATATA	1200

TCTGATAAAG	ATATGGAAAA	AGAATATAGA	GGTCAGAATA	AAGCTATAAA	TAAACAAGCT	1260
TATGAAGAAA	TTAGCAAGGA	GCATTTGGCT	GTATATAAGA	TACAAATGTG	TAAAAGTGTT	1320
AAAGCTCCAG	GAATATGTAT	TGATGTTGAT	AATGAAGATT	TGTTCTTTAT	AGCTGATAAA	1380
AATAGTTTTT	CAGATGATTT	ATCTAAAAAC	GAAAGAATAG	AATATAATAC	ACAGAGTAAT	1440
TATATAGAAA	ATGACTTCCC	TATAAATGAA	TTAATTTTAG	ÄTACTGATTT	AATAAGTAAA	1500
ATAGAATTAC	CAAGTGAAAA	TACAGAATCA	CTTACTGATT	TTAATGTAGA	TGTTCCAGTA	1560
TATGAAAAAC	AACCCGCTAT	AAAAAAATT	TTTACAGATG	AAAATACCAT	CTTTCAATAT	1620
TTATACTCTC	AGACATTTCC	TCTAGATATA	AGAGATATAA	GTTTAACATC	TTCATTTGAT	1680
GATGCATTAT	TATTTTCTAA	CAAAGTTTAT	TCATTTTTT	CTATGGATTA	TATTAAAACT	1740
GCTAATAAAG	TGGTAGAAGC	AGGATTATTT	GCAGGTTGGG	TGAAACAGAT	AGTAAATGAT	1800
TTTGTAATCG	AAGCTAATAA	AAGCAATACT	ATGGATAAAA	TTGCAGATAT	ATCTCTAATT	1860
GTTCCTTATA	TAGGATTAGC	TTTAAATGTA	GGAAATGAAA	CAGCTAAAGG	AAATTTTGAA	1920
AATGCTTTTG	AGATTGCAGG	AGCCAGTATT	CTACTAGAAT	TTATACCAGA	ACTTTTAATA	1980
CCTGTAGTTG	GAGCCTTTTT	ATTAGAATCA	TATATTGACA	АТАААААТАА	AATTATTAAA	2040
ACAATAGATA	ATGCTTTAAC	TAAAAGAAAT	GAAAAATGGA	GTGATATGTA	CGGATTAATA	2100
GTAGCGCAAT	GGCTCTCAAC	AGTTAATACT	CAATTTTATA	CAATAAAAGA	GGGAATGTAT	2160
AAGGCTTTAA	ATTATCAAGC	ACAAGCATTG	GAAGAAATAA	TAAAATACAG	ATATAATATA	2220
TATTCTGAAA	AAGAAAAGTC	AAATATTAAC	ATCGATTTTA	ATGATATAAA	TTCTAAACTT	2280
AATGAGGGTA	TTAACCAAGC	TATAGATAAT	ATAAATAATT	TTATAAATGG	ATGTTCTGTA	2340
TCATATTTAA	TGAAAAAAAT	GATTCCATTA	GCTGTAGAAA	AATTACTAGA	CTTTGATAAT	2400
ACTCTCAAAA	AAAATTTGTT	AAATTATATA	GATGAAAATA	AATTATATTT	GATTGGAAGT	2460
GCAGAATATG	AAAAATCAAA	AGTAAATAAA	TACTTGAAAA	CCATTATGCC	GTTTGATCTT	2520
TCAATATATA	CCAATGATAC	AATACTAATA	GAAATGTTTA	ATAAATATAA	TAGC	2574

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2574 base pairs

 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

ATGCCAGTTA	CAATAAATAA	TTTTAATTAT	AATGATCCTA	TTGATAATAA	TAATATTATT	60
ATGATGGAGC	CTCCATTTGC	GAGAGGTACG	GGGAGATATT	ATAAAGCTTT	TAAAATCACA	120
GATCGTATTT	GGATAATACC	GGAAAGATAT	ACTTTTGGAT	ATAAACCTGA	GGATTTTAAT	180
AAAAGTTCCG	GTATTTTTAA	TAGAGATGTT	TGTGAATATT	ATGATCCAGA	TTACTTAAAT	240

ACTAATGATA	AAAAGAATAT	ATTTTTACAA	ACAATGATCA	AGTTATTTAA	TAGAATCAAA	300
TCAAAACCAT	TGGGTGAAAA	GTTATTAGAG	ATGATTATAA	ATGGTATACC	TTATCTTGGA	360
GATAGACGTO	TTCCACTCGA	AGAGTTTAAC	ACAAACATTG	CTAGTGTAAC	TGTTAATAAA	420
TTAATCAGTA	ATCCAGGAGA	AGTGGAGCGA	AAAAAAGGTA	TTTTCGCAAA	TTTAATAATA	480
TTTGGACCTG	GGCCAGTTTT	AAATGAAAAT	GAGACTATAG	ATATAGGTAT	ACAAAATCAT	540
TTTGCATCAA	GGGAAGGCTT	CGGGGGTATA	ATGCAAATGA	AGTTTTGCCC	AGAATATGTA	600
AGCGTATTTA	ATAATGTTCA	AGAAAACAAA	GGCGCAAGTA	TATTTAATAG	ACGTGGATAT	660
TTTTCAGATO	CAGCCTTGAT	ATTAATGCAT	GAACTCATCC	ACGTCCTCCA	CGGTCTCTAC	720
GGTATCAAAG	TAGACGACCT	CCCGATCGTC	CCGAACGAAA	AAAAATTCTT	CATGCAGAGC	780
ACCGACGCAA	TCCAGGCAGA	AGAACTCTAC	ACCTTCGGTG	GTCAGGACCC	GAGCATCATC	840
ACCCCGAGCA	CCGACAAAAG	CATCTACGAC	AAAGTCCTCC	AGAACTTCCG	TGGTATCGTC	900
GACCGTCTCA	ACAAAGTCCT	CGTCTGCATC	AGCGACCCGA	ACATCAACAT	CAACATCTAC	960
AAAAACAAAT	TCAAAGACAA	ATACAAATTC	GTCGAAGACA	GCGAAGGTAA	ATACAGCATC	1020
GACGTCGAGA	GCTTCGACAA	ACTCTACAAA	AGCCTCATGT	TCGGTTTCAC	CGAAACCAAC	1080
ATCGCAGAAA	ACTACAAAAT	CAAAACCCGT	GCAAGCTACT	TCAGCGACAG	CCTCCCGCCG	1140
GTCAAAATCA	AAAACCTCCT	CGACAACGAA	ATCTACACCA	TCGAAGAAGG	TTTCAACATC	1200
AGCGACAAAG	ACATGGAAAA	AGAATACCGT	GGTCAGAACA	AAGCAATCAA	CAAACAAGCT	1260
TACGAAGAAA	TCAGCAAAGA	ACACCTCGCA	GTCTACAAAA	TCCAGATGTG	CAAAAGCGTC	1320
AAAGCACCGG	GTATCTGCAT	CGACGTTGAC	AACGAAGACC	TCTTCTTCAT	CGCAGACAAA	1380.
AACAGCTTCA	GCGACGACCT	CAGCAAAAAC	GAACGTATCG	AATACAACAC	CCAGAGCAAC	1440
TACATCGAAA	ACGACTTCCC	GATCAACGAA	CTCATCCTCG	ACACCGACCT	CATCAGCAAA	1500
ATCGAACTCC	CGAGCGAAAA	CACCGAAAGC	CTCACCGACT	TCAACGTTGA	CGTCCCGGTC	1560
TACGAAAAAC	AGCCGGCAAT	CAAAAAAATC	TTCACCGACG	AAAACACCAT	CTTCCAGTAC	1620
CTCTACAGCC	AGACCTTCCC	GCTAGATATA	AGAGATATAA	GTTTAACATC	TTCATTTGAT	1680
GATGCATTAT	TATTTTCTAA	CAAAGTTTAT	TCATTTTTT	CTATGGATTA	TATTAAAACT	1740
GCTAATAAAG	TGGTAGAAGC	AGGATTATTT	GCAGGTTGGG	TGAAACAGAT	AGTAAATGAT	1800
TTTGTAATCG	AAGCTAATAA	AAGCAATACT	ATGGATAAAA	TTGCAGATAT	ATCTCTAATT	1860
GTTCCTTATA	TAGGATTAGC	TTTAAATGTA	GGAAATGAAA	CAGCTAAAGG	AAATTTTGAA	1920
AATGCTTTTG	AGATTGCAGG	AGCCAGTATT	CTACTAGAAT	TTATACCAGA	ACTTTTAATA	1980
CCTGTAGTTG	GAGCCTTTTT	ATTAGAATCA	TATATTGACA	ATAAAAATAA	AATTATTAAA	2040
ACAATAGATA	ATGCTTTAAC	TAAAAGAAAT	GAAAAATGGA	GTGATATGTA	CGGATTAATA	2100
GTAGCGCAAT	GGCTCTCAAC	AGTTAATACT	CAATTTTATA	CAATAAAAGA	GGGAATGTAT	2160
AAGGCTTTAA	ATTATCAAGC	ACAAGCATTG	GAAGAAATAA	TAAAATACAG	ATATAATATA	2220
TATTCTGAAA	AAGAAAAGTC	AAATATTAAC	ATCGATTTTA	ATGATATAAA	TTCTAAACTT	2280

PCT/GB97/02273

- 114 -

AATGAGGGTA	TTAACCAAGC	TATAGATAAT	ATAAATAATT	TTATAAATGG	ATGTTCTGTA	2340
TCATATTTAA	TGAAAAAAAT	GATTCCATTA	GCTGTAGAAA	AATTACTAGA	CTTTGATAAT	2400
ACTCTCAAAA	AAAATTTGTT	AAATTATATA	GATGAAAATA	AATTATATTT	GATTGGAAGT	2460
GCAGAATATG	AAAAATCAAA	AGTAAATAAA	TACTTGAAAA	CCATTATGCC	GTTTGATCTT	2520
TCAATATATA	CCAATGATAC	AATACTAATA	GAAATGTTTA	ATAAATATAA	TAGC	2574

CLAIMS

- 1. A polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and wherein said second domain is adapted (i) to translocate the polypeptide into a cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into a cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of clostridial neurotoxin precursor that can be converted into toxin by proteolytic action.
- 2. A polypeptide according to Claim 1 wherein said first domain comprises a clostridial toxin light chain.
- 3. A polypeptide according to Claim 1 wherein said first domain comprises a fragment or variant of a clostridial toxin light chain.
- 4. A polypeptide according to Claim 2 or 3 wherein the clostridial toxin is a botulinum toxin.
- 5. A polypeptide according to any preceding claim wherein the first domain exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin.
- 6. A polypeptide according to any preceding claim wherein said second domain comprises a clostridial toxin heavy chain H_N portion.
- 7. A polypeptide according to any of Claims 1-5 wherein said second domain comprises a fragment or variant of a clostridial toxin heavy chain H_N portion.
- 8. A polypeptide according to Claim 6 or 7 wherein the clostridial toxin is a

botulinum toxin.

- 9. A polypeptide according to any of Claims 1-8 further comprising a third domain adapted for binding of the polypeptide to a cell, by binding of the third domain directly to a cell or by binding of the third domain to a ligand or to ligands that bind to a cell.
- 10. A polypeptide according to Claim 9 wherein said third domain is for binding the polypeptide to an immunoglobulin.
- 11. A polypeptide according to Claim 10 wherein said third domain is a tandem repeat synthetic IgG binding domain derived from domain β of Staphylococcal protein A.
- 12. A polypeptide according to Claim 9 wherein said third domain comprises an amino acid sequence that binds to a cell surface receptor.
- 13. A polypeptide according to Claim 12 wherein said third domain is insulin-like growth factor-1 (IGF-1).
- 14. A polypeptide according to any preceding claim comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and a portion designated H_N of a botulinum toxin heavy chain.
- 15. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type A.
- 16. A polypeptide according to Claim 15 wherein the botulinum toxin type A light chain variant has at residue 2 a glutamate, at residue 26 a lysine and at residue 27 a tyrosine.

- 17. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type B.
- 18. A polypeptide according to any of Claims 1-13 comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and at least 100 N-terminal amino acids of a botulinum toxin heavy chain.
- 19. A polypeptide according to Claim 18 comprising a botulinum toxin type B light chain, or a fragment or variant thereof, and 107 N-terminal amino acids of a botulinum toxin type B heavy chain.
- 20. A polypeptide according to Claim 15 or 16 comprising at least 423 of the N-terminal amino acids of botulinum toxin type A heavy chain.
- 21. A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain and 423 N-terminal amino acids of a botulinum toxin type A heavy chain.
- 22. A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain variant wherein residue 2 is a glutamate, residue 26 is a lysine and residue 27 is a tyrosine, and 423 N-terminal amino acids of a botulinum toxin type A heavy chain.
- 23. A polypeptide according to Claim 17 comprising at least 417 of the N-terminal amino acids of botulinum toxin type B heavy chain.
- 24. A polypeptide according to Claim 23 comprising a botulinum toxin type B light chain and 417 N-terminal amino acids of a botulinum toxin type B heavy chain.
- 25. A polypeptide according to any of Claims 14-24 lacking a portion designated

H_c of a botulinum toxin heavy chain.

- 26. A polypeptide comprising a botulinum toxin light chain and a fragment of a botulinum toxin heavy chain, said fragment being not capable of binding to cell surface receptors.
- 27. A polypeptide according to Claim 26 lacking an intact portion designated H_c of a botulinum toxin heavy chain.
- 28. A polypeptide according to any preceding claim comprising a variant of a clostridial toxin and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin.
- 29. A polypeptide according to Claim 28 comprising a variant of a clostridial toxin light chain and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin light chain.
- 30. A polypeptide according to Claim 28 or 29 comprising a variant of a clostridial toxin heavy chain H_N portion and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin heavy chain H_N portion.
- 31. A polypeptide according to Claim 28, 29 or 30 obtainable by modification of a DNA encoding the polypeptide so as to introduce one or more nucleotides coding for the cleavage site.
- 32. A fusion protein comprising a fusion of (a) a polypeptide according to any of Claims 1-31 with (b) a second polypeptide being a polypeptide or oligopeptide adapted for binding to an affinity matrix so as to enable purification of the fusion protein using said matrix.
- 33. A fusion protein according to Claim 32 wherein said second polypeptide is


adapted to bind to a chromatography column, such as an affinity matrix of glutathione Sepharose.


- 34. A fusion protein according to Claim 32 or 33 wherein a specific protease cleavage site is incorporated between the first and second polypeptides, said protease site enabling proteolytic separation of first and second polypeptides.
- 35. A composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the botulinum toxin, said derivative further being non-toxic *in vivo* due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic *in vivo*.
- 36. A composition according to Claim 35 or a polypeptide according to any of Claims 1-31 or a fusion protein according to Claim 32, 33 or 34 for use as a positive control in a toxin assay.
- 37. A composition according to Claim 35 or a polypeptide according to any of Claims 1-31 or a fusion protein according to Claim 32, 33 or 34 for use as a vaccine against clostridial toxin.
- 38. A composition according to Claim 35 or a polypeptide according to any of Claims 1-31 or a fusion protein according to Claim 32, 33 or 34 for *in vivo* use.
- 39. A pharmaceutical composition comprising a composition according to Claim 35, a polypeptide according to any of claims 1-31 or a fusion protein according to Claim 32, 33 or 34, in combination with a pharmaceutically acceptable carrier.
- 40. A nucleic acid encoding a polypeptide or a fusion protein according to any of Claims 1-34.
- 41. A nucleic acid encoding a polypeptide or a fusion protein according to Claim


- 40 and comprising nucleotides encoding residues 1-448 of a botulinum toxin type A light chain.
- 42. A nucleic acid according to Claim 40 or 41 comprising nucleotides encoding residues 1-423 of a botulinum toxin type A heavy chain H_N domain.
- 43. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 and comprising nucleotides encoding residues 1-470 of a botulinum toxin type B light chain.
- 44. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 or 43 comprising nucleotides encoding residues 1-417 of a botulinum toxin type B heavy chain H_{N} domain.
- 45. A nucleic acid according to any of Claims 40-44 comprising nucleotides encoding a restriction endonuclease cleavage site not present in native clostridial toxin sequence.
- 46. A nucleotide according to Claim 45 obtainable by modification of a nucleotide encoding a polypeptide or fusion protein according to any of claims 1-34 so as to introduce said cleavage site.
- 47. A DNA according to any of claims 40-46.
- 48. A DNA selected from SEQ ID No:s 1, 8, 10, 12, 14, 16, 18, 23 and 24.
- 49. A method of manufacture of a polypeptide according to any of Claims 1-31 comprising expressing in a host cell a nucleic acid according to any of Claims 40-48 and recovering the polypeptide.
- 50. A method of manufacture of a polypeptide according to any of Claims 1-31 comprising expressing in a host cell a nucleic acid encoding a fusion protein

according to Claim 32, 33 or 34, purifying the fusion protein by eluting the fusion protein through an affinity matrix adapted to retain the fusion protein and eluting through said matrix a ligand adapted to displace the fusion protein, and recovering the fusion protein.

- 51. A method of manufacture according to Claims 49 or 50 in which the nucleic acid is DNA.
- 52. A cell expressing a polypeptide or fusion protein according to any of Claims 1-34.







Protein concentration (ng/ml)

FIG. 3

NYKDPVNGVDIAYIKIPNAGOMOPV (SeqID.2)		K Y G Q M Q P V (Seq I D 4)	6 V D I A Y I K I P K Y G Q M Q P V (Seq I.D. 6) 7		>
>		<u> </u>	_	<u> </u>	_
~		0	0	0	0
Σ	•	Σ	Σ	Σ	Σ
0		0	0	0	0
٠		<u> </u>	ၒ	ی	ی
4		>	· >	N A G Q M Q P	⋖
Z		×	×	z	FNYKDPVNGVDIAYIKIPNAGQMQP
۵		FNYKDPVNGVDIAYIKIP	<u>م</u>	NGVDIAYIKIP	<u> </u>
H		H _.	H	H	H
× .		×	×	×	×
H	•	H			
7		- -	. 🗸	. A	A
1	٥	H	H	H	H
_		۵	Δ.		0
: - :>	RLQKLLEFEL	>	> .	>	>
5	u_	ی	ی	S	.
z	ш	Z	FNYKDPVN	Z	Z
>	ب	>	>	N Y K D P V	>
٥		•	٩	٠.	٩
۵	×	۰	٥	. a	<u> </u>
×	♂ .	¥	×	×	~
>		>	→	>	>
Z L	~	Z	Z		2
	<u>,-</u>			٦ ٦	
0	. VI	<i>y</i>		~ ~	· 👱
-	5	-	-	_ z	z
>	=	>	>	>	>
<u>u</u>	H	<u>ı</u>	· LL	LL.	<u> </u>
MQFVNKQ	GSPGIHMTS	G T M E F V N K Q	G S M E F V N K Q	1 0 F V N K Q	MPFVNKQ
X -	۵.	₹ 42	Σm	∑ ⊣	₹ ~
-	· ·	, – ′	G S M 123		
	104	9	5 7		• .
LH ₄₂₃ /A	23LH423/A	(Q ₂ E, N ₂₆ K, A ₂₇ Y)	2LH423/A (Q2E, N26K, A27Y)	Native BoNT/A, C. botulinum 2169 Thompson et al.1990	Native BoNT/A, C. botulinum 62A Binz et al.1990
		: <u>S</u>	۵ ت	Z C Z	S C ig

= REGIONS OF NON-IDENTITY WITH THE NATIVE SEQUENCES.

F1G 4

1321/441 TCA TTA GAT AAA GGA TAC AAT AAG agc gct gat ggg GCA TTA AAT GAT TTA TGT ATC AAA S L D K G Y N K S A D G A L N D L C I K Eco47 III

1321/441

TCA TTA GAT AAA GGA TAC AAT AAG atc gaa ggt cgt tgc gat ggg GCA TTA AAT GAT TTA

S L D K G Y N K I E G R C D G A L N D L Factor Xa protease motif

AGG R ACA T 767 CAG GAC D TAT Y ATG M egg g CCT P GAG E TCT S 900 P 161 AAG K 6TG . AGG R CT6 C66 AGG R 11C. TAT CAG AGT S AGG R AGC S CTA 2617/873 TTT ACT F T 2677/893 GAT GCT D A 2737/913 GGC TCC G S 2797/933 TGT GAT C D 2857/953 GCT TAG A B GTG V A6C S TAT Y TCT S CTG L 999 CGG R GCT A 27 Z TTA L ACA T GAG E TT F TT A AAG K GCT. <u>)</u> 757 C AGA R ا م م 999 AAG K 16C C O CA GAG E 767 C AAC N CCT 9 AAG K TTC F GAT D CTC L <u>ل</u> را 6T6 V ACG T TAT Y


2587/863 1AC GTA (Y V L 2647/883 CCG GAG (P E E Z707/903 GGC TTT G F L G F Z767/923 GGT ATC G I L G I Z827/943 GCA CCC A P P P F16. 7

AGA R A S CAT AAT H N ACA T TCT S GAT D AAG K ATT ATT I GAT D TAT Y TCT S GAA E 2617/873 TTT ACT F T 2677/893 TAT CAA Y Q ACA T ပ္ပိ ပ TCA S TCT S TT A L E 4 TT L ATA TGA stop AGA R **8** 0 T L ¥o o AGA R SAA E AAA K AAT N F5 > GAT D GAT D 2587/863 TAC GTA Y V 2647/883 TCT AAA S K S K ATT AAG ATT AAG


(E)

A A A CGA GGC GCC AAT AAA K CAA Q GCA A GAA E CTG L AAC N AAC N GCT A و وور TTC F AAA K GAA E TTA L GAA E CGA R TCA. AAA K GAA E E _ 1 AAC N CAA Q AAG K AAC N AAC AAC N TTC F GAA E TTA L ATT I GAC D TTA L AAA K GCT A GAA E TAT Y GTA V AAC N AAC N AGC S AAC N 2617/873
TTT ACT GAA 1
F T E Y
2677/893
GAT GAA GCC C
D E A V
2737/913
CAT TTA CCT H
H L P N
2797/933
CCA AGC CAA P
S Q S
2857/953
AAA GTA GAC P
K V D N
CCT AAC TTA A
P N L N
2977/993
CCA AGC GCT A
CAA AGC GCT A , GCG CCG A A P TTA CAT TT TTA ACA T GAC D T G CAA O TCT S ATC I GAT D CCA P TTA L GAG E AAA K GCG A GAC D TTA L TAT Y TTA L GCT A GAT D ATC I GAG E AGA R T F AGT S AAA K GAT D S CAG F F A S & & GCG A TA L A A AAT TAT Y CTA L A GCA AAC N ATC I TTC F GAT AGT S

8/11 LH₄₂₃/A



$LH_{423}/A^{9/11}$



10/11





FIG. 12

11 / 11

Panel A. 1 2 3 4



Panel B.




FIG. 13

INTERNATIONAL SEARCH REPORT

PCT Application No 97/02273

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/31 C12N C12N1/21 C07K14/33 A61K38/16 C12P21/02 A61K39/08 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N C12P A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. WO 96 12802 A (OPHIDIAN PHARM INC 1-52 X ; WILLIAMS JAMES A (US); PADHYE NISHA V (US); KI) 2 May 1996 see the whole document "Minimal essential 1-52 X KURAZONO H ET AL: *domains* specifying toxicity of the *light* *chains* of tetanus toxin and botulinum neurotoxin type A." J BIOL CHEM, JUL 25 1992, 267 (21) P14721-9, UNITED STATES, XP002047910 see table II Patent family members are listed in annex. Further documents are listed in the continuation of box C X * Special categories of cited documents : ater document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone " document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docu-*O* document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 3 0. m. 98 9 December 1997 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Ruswuk

Hillenbrand, G

Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,

Fax: (+31-70) 340-3016

INTERNA DNAL SEARCH REPORT

Internal Application No PC17GB 97/02273

		PC17GB 97/02273			
C.(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
X	LI ET AL: "A SINGLE MUTATION IN THE RECOMBINANT LIGHT CHAIN OF TETANUS TOXIN ABOLISHES ITS PROTEOLYTIC ACTIVITY AND REMOVES THE TOXICITY SEEN AFTER RECONSTITUTION WITH NATIVE HEAVY CHAIN" BIOCHEMISTRY, vol. 33, no. 22, 1994, pages 7014-7020, XP002015938 see the whole document		1		
A	BINZ T ET AL: "THE COMPLETE SEQUENCE OF BOTULINUM NEUROTOXIN TYPE A AND COMPARISON WITH OTHER CLOSTRIDIAL NEUROTOXINS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 16, 5 June 1990, pages 9153-9158, XP002009348 see the whole document		1,26,35		
	·				
	·				
4					
			·		
	·				

INTERNATIONAL SEARCH REPORT

PCT Population No 97/02273

						101/ 37/02270		
Patent document cited in search report			Publication date		Patent family member(s)		Publication date	
WO	9612802	A	02-05-96	US	5601823	Α	11-02-97	
	 		•	US	5196193	Α	23-03-93	
•				AU	3968395	Α	15 - 05-96	
				ΕP	0796326	Α	24-09-97	
				FI	971732	Α	23-06-97	
				NO	971868	Α	24-06-97	
				PL	320214	A	15-09-97	
	•			ZA	9508990	A	15-05-96	
				AU	6653894	A ' '	04-07-94	
				CA	2150935	Α	23-06-94	
				EP	0671902	Α	20-09-95	
•			•	WO	9413264	. A	23-06-94	
				US	5466672	Α	14-11-95	
*		-		US	5599539	Α	04 -0 2-97	
			•	AU	638786		08-07-93	
				AU	6895191		31-05-91	
				EP	0498854		19-08-92	
				WO	9106306		16-05-91	
	•		•	US	5443976	Α	22-08-95	
			•	US	5340923	Α	23-08-94	

THIS PAGE BLANK (USPTO)

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)